The design and synthesis of inhibitors of the enzyme poly (adenosine diphosphate ribose) polymerase and the investigation of the mechanism of action of the suspected ultimate carcinogen chloroacetaldehyde by Rhodes, Darren
The Design and Synthesis of Inhibitors of the Enzyme 
Poly(Adenosine Diphosphate Ribose)polymerase 
and the Investigation of the Mechanism of Action of the 
Suspected Ultimate Carcinogen Chloroacetaldehyde 
D Rhodes BSc MPhil 
University of Newcastle upon Tyne 
,I 
June1995 
NEWCASTLE UNIVERSITY LIBRARY 
---------------------------- 
095 50485 9 
---------------------------- 
VveýA_s LS 
Acknowledgments 
The work presented in this thesis was carried out in the Department of Chemistry at 
the University of Newcastle upon Tyne between January 1990 and September 1992. 
I would like to express my gratitude to my supervisors Professor BT Golding, Dr C 
Bleasdale and Dr RJ Griffin for their constant guidance and encouragement during 
my research at Newcastle. 
I would like to thank Professor W McFarlane for his suggestions and help regarding 
the nuclear magnetic resonance experiments reported in this thesis. 
I should also like to express my thanks to: - 
Dr MNS Hill, Mr I McKeag and Ms L Cook for their help with NMR spectra 
determination; Mr D Dunbar for elemental analyses and infra red spectra and Mr S 
Addison for mass spectra. 
Ile technical staff in the Department of Chemistry especially T Johnstone, ER Hart, 
J Marshall, R Anderson and A Wright. 
I am also grateful for the support given to me by my colleagues in the laboratory 
including Oonah, Joe, Keith, Jane, Frank, Leslie and Orrock. 
A maintenance grant from the Northern Cancer Research Campaign is also 
acknowledged. 
Abstract 
'Ibis thesis describes the preparation of inhibitors of the enzyme poly(adenosine 
diphosphate ribose)polymerase (PARP) and the mechanism of action of the 
carcinogen vinyl chloride. Initially the enzyme's function, purification and its known 
inhibitors are discussed. The enzyme's cofactor, nicotinamide adenine diphosphate 
(NAD+), is described in terms of its function in PARP and other enzymes, and its 
crystal structure and solution conformation(s). The high field proton and carbon-13 
NMR spectra of this compound are fully assigned using two dimensional NMR 
experiments (COSY and ROESY) and selective spin decoupling. Using similar 
techniques the high field proton and carbon- 13 NMR spectra of the reduced analogue, 
NADH, are assigned. This NMR data showed that the conformation of the 1,4- 
dihydropyridine ring of this molecule was a dynamic equilibrium mixture of two 
boats. However, it was discovered that these boat conformations were unequally 
populated and a rationale for this phenomenon is given. 
The rationale of enzyme inhibitor design with respect to PARP is described and the 
subsequent preparation and potencies of PARP inhibitors are both described and 
discussed. These included the preparation of 3-methoxycyclohexane carboxamide 
which was synthesised to test a hypothesis of the nature of PARP inhibitors. Partially 
saturated substituted benzamide systems were synthesised to determine the degree of 
unsaturation necessary for inhibition while similar compounds were synthegised by 
reducing N-alkylnicotinamides. Direct NAD+ analogues were prepared in which an 
adenine unit was separated by a methylene chain from a 3-oxy substituted benzamide. 
By varying the length of the methylene chain 3-(9-(12- 
dodecyloxy)adenine)benzamide was shown to inhibit the enzyme. Amongst these 
inhibitors were the unique compounds benzoxazole-4-carboxamides which were 
found to be the most potent inhibitors to be synthesised during this period. A 
correlation of the physical properties of literature compounds with their activity is 
discussed along with the applicability of this technique to PARP and its inhibitors. 
The metabolic activation and carcinogenesis of vinyl chloride are described. The 
reaction of chloroacetaldehyde (a metabolite of vinyl chloride) is discussed with a 
detailed description of its reaction with nucleosides to form the fluorescent etheno 
compounds, with particular emphasis on the adeninq system. A detailed investigation 
of the reaction mechanism of chloroacetaldehyde with adenosine was undertaken by 
determining the intermediates and products of the acid catalysed decomposition of 
N6-(2,2-dimethoxyethyl)adenosine. An ethenoadenine deuteriation experiment along 
with the previous experiment gave evidence toward the reaction mechanism of 
chloroacetaldehyde with adenosine. 
In summary, the cofactor of PARP NAD+ has been fully characterised by proton and 
carbon-13 NMR spectroscopy; a unique conformational. property of NADH has been 
characterised; a new and novel class of potent inhibitors of PARP has been 
discovered and the reaction mechanism of chloroacetaldehyde with adenosine has 
been determined. 
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Chapter I 
1.1 The Chromosomal Structure of DNA 
Carcinogenesis, cell differentiation, DNA repair and replication seem to have the 
common link that they are dependent upon the chromatin structure of DNA. Within 
an organism all the different cell types (eg skin, hair, muscle etc ... ) contain the same 
DNA molecules. It is, however, changes of chromatin structure about specific sets of 
genes from one cell type to another that are responsible for cell differentiation (ie 
what makes a skin cell a skin cell, a hair cell a hair cell etc... ). Chromatin structure 
participates in both the initiation of DNA replication and DNA repair processes at 
specific sites that have been damaged by carcinogens. It is for these reasons that an 
understanding of the chromatin structure of DNA is warranted. 
About 1.8 metres of DNA containing approximately five billion base pairs is packed 
into a single mammalian nucleus of 8 gmetres diameter. The DNA's double helix is 
organised around twenty five million nucleosomes - protein structures consisting of 
eight individual basic proteins called histones - which in turn form partially 
understood secondary, tertiary and quaternary structures. The condensed chromatin 
thus formed contains about fifty thousand loops or domains with each domain 
containing five to two hundred kilo bases of DNA. These domains can either be, 
transcriptionally active or inactive depending upon the presence or absence of various 
proteins such as histone HI and high mobility group nonhistones, as well as variant or 
modified histones. 1,2,3,4 
1.2 The Function of Poly(Adenosine Diphosphate Ribose) 
The necessary processes of DNA transcription, replication and repair are all 
I 
dependent upon poly(adenosine diphosphate ribose) or poly(ADPR). Before any of 
these processes can occur two events have to take place: a specific alteration in the 
three dimensional chromatin structure (to make the DNA accessible) and the binding 
of requisite enzymes and proteins to the exposed DNA. The first of these two events 
occurs when poly(ADPR) is formed upon one of the chromatin histones. When this 
happens a large build up of localized negative charge occurs which alters the three 
dimensional structure of chromatin. In a similar manner poly(ADPR) can modify the 
structure (and hence function) of other enzymes and other proteins. Thus, changes in 
chromatin structure inevitably lead to alterations in gene expression, replication and 
repair. 
1.3 The Structure and Synthesis of Poly(Adenosine 
Diphosphate Ribose) 
Poly(ADPR) is the third most abundant naturally occurring nucleic acid after DNA 
and RNA and consists of repeating units of adenosine diphosphate ribose (1, see 
Figure 1). Initially a protein displaces nicotinamide from nicotinamide adenosine 
diphosphate (2, NAD+) with a carboxylate (in the case of histones H1 and H2B) to 
form an a bond to the sugar. Then units repeat via bonds from the 2'-hydroxyl of the 
ribose attached to adenine and the anomeric carbon (in an a manner), of another 
monomer, of the ribose that is not attached to adenine. Along these polymeric chains 
branch points can occur when the 2'-hydroxyl of the ribose which is not attached to 
adenine forms a bond with the anomeric carbon (again, in an a manner) of another 
monomeric non-adenine attached ribose (see Figure 1). 
1.4 Poly(Adenosine Diphosphate Rib ose) Polym erase 
The chromatin structural modifier, poly(ADPR), is formed from the cofactor NAD+ 
(see Section 1.3) by the enzyme poly(adenosine diphosphate ribose)polymerase 
(PARP). In addition to catalysing the synthesis of poly(ADPR), PARP catalyses the 
transfer of poly(ADPR) onto various proteins modifying their structures and hence 
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their function. Examples of the proteins the enzyme regulates include histones (see 
Section 1.3), it is automodifying, and various other DNA dependent enzymes. Thus, 
enzymes involved in the breaking and joining of DNA strands, ligase II and 
topoisomerase I and H, are regulated by this enzyme. PARP is involved in the 
modification of proteins involved in gene expression and DNA replication (such as 
acetylated histones) and further, it modifies nuclear matrix proteins. 
The effect of PARP, the formation of poly(ADPR), was first demonstrated in 1963 
(and further in 1966) when it was observed in liver extracts. 5,6 Since then PARP has 
been found in a large variety of cells from vertebrate to invertebrate animals and has 
also been found in single celled organisms and plants. It is now thought to be 
ubiquitous within the plant and animal kingdoms. PARP can be described as a zinc 
binding nuclear DNA dependent enzyme. 
1.5 Zinc Finger ProteinS7,8 
A necessary part of the function of many cellular enzymes is to bind to DNA (or 
RNA). An example of such a protein is Xenopus transcription factor III A (TF III A). 
It was discovered that this enzyme contained repeated amino acid units along its 
length which were characterized by two cysteines and two histidines. The two 
cysteines were usually separated by one or two amino acids. Several amino acids 
separated the second cysteine from the first histidine, which was separated from the 
second histidine by one or two amino acids. This enzyme was found to contain seven 
to eleven mole equivalents of zinc which were crucial to its activity. X-ray absorption 
experiments showed that the zinc atoms reside in a similar environment. This 
environment was thought to be that of a tetracoordinated atom with two sulphur 
ligands and two nitrogen ligands. The effect of this phenomenon was to produce a 
tertiary structure of 'fingers' within the protein held in place by the zinc. These 
fingers were found to be rich in basic and polar amino acids suggesting that binding 
to DNA (or RNA) could occur about these regions. 
It was found that this arrangement was not peculiar to TF III A. A number of zinc 
containing DNA (RNA) binding proteins were found to have this cysteine/histidine 
arrangement indicating that zinc fingers are an evolutionary mechanism for the 
binding of protein to DNA or RNA. 
1.5.1 PARP: A Zinc Finger Protein9 
PARP is a DNA binding enzyme which was found to contain zinc fingers for this 
purpose. However, these zinc fingers are different from the zinc fingers found in the 
class of proteins described earlier. Tbe zinc within PARP is bound by three cysteines 
and one histidine rather than by two cysteines and two histidines. Another difference 
is in the size of PARP's fingers; they have more amino acids between the inner zinc 
binding cysteines and are thus much longer. A further feature of PARPs zinc fingers 
is that they are different from each other. 
The binding of PARP to DNA was investigated by obtaining PARP molecules that 
had been mutated in such a manner that the integrity of one of the fingers was 
corrupted. In this way it was observed that one of the fingers binds much more 
tightly to DNA than the other one. The results of this mutation study indicate that the 
tighter binding finger may be responsible for both DNA binding and DNA strand 
break recognition, whilst the other finger may not bind to DNA but may have the role 
of interacting with another PARP molecule. Therefore, a dimer of PARP binds to 
DNA. This rationalisation is consistent with the observations that when PARP binds 
to a single strand break DNA molecule, a symmetrical footprint of seven nucleotides 
on each side of the nick is observed. Thus, both the size and symmetry of the PARP 
bound DNA region suggest that PARP binds to DNA as a dimer. 
1.6 Purification of PARP 
The isolation and purification of PARP has become increasingly efficient over a 
relatively short period of time. Initially PARP was extracted from cells by classical 
wet techniques and purified by column chromatography. The purification steps of 
this technique weri: further improved using affinity chromatography. Genetic 
engineering has subsequently been used to give a good supply of PARP. 
1.6.1 Classical Techniques 
PARP has been previously obtained from many sources including calf thymus which 
is briefly described below. 10 The procedure began with the homogenisation of 
frozen calf thymus in a buffered solution. Centrifugation produced a supernatant 
which was treated with salmon protamine sulphate (to precipitate DNA) and 
centrifuged again. The supernatant obtained from this process was purified by 
column chromatography: 
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firstly, with DNA-agarose as stationary phase and secondly, with hydroxylapatite as 
the stationary phase. Ilie proteinaceous fraction obtained was then gel filtered on a 
Sephadex G-150 column to give the enzyme. 
1.6.2 Affinity Chromatography 
Purification of the enzyme was improved by the use of affinity chromatography. The 
stationary phase of a column was modified in such a manner as to incorporate 
molecules that bind to the enzyme. In this examplel 1 3-aminobenzamide (3) was 
coupled (via a succinyl linker) to Sepharose 4B (see Figure 2). A supernatant 
obtained by classical techniques was passed through the modified column to leave the 
enzyme adsorbed upon it. The enzyme was then eluted from the column using a 
buffer that contained another compound (3-methoxybenzamide (4)) that binds to the 
enzyme. A further column removed the 3-methoxybenzamide and the pure enzyme 
was obtained. Using this technique the pure enzyme could be prepared within a few 
hours. The procedure was shown to be effective in preparing the enzyme from a 
number of different sources, such as human placenta and horse, rat and chicken liver. 
1.6.3 Genetic Engineering 
In this technique the nucleus of a cell was transfected with a piece of complementary 
DNA that codes for PARR The cell was then multiplied by cultivation and the 
enzyme obtained by the methods described earlier. Escherichia coli was initially 
used for this process but the enzyme obtained from this cultivation was found to be 
incomplete. It was only when insect cells were used12 that pure PARP was obtained. 
The classical technique produced 3.2 mg of enzyme from 29,800 mg of crude extract; 
the affinity chromatography technique gave 0.3 mg of enzyme from 20,000 mg of 
crude extract whilst the genetically engineered cells produced 20 mg of enzyme from 
365 mg of crude extract. 
For 1 kg of crude extract the amount of enzyme produced. is: 
classical technique 107 mg 
affinity chromatography 15 mg 
genetic engineering 55,000 mg 
1.6.4 Enzyme Characteristics 
PARP can be characterised. in terms of its mass and its Michaelis constant for NAD+. 
The values for the three techniques, classical, affinity chromatography and genetic 
engineering are: 110 kDa, 55 gM; 115 kDa, 52 gM and 116 kDa, 50 gM, 
respectively. 
1 1.7 DNA Repair and PARP 
When DNA is attacked by electrophiles a number of repair mechanisms become 
operational. 13 The repair mechanism in which PARP is involved occurs when DNA 
strand breaks appear: this phenomenon 'switches on'PARP. This has been shown 
when DNA strand breaks are produced by nucleases - the result is the rapid synthesis 
of poly(ADPR) upon histones. As described earlier, this has the effect of making the 
damaged DNA accessible to repair enzymes. The exposed DNA is then repaired by a 
multi - enzymic process and PARP is poly (ADP-ribosylated); this has results in the 
inactivation of PARP, thus the DNA is repaired and is then allowed to supercoil and 
the metabolism of the cell carries on as before. 
8 
The electrophiles that attack DNA are usually the metabolites of cherrficals that the 
body has ingested (Scheme 1). A chemical that the body has no use for is usually 
oxidised which has the effect of increasing its water solubility making it easier for the 
body to excrete. This oxidising process, however, sometimes has the detrimental 
effect of creating an electrophile. Therefore, if the body ingests benzene (5), which is 
found in car exhaust fumes, it can be oxidized to (z, z) muconaldehyde (6) which may 
subsequently react with DNA. 14 Other examples of these chemicals include urethane, 
or O-ethyl carbarnate (7), 15,16,17 which is found in food and beverages: this 
compound may be oxidised to O-epoxyethyl carbarnate (8), which may react with 
DNA. A further example is the industrial chemical vinyl chloride (9), 17 the 
monomer of polyvinylchoride (PVC), which is thought to be metabolically oxidised 
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to chlorooxirane (10). Subsequent rearrangement of 10 forms the bifunctional 
electrophile chloroacetaldehyde (11 , see Chapter 
6) which is thought to form adducts, 
with DNA (see Scheme 1). 
It is thus apparent that if it were not for the many repair processes mentioned earlier 
carcinogenesis would be much more prevalent. 
The effect of DNA alkylation, apart from DNA repair or carcinogenesis, is cell death. 
(This was first observed in soldiers who survived the effects of mustard gas (bis(2- 
chloroethane)sulphide 12). 18 If healthy cells could be killed by DNA alkylation then 
cancerous cells could be killed in a similar manner and furthermore, since cancerous 
cells tend to have a higher metabolic rate than healthy cells, there should be 
discrimination in alkylating agent (i. e. drug) uptake between healthy and cancerous 
cells. Chemotherapy is therefore the treatment of cancer patients with cytotoxic drugs 
that preferentially kill cancerous cells due to their higher metabolic rate. 
For example, one treatment of melanoma utilises the drug Dacarbazine, which has, as 
its active constituent, 5-(3,3-dimethyl-l-triazeno)-4-imidazole carboxamide (DTIC, 
13). 19 After ingestion of this compound it is metabolized to 5-(3-methyl-l-triazeno)- 
4-imidazole carboxamide (MIC, 14) which forms, after tautomerisation and cleavage, 
5-amino-4-imidazole carboxamide (AICA, 15) and the methylating agent, methyl 
diazonium ion (16, see Scheme 2). 
A further example of a cytotoxic alkylating agent is 1,3-bis(2-chloroethyl)- 1- 
nitrosourea (BCNU, 17) which is used to treat acute lymphocytic leukeamia. 20 
Decomposition of this compound gives the chloroisocyanate (18) and 2-chloro-l- 
nitrosoethylamine (19a) which can tautomerise to the diazotic acid 19b. This 
compound can then go on to form the diazonium compound (20) shown in Scheme 3. 
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Unfortunately the same repair mechanism that protects healthy cells from 
electrophilic metabolites also protects cancerous cells from chemotherapeutic drugs. 
Thus, tumors do not always respond to chemotherapy. 
Therefore, the effectiveness of anticancer drugs will be increased by inhibiting 
the DNA repair enzyme PARP. 
'Mis central premise is supported by a large amount of evidence showing that 
inhibitors of PARP inhibit DNA repair and potentiate the cell killing capacity of 
alkylating agents. When cells were exposed to dimethyl sulphate (DMS, 21), a potent 
alkylating agent, the NAD+ concentration of these cells was found to decrease. When 
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DMS was applied to cells in the presence of a PARP inhibitor (3-aminobenzamide, 3 
or 3-methoxybenzamide, 4) there was no decrease in NAD+ concentration observed. 
During this experiment the strand length of the DNA of the cells was determined by 
sedimentation studies. Immediately after incubation with DMS the cellular DNA was 
found to appear in the middle of a sedimentation gradient. Forty minutes after the 
removal of DMS, sedimentation studies showed that the DNA had increased 
significantly in size and after eighty minutes the DNA appeared at the same place as 
undamaged DNA. When this sedimentation study was repeated, with the application 
of a PARP inhibitor immediately after removal of DMS, it showed that there was no 
appreciable increase in the size of DNA after forty minutes. That is, the DNA was 
not repairing itself. Eighty minutes later the DNA showed only a slight increase in 
size, whilst after five hours the bulk of the DNA had not yet returned to its original 
size. This same study also showed the increase in cYtotoxicity of cells towards DMS 
in the presence of PARP inhibitors. 21 Other studies have shown similar results using 
12 
other DNA-damaging agents (eg N-methyl-N-nitrosourea (22) and T-radiation) and 
other PARP inhibitors. 22 
These experiments have progressed by studying the effects of antiturnour drugs in the 
presence of inhibitors of PARP. Thus, the active metabolite 5-(3-methyl-l-triazeno)- 
4-imidazole carboxamide (MIC, 14) of the drug 5-(3,3-dimethyl-l-triazeno)-4- 
imidazole carboxamide (DTIC, 13, see earlier) has been shown to increase cell death 
in the presence of PARP inhibitors. 23 Another antiturnour drug, bleomycin, which is 
thought to cleave DNA strands has also been shown to have an increased potency in 
the presence of PARP inhibitors. 24 
13 
Chapter 2 
2.1 Inhibitors of PARP 
Inhibitors of PARP have been sought since its discovery. They were required as 
molecular mechanistic probes of the enzyme: if an inhibitor of PARP was given in 
vivo, then any cellular dysfunction observed meant that PARP played a role in that 
cellular function. Throughout the course of PARPs history many compounds have 
been discovered which inhibit this enzyme. A large proportion of these inhibitors 
also participate in other known metabolic pathways and so would be useless for 
PARP in vivo dysfunction studies. However, this complication is overshadowed by 
the lack of inhibitors that have both potency and aqueous solubility. The latter two 
points must be overcome in order to obtain suitable inhibitors of PARP. 
2.1.1 3-Substituted Benzamides 
Benzamide (23) has been known to be an inhibitor of PARP since 1975. It is a close 
analogue of nicotinamide (24) but does not have a ring nitrogen, which means that it 
cannot be metabolised by NAD+ biosynthetic enzymes. However, benzamide has 
0 
2 
0 
3-Aminobenzamide 3 3-Methoxybenzamide 4 
Inhibitors of PARP 
Figure 3 
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low aqueous solubility and is very hydrophobic making it unsuitable for physiological 
studies. 
3-Substituted benzamides, such as 3-methoxybenzamide and 3-aminobenzamide (4 
and 3, Figure 3), were shown to be strong inhibitors of PARP and have good 
solubility properties, which meant that they could be used in physiological studies. 
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2.1.2 Dihydroisoquinolines26 
It was realised that inhibition of PARP would increase the effectiveness of 
chemotherapy and radiotherapy. With this in mind certain dihydroisoquinolines were 
tested. These compounds were chosen because of their similarity to 3-substituted 
benzamides. They were designed so that they had a rigid amide orientation- it was 
thought that this particular orientation was optimal for inhibition. This hypothesis 
was proved by synthesizing and testing 2-alkyl-3-substituted benzamides. These 
compounds have the opposite preferred amide orientation to that of the 
dihydroisoquinolines. The 2-alkyl-3-substituted benzamides were found to be 
inactive whilst the dihydroisoquinolines were found to be inhibitors (Figure 4). 
Substitution of the dihydroisoquinolines at the 5 position gave extremely potent 
inhibitors of PARP (with the exception of the 5-nitro, substituent). Substituted 
dihydroisoquinolines were also tested but were shown to be less potent than the 
corresponding 5-substituted compounds. 
This work suggests that both a fixed amide orientation and a meta substituent are both 
necessary for potent inhibition. It is interesting to note that a para substituent, which 
can directly donate electron density to the amide carbonyl, shows less inhibition than 
the corresponding meta compound (Figure 5). 
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2.1.3 Other Inhibitors of PARp27 
The most potent inhibitor found by Banasik et al was 4-amino-1,8-naphthalimide 
(25). This compound has a rigid amide and can be viewed in two ways with respect 
to the amide substituent. It can be regarded as a compound that has a para amine and 
a meta sp2 carbon or simply as an amide that has an electron rich meta Sp2 carbon. In 
the former case, even though direct para electron donation from the amine is seen, the 
magnitude of this electron donation is tempered by the other canonical forms of the 
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The Canonical Forms of 4-An-dno-LB-Naphthalftnide 
f1gure 6 
molecule. For this reason this molecule cannot be regarded as a. simple analogue of a 
para substituted benzamide (Figure 6). 
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2.1.4 The Design of PARP Inhibitors Based Upon 
Literature Precedent 
A study of the literature of PARP inhibitors indicates that three requirements are 
necessary for these compounds to be effective: 
(i) A 6-membered ring. 
(ii) An amide functional group. 
(iii) A substituent at the three position relative to 
the amide. 
The extent that the literature has explored these three aspects will now be discussed 
(Figure 7). 
Proposed Molecular Template for Inhibitors of PARP 
Figure 7 
(i) 6-membered ring 
Literature inhibitors generally have the molecular skeleton depicted above (Figure 7). 
It is thought that an unsaturated ring is necessary for activity, however, partially 
unsaturated ring systems have not been investigated. 
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Heterocyclic systems, such as nicotinamide (3), have shown activity but not to as 
great an extent as non-heterocyclic systerns. In addition nicotinamide systems 
decrease in potency when they are substituted at the three position. This is thought to 
be a consequence of starving the carbonyl group of electrons. A method of 
incorporating an alkyl substituted nicotinamide without incurring loss of electron 
density from the carbonyl group is through the formation of N- 
alky1dihydronicotinamides (see Section 4.3.2). 
(ii) Amide functionality 
The orientation of the amide function necessary for inhibition has been shown to be 
that depicted above by the workers who designed the dihydroisoquinoline class of 
inhibitors26 (Figure 4, Section 2.1.2). 
Another aspect of the amide function is the extent of substitution upon the nitrogen 
atom. Potent inhibitors have been discovered which have one nitrogen proton 
substituted for an alkyl group27 but it is not known if both protons can be substituted. 
That is, does the enzymic site have a hydrogen bond accepting group that 
accommodates an amide nitrogen proton? 
A third aspect to the amide functionality is its carbonyl group. It could be envisaged 
that within the enzyme the inhibitor binds by forming a 'hydrogen bond' at the 
carbonyl oxygen. If this were the case then a correlation between inhibition and 
carbonyl electron donation would be expected to be seen. The extent of carbonyl 
electron donation can be quantitatively determined spectroscopically: either by IR 
carbonyl stretching frequencies or carbon-13 NMR chemical shifts. In this way it 
should be possible to show a correlation between carbonyl electron donation and 
inhibitory potency (see Section 5.1.1). 
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(iii) 3-Substituent 
Inhibition has been observed within compounds that do not have a 3-substituent, 
however it seems that potency is increased with an electron - donating substituent (eg 
amino) at the three position. Further work is required to determine the nature and 
function of the 3-substituent. 
2.2 Assay of PARP Inhibitor Potency 
The activity of PARP, with or without the presence of an inhibitor, was determined 
by incubating permeabilized cells with radioactively labelled NAD+ in the presence 
of double stranded oligonucleotide. The amount of poly(ADPR) produced, 
determined by the amount of material obtained after work up, was a measure of the 
activity of PARP (see Materials and Methods). 
Nucleotides, such as NAD+ and the oligonucleotides mentioned above, do not 
permeate intact living cells. The cells used in the assay were made permeable to 
nucleotides by suspending in hypotonic buffer. After suspension in this buffer the 
cells were suspended in an isotonic buffer where the assay was carried out. It was 
originally thought that it was possible to do the assay using isolated nuclei, however, 
it has been shown that this procedure gave misleading results. PARP activity was 
shown to depend upon the number of DNA strand breaks, which in isolated nuclei are 
comparatively high and thus the activity of PARP was comparatively high. 'Me DNA 
structure of permeabilized cells is very nearly the same as that of intact cells and so 
the activity of PARP is comparable to that in the cell. 28 
The enzyme in the permeabilized cells was activated by the presence of double 
stranded oligonucleotides. 29,30 It is possible to activate indirectly cellular PARP by 
inducing DNA lesions with carcinogens or DNase 1, both of which cause strand 
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breaks in the chromosomal DNA. The addition of double stranded oligonucleotides 
however, directly activates the enzyme within the cell. Thus, using this method the 
percentage inhibition of a potential inhibitor can be determined at various 
concentrations and by making a plot of percentage inhibition against concentration of 
inhibitor an IC50 can be determined. 
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Chapter 3 
3.1 The Cofactor NAD+ 
3.1.1 The Design of Enzyme Inhibitors 
A number of approaches are available for the rational design of enzyme inhibitors. 
The two approaches we used were the synthesis of molecules based upon the 
structures of: 
(a) the enzyme's cofactor. 
(b) known inhibitors found in the literature. 
Thus, a prerequisite of molecule design based on (a) above is the full characterisation 
of the cofactor with particular emphasis upon its crystal structure(s), enzyme bound 
crystal structure(s) and solution conformation(s). 
The cofactor of PARP and of a large number of other enzymes is nicotinamide 
adenosine diphosphate (NAD+ 2, Figure 8). 
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Nicotinaridde Adenosine Diphosphate 
Figure 8 
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As can be seen from Figure 8a pyridinium cation (a good nucleofuge) is attached via 
an N-glycosidic bond to the C- I of D-ribose in aP- manner ((x forms have also been 
observed but are usually enzymically inactive). This nicotinamide - ribose moiety is 
linked to adenosine via a pyrophosphate group making the molecule a dinucleotide (Cf 
Section 1.3). Usually NAD+ is involved in enzymic redox reactions where, as 
cofactor, it acts as a hydride acceptor. The hydride anion is accepted at C-4 of the 
nicotinamide ring (the aromaticity of which is lost) forming a quinoid type structure. 
The reduced form of NAD+ is represented as NADH (26, see Figure 9). 
Ethanol alcohol dehydrogenase is an example of an enzyme which has NAD+ as a 
cofactor and which effects a redox reaction. This enzyme oxidises ethanol (27) to 
ethanal (28), in the manner shown in Figure 10, with NAD+ accepting the hydride 
anion produced (the proton which is also produced goes into solution). 
H- 0 pro 
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NAD+ as a Hydride Acceptor 
Figure 9 
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Figure 10 
When NAD+ accepts a hydride ion in this manner, a prochiral centre is produced (at 
C-4 of the dihydronicotinamide ring) within the resulting NADH. That is, hydride 
transfer is stereospecific. Thus, ethanol, lactate and malate dehydrogenases transfer 
the pro-R hydride, whilst 3-phosphoglyceraldehyde and glucose dehydrogenases are 
pro-S specific (see Figure 9). 
A large number of enzymic redox reactions which have NAD+ as a cofactor have 
been studied and described in the literature. However, care must be taken if we are to 
take any of the results - such as enzyme bound crystal structures of NAD+ - as 
premises for the design of our molecules. This is because PARP is not a redox 
enzyme but an ADP-ribosylating enzyme. The crystal structure of NAD+ (which was 
determined by Saenger et a13 I) can be used as a premise for our work. The 
description of this crystal structure will help explain some of our ideas for drug 
design and introduce all the nomenclature necessary for an explanation of the results 
of a two dimensional NMR spectroscopic solution conformation study of NAD+ (see 
Section 3.4). 
3.2 The Crystal Structure of NAD+ 
The crystal structure of the dihydrate of the lithium salt of NAD+ - Li+NAD+, 
C2lH26N7014P2Li. 2H20 - is detailed below and is reproduced in Diagram 1. 
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The Crystal Structure of NAD4' 
Diagram I 
Furthermore, it is described by a consideration of various components and bonds, 
such as: the two sugars, the sugar base bonds-, the C4! -C5' bonds and the 
pyrophosphate linkage. 
Nomenclature32 
Within a system of four atoms designated ABCD, the three atoms ABC can describe a 
plane as can the three atoms BCD. The angle at which these planes intersect is called 
the dihedral angle. Angles formed by a clockwise rotation of the rear bond are 
designated positive, whilst anticlockwise rotations are negative. If the dihedral angle 
is 0* the system is synperiplanar (cis), if the dihedral angle is 1801 the system is 
antiperiplanar (trans). The region between 0' and 901 is the synclinal or gauche 
els 
synpe(iplanor 
antiperiiplonar 
trans 
gauche (syndinal) 
+ 
onfi (onficlinal) 
Illustration of the Nomenclature of the Dihedral Angle 
Figure II 
region and the region between 90" and 180" is the anti or anticlinal region (see Figure 
11). 
3.2.1 The Sugar Conformations 
The conformations of the furanose sugars are succinctly described by the 
pseudorotation concept. 33 Briefly, the sugar's CV, C4'and 0 atoms describe a plane; 
any atoms above that plane (ie on the same side as the CY atom) are called endo 
whilst the atoms below it are said to be exo. Ibis gives rise to two conformations: 
envelope (E) and twist (T). An envelope occurs when one atom does not deviate or 
only slightly deviates from the plane, whilst the other atom shows a large deviation; a 
twist conformation occurs when both atoms display similar (but opposite) deviations 
from the plane. In Figure 12 the arrows show the direction of deviation from the 
plane defined by the remaining atoms indicated byW. The adenosine ribose has a 
C(2')-endo (2E) envelope whilst the nicotinamide ribose has a C(T)-endo C(2)-exo 
(3T2) twist conformation, both of which are also represented in Figure 12. 
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3.2.2 The Glycosidic Bonds 
The relative orientation of the bases with respect to the sugars is described by the 
torsional angle about the glycosidic bonds. The angles for adenosine (0(1')-C(1')- 
N(9)-C(8)) and nicotinamide ribose (0(1')-C(1')-N(l)-C(6)) show that both bases 
adopt an anti conformation: ie the bases are directed away from the sugars. 'Mis is 
represented in Figure 13 where the bold lines represent the bonds which form the 
torsion angle. In the crystal structure the value for the adenosine moiety is 521 and 
for the nicotinamide the value is 15". 
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3.2.3 The C4'-C5' Orientation 
The orientation observed for (0(5')-C(5')-C(4')-C(3')) in NAD+ is the preferred 
conformation for other nucleotides. In both cases within NAD+ the orientation can 
be described as + gauche. Thus, the 05' atoms are above the ribose ring, which is 
depicted in Figure 14. The torsion angles (described by the bold bonds) for the two 
sugars are 48* and 47' for the adenosine aqd nicotinamide riboses, respectively. 
Base 
110 OH 
The C4'-C5' Orientation of Ribose 
Figure 14 
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3.2.4 The Pyrophosphate Linkage 
Many crystal structures of compounds containing the pyrophosphate linkage have 
been determined making comparisons between them and NAD+ possible. The P-0 
bond distances in the P- O-P group tend to differ by about 0.1 A for molecules such as 
CDP and ADP (depending upon their counterions), whilst the P-0 bond distances are 
similar for symmetrical molecules such as di-p-naphtholpyrophosphate. Since the 
pyrophosphate group within NAD+ is symmetrically substituted by ribose units 
connected in the same way (via 05') then the P-0 bond distances should be very 
similar. However, the bond distances were found to be disymmetrical, one bond was 
about 0.1 A longer than the other. The PN-Opp bound was found to be longer than 
the PA-Opp bond. This was thought to be a consequence of the lithium cation 
coordination (see Diagram 2). 
Another feature of the pyrophosphate group was its POP bond angle of 130". This 
was consistent with the values observed for this angle in other nucleotides, but not 
with phosphoesters, where the bond angle about POC is usually 1201. This 
phenomenon has important consequences for the dihedral angles of the pyrophosphate 
group and can allow it to occupy a synperiplanar (cis) orientation. 
The 05'-PN torsion angle was found to be + gauche (79') whilst the 05'-PA torsion 
angle was - anticlinal (-125"). The latter result, again, was thought to be a 
consequence of lithium cation coordination. However, in solutions without any 
cations, greater flexibility can be envisioned. 
3.2.5 The Bases and Li+ Cation Coordination 
Both bases are almost planar and orientated nearly perpendicular to one another. The 
Li+ cation is tetrahedrally coordinated to adenine N7 and a pyrophosphate oxygen of 
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The Crystal Structure of NAW Showing Lithium Coordination 
Diagram 2 
the nicotinamide part of the pyrophosphate group. Tle Li+ cation is further 
coordinated to the pyrophosphate oxygens of another NAD+ molecule (see Diagram 
2). 
3.3 Solution conformation of NAD+ 
The proposed solution conformation of NAD+ was determined from the analysis of 
NMR spectroscopic data of various reduced and oxidized pyridine dinucleotides. 
This research began in the late 1960's and early 1970's and initially no useful data was 
won due to the low field strengths (60 MHz) used to deterrnine the spectra. In 1970 
Sarma and Kaplan, 34 obtained higher field (220 MHz) spectra of some reduced and 
deuterio labelled pyridine dinucleotides. They observed an AB splitting pattern 
which was assigned to the H4' and 1-14" protons of a 1,4-dihydropyridine dinucleotide. 
That is, the two protons (114' and H4") were seen to have different chemical shifts. 
This difference in chemical shift was rationalized by employing the idea of a folded 
dinucleotide: the nucleotide was thought to be folded in such a manner that the 
adenine half of the molecule resided over the reduced pyridine half of the molecule. 
In this way one of the protons at position four would exist in a different chemical 
environment to the other proton and a chemical shift difference, induced by the 
adenine ring current, would be seen between them. From this premise and using 
specifically deuteriated (D4'or D4") 1,4-dihydropyridine dinucleotides they proposed 
the proportions of dinucleotide conformer (right or left handed helix) in solution. 
This paper and other similar papers were later appraised by Jacobus. 35 Before 
turning to the previous paper he presented various stereochernical definitions and 
related these definitions to the NMR properties of the reduced pyridine dinucleotides. 
In particular the reduced pyridine protons 114' and 1-14" within the previous example 
were diastereotopic: and as such were anisochronous. That is, they have different 
chemical shifts whatever their environment. Thus, the results described by Sarma and 
Kaplan could be rationalized without the need to invoke a helical model. It was 
concluded that the NMR results so far could only define the topography of these 
molecules with ambiguity. 
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Tbis'observation however, does not preclude the existence of helical conformers. In a 
dynamic system with a pyrophosphate linkage that possesses the capacity for the 
degree of flexibility described earlier (see above), then NAD+ (NADH etc ... ) most 
probably exists in three forms: an extended one similar to its crystal structure and two 
stereochernically distinct helical or folded conformations. Furthermore, this 
hypothesis could be tested by nOe NMR experiments and perhaps even the 
proportions of the folded species could be determined by expeditýous use of deuterio- 
labelled dihydropyridine dinucleotides (see Future Work). 
In summary NAD+ adopts the expected conformations derived from comparison with 
other nucleotides. The peculiarities of the crystal structure seem to be a consequence 
of the lithium cation coordination. 
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3.4 Further Investigations of The Solution 
Conformation of NAD+ 
The design of some of our inhibitors of PARP was to be based upon the structure of 
PARP's cofactor NAD+. The 500 MHz 
IH and 125 MHz 13C NMR spectra of 
NAD+ were determined with a view to discovering some empirical data that would 
help to describe its solution conformation. 
3.4.1 The NMR Spectra of Adenosine 5'-(Trihydrogen 
Diphosphate)51-4 5' ester with 3-(Aminocarbonyl-l-B-D- 
Ribofuranosyl-Pyridinium, hydroxide, inner salt (NAD+) 
Notation: A position about the nicotinamide ring will be designated Nn where n is a 
number. A position about the sugar ring attached to the nicotinamide ring will be 
designated Nn'- In the adenosine system the letter N will be replaced by A. 'Ibis 
numbering system is illustrated in Figure 15. 
NAD+: This compound consists of two parts joined by a diphosphate linkage: one 
part consists of adenosine which is attached to the diphosphate group via the 5' (AS) 
hydroxyl group; the other part consists of nicotinamide attached to ribofuranose from 
the NI nitrogen to the anomeric Nl'carbon in aD manner with the N5hydroxyl 
joined to the diphosphate linkage (see Figure 15). 
3.4.2 NMR Spectrum of NAD+ 
When considering the NMR (1H or 13C) spectra of NAD+ we expect to see a 
problem with the differentiation of the two ribose units. 'Ibis problem has been 
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overcome for the 1H NMR spectrum of this compound by using a high field 
spectrometer (500 MHz) and correlation spectroscopy (COSY) to assign coupled 
peaks. Our assignments have been further confirmed by rotating frame Overhauser 
effect spectroscopy (ROESY). 
The 13C spectrum of NAD+ has been assigned by using heteronuclear shift 
correlation spectroscopy and selective spin decoupling. Carbon-phosphorus coupling 
indicating the conformation of the molecule about the phosphodiester linkage is also 
observed and discussed. 
3.4.3 The 500 MHz 1H NMR Spectrum of NAD+ 
This spectrum (spectrum 1) has three distinct regions: the first, between 8 9.6 and 8 
8.2, contains the aromatic protons; the second, between 6 6.4 and 8 6.0, contains the 
two anomeric protons; and lastly the sugar protons are between 8 5.0 and 8 4.0. This 
is in accord with the III NMR spectra of N-alkyl nicotinamide saltS36 and 
adenosine. 37 
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The signal furthest downfield is a singlet at 8 9.41, which arises from N2. Ile 
protons N6 and N4, both doublets, have chemical shifts of 8 9.28 and 8 8.91, 
respectively. The adenine protons appear next, with A8 further downfield (8 8.50) 
than A2 (8 8.30). The signal at 8 8.30 merges with what should be a triplet centred at 
8 8.28: this corresponds to N5. At other concentrations these two signals separate. 
Of the two anomeric: protons, the one alpha to the positive nitrogen is confirmed to be 
the furthest downfield by ROESY experiments. So we have a doublet at 8 6.18 
representing NIand another doublet at 8 6.05 (Al'). 
The sugar protons in spectrum I were assigned with the help of COSY spectra of 
NAD+. The COSY spectra 2 and 3 show which protons are coupled to each other 
within the NAD+ molecule. Coupling between the anomeric protons Nl'and Al'is 
seen with N2'and AT(spectrum 2). The A2'proton appears at 8 4.67 whilst the NT 
proton appears at 8 4.55; these two signals are seen as triplets in the one dimensional 
spectrum of NAD+ (spectrum 1). Spectrum 3 shows details of the sugar region. It 
shows correlation between A2'and AT(b 4.49), whilst N2'correlates with N3'(8 
4.47): these are seen to be a triplet (AT) and a poorly resolved double-doublet in 
spectrum 1. AT correlates with A4' (8 4.38) and this signal is seen to correlate with 
the AT and AF protons, which are in the region 8 4.3 -84.2. In spectrum 1, A4' 
appears as a broad singlet whilst the A5' and A5" protons appear as a broad multiplet. 
At NT a correlation is seen to N4' (8 4.59) which appears as a broad singlet downfield 
of N3'in spectrum 1. The N4' signal is coupled to N5'(8 4.39) and NY (8 4.27); 
these two signals occupy two widely spaced multiplets in spectrum 1. 
The adenine sugar rings protons appear at higher field with increasing distance from 
the anomeric position. The nicotinamide sugar ring does not have this property: the 
proton Wis downfield to NT. Another difference in the two sugars is that the 
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chemical shifts of the protons NY and NY are dissimilar, whilst the corresponding 
AY and AF protons are similar. 
6H Integral multi- coupling 
constant 
assignment 
9.41 1H S N2 
9.28 111 d 6.2 N6 
8.91 1H d 8.0 N4 
8.50 1H S - A8 
8.30 1H S A2 
8.28 1H t 7.9 N5 
6.18 1H d 5. Nl' 
6.05 1H d 5.3 
_ 
Al' 
4.67 1H t 5.2 AT 
4.60 1H s N4' 
4.55 1H t 5.1 NT 
4.49 1H t 4.4 AT 
4.47 1H M - NT 
4.39 1H M - NS 
4.38 m - A4' 
4.27 m - NS 
4.2-4.3 2H M AN, AF 
Table 1 
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The conformations of the two sugars seem to be very similar because their coupling 
constants, between corresponding protons, are similar. For instance the anomeric 
doublets both have a5 Hz coupling to the triplets of NT and AT. 
3.4.4 Rotating Frame Overhauser Effect Spectroscopy of NAD+ 
Rotating frame Overhauser effect spectroscopy (ROESY) can be used to estimate 
distances between the protons (usually) within a molecule. When this technique was 
applied to a solution of NAD+ in D20 it was hoped that two pieces of information 
would be obtained: 
a. It would confirm our previous assignments. 
b. It would give a strong indication of the solution 
conformation of NAD+. 
The ROESY spectrum of NAD+ (spectrum 4a) is a two dimensional spectrum which 
shows contours along a diagonal, the colour and density of the contours giving an 
indication of the strength of the signal represented. Off this diagonal, signals are seen 
which represent nuclear Overhauser effect interactions between the protons of the 
different parts of the molecule but which are spatially proximate. It is obvious that 
these signals should occur when the protons are alpha to one another, but weaker 
interactions can also occur between protons of larger separations even when it is not 
immediately obvious that such protons are close to one another. Ibis is shown in 
Spectrum 4b. 
As well as the qualitative interpretation of these spectra it is also possible to give a 
quantitative interpretation of the spectra by obtaining the relative intensities of the off 
diagonal signals. These are actually proportional to the volume integrals of the peaks 
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which were obtained by numerical integration. This process gives a numerical value 
of the extent of nOe interaction between protons within the molecule. For the 
purposes of discussion these values are tabulated throughout the following text. 
Note that the nOe interactions between a pair of protons depends upon the inverse 
sixth power of their separation, and hence a relatively low precision in the volume 
integrals can give quite accurate distance information. 
The aromatic region of NAD+ is represented in spectrum 4c with the corresponding 
relative intensities given in Table 2. 
Chemical 
Shift (ppm) 
Proton N2 N4 N5 N6 
9.41 N2 23 8 132 
8.91 N4 226 36 
8.28 N5 317 
9.28 N6 
Table 2 
The relative intensities given for N2 (5 9.41) are consistent with this proton being 
meta to N4 (8 8.9 1) and N6 (8 9.28) and para to N5 (8 8.28). The N4 proton shows 
relative intensities which are consistent with its being ortho to N5 and meta to N6. 
The N6 proton is seen to be ortho to N5. These signals all corroborate our previous 
assignments of the nicotinamide protons. 
The relative intensity between the two adenine protons A2 (8 8.30) and A8 (8 8.50) 
has a value of 46 (and is not tabulated). This value is larger than what would be 
45 
+ 
4 
E 
CID 
CID 
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9.9 
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expected for this interaction (cf N2/N5) and it is thought that this signal also 
represents the extent of interaction between A8 and N5 (see later) as well as the two 
adenine interactions. This is thought to be a consequence of the similarity in 
chemical shifts of A2 (8 8.30) and N5 (8 8.28). 
The next region of spectrum 4 (highlighted by spectrum 4d) shows the relative 
intensities between the bases and their sugars. The nicotinamide part of the molecule 
(Table 3) shows interactions between the N2 and N6 protons with the protons on the 
nicotinamide sugar. 
Proton N2 N4 
Chemical 
Shift (ppm) 
9.41 9.28 
N l' 6.18 350 255 
NT 4.55 73 79 
NY 4.47 20 33 
N4' 4.60 9 7 
NS 4.39 14 
- 
21 
- 
NY 4.27 5 9 
T 
Table 3 
Immediately our previous assignment of NV (8 6.18) is corroborated by the presence 
of strong interactions with N2 and N6. There is also a marked difference between the 
values of the relative intensities between N I' with N2 and NF with N6: the value for 
NIVN2 is larger. On this basis it is possible to say that the conforrnation about the 
glycosidic bond of the nicotinamide part of the molecule is the same as that of the 
crystal structure (see Section 3.2.2) ie it has an anti conformation. Interactions are 
47 
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seen between the nicotinamide protons and the other sugar protons, in this manner it 
is possible to discriminate between the nicotinamide ribose and the adenosine ribose 
signals. Unfortunately it is not possible to draw any conclusions about the 
conformation of the nicotinamide ribose with this information. The difference in 
interactions between the N2 and N6 protons with the other sugar protons is not large 
enough to form a basis for any firm conclusions. 
A similar analysis of the adenosine part of the molecule (spectrum 4d and Table 4) 
gives similar results. The assignment of A l' (5 6.05) is further confirmed by 
interactions with A2 and A8 but unlike the nicotinamide part of the molecule it is not 
possible to draw any conclusions about the dihedral angle of the glycosidic bond from 
this infonnation. 
Protons Al' AT AT- A4' A5, A5" 
Chemical 
Shift 
m 
6.05 4.67 4.49 4.38 4.2-4.3 
A2 8.30 20 49 
A8 8.50 54 154 49 (23 
Table 4 
It is possible to say that if the glycosidic dihedral angle (01'Cl'N9C8) were ca, 180* 
then the interaction between A8 and A I'would be a lot larger than the interaction 
betweenýA2andAl'- Since these interactions are not very different from one another, 
perhaps the conformation about the glycosidic bond is not the same as that of the 
crystal structure (see Section 3.2.2). The interaction observed between A8 and A2'is 
comparatively large: on this basis it is possible to say that adenine adopts an anti 
49 
conformation with its sugar in NAD+. A further interaction is seen between A8 and 
ATwhich is of the same value as the total value of the interactions between A2 and 
AT, AT and A4'. 
Protons Cherni- 
cal Shift 
(ppm) 
Nl' NT NY N4' NY NY 
Nl' 6.18 69 35 57 
NT 4.55 (120) (120) 
NT 4.47 159 206 
N4' 4.60 (186) 201 
N5' 4.39 
NY 4.27 
Table 5 
Protons Chemical 
shift 
m 
Al' AT AT A4' A5', A5" 
Al' 6.05 94 32 64 3 
AT 4.67 255 82 1517 
AT 4.49 2061()4 
A4' 4.38 53 
A5', A5" ý 4.2-4.3 
Table 6 
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The extent with which the anomeric sugar protons (NI'and Al') interact with the 
other sugar protons is highlighted by spectrum 4e. This information further 
corroborates the assignments of the sugar protons. Thus, N1' interacts with the 
protons: N2', NT and N4' (see Table 5) while A 1' interacts with AT, AT, A4' and 
slightly with AY, AY (see Table 6). 
The extent with which the sugar protons interact with each other is depicted in 
I 
Spectrum 4f. Here we can see that N2'interacts with NTand NY(Table 5), the 
interaction is most probably greater with NY than NY but because of the complicated 
nature of this region of the spectrum, it was not possible to differentiate between 
these two signals. Similarly, no interaction between N2'and Wis indicated: this 
does not mean that that there is no interaction; rather, it was not possible to detern-fine 
a 'meaningful' relative intensity. A large relative intensity was observed between NT 
and N4'while an even larger interaction was seen between NTand NY. Ibis - 
phenomenon can be explained by supposing that the conformation of this ribose is 
such that NTis endo. (Whether this is a twist or envelope conformation is not 
apparent). An unequal interaction is seen between N4'and the NYand NY protons 
which simply means that the N4'proton is not equidistant to the NY and NY protons. 
The adenine ribose system (Table 6) appears to adopt a similar confon-nation to that 
of the nicotinamide ribose. Based upon the large value of the relative intensity 
observed for the interaction between AY and the A5' and AY protons it can be 
supposed that this ring is AY endo. This result corroborates the earlier assertion that 
the two rings had similar conformations (this was based upon them having similar 
anomeric coupling constants; see earlier, Section 3.4.3). 
An aspect of conformation that this technique allows us to explore is the proximity of 
the two bases to each other. It is seen that interactions occur between the adenine and 
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ppm 4.8 4.7 4.6 4'5 4.4 4.3 4.2 
nicotinamide protons (see Spectrum 4b and Table 7). Thus, A8 is seen to interact 
with N2 and to a larger extent with N4 and also with N6. 
Proton N2 N4 N5 
I 
N6 
_ 
Chemical 
Shift (ppm) 
9.41 8.91 8.28 9.28 
A2 8.30 8 
A8 8.50 10 18 14 
Table 7 
3.4.5 The Assignment of the 13C NMR Spectrum of NAD+ 
The 13C NMR spectrum of NAD+ has been measured previously. 38 The spectrum 
was obtained at an operating frequency of 25.1 MHz with 13C-enriched acetic acid 
(CH3*CO2H) as a standard. The spectrum was expressed in cycles per second (cps) 
with all the shifts upfield relative to the standard. The spectrum can be expressed in 
parts per million (ppm) by dividing the cps value of the signals by 25.1 (the operating 
frequency) and subtracting this number from 178.1 (the chemical shift of the Cl atom 
of acetic acid). However, after this process has been done it is not possible to 
compare this spectrum with our spectrum because the chemical shifts of some of 
NAD+'s signals are solvent and concentration dependent. Further, our spectrum was 
of superior quality (a consequence of greater operating frequency, 125 MHz) and 
gave more information (eg carbon-phosphorus coupling constants). 
The full assignment of our NAD+ spectrum was achieved by the application of two 
processes: 
54 
(i) Heteronuclear Shift Coffelation (HSQ 
(ii) Heteronuclear Selective Spin Decoupling 
The carbon atoms of NAD+ can be classified into two types: carbons with one or 
more protons attached to them and carbons with no protons attached to them. 71be 
HSC experiment correlates the chemical shift of a carbon atom with that of its 
attached proton(s). Since the 1H NMR spectrum of NAD+ has been fully assigned 
(see earlier) then any carbon with a proton attached to it can be assigned using this 
technique. 
An HSC spectrum is a two dimensional spectrum with the one dimensional 1H NMR 
spectrum of NAD+ along one axis and the one dimensional 13C NMR spectrum 
along the other. A coupling between a carbon and its attached proton is indicated by 
a peak at the intersection of the chemical shifts of the two signals. 
The IH NMR signal that appears furthest downfield is N2 (8 9.41) and is seen to 
correlate with the 13C NMR signal at 8 142.41 (see Spectrum 5). In this manner the 
13C NMR signal at 8 142.41 is assigned to the N2 carbon. The next signal assigned 
was the one that correlated to the 1H NMR signal of N6 (8 9.28), this appeared at 5 
145.08 and so was ascribed to the N6 carbon. In this manner all of the hydrogen- 
bearing carbons of NAD+ were assigned (see Table 8). 
All of the carbons thus described have a coupling constant, 'JC-H, of between 140 to 
220 Hz and appear as doublets in the IH coupled 13C NMR spectrum. They may 
also have a larger range (normally 2JC-H or 3JC-H) coupling which makes these 
signals appear as double multiplets. In this spectrum a feature of the carbon atoms 
that do not have an attached hydrogen is that they usually have a three bond coupling 
to at least one proton. It is therefore possible to determine exactly which proton is 
associated with which multiplet by the technique of selective spin decoupling. 
55 
V 
we 
---W. og 
b 
t! Z. e 
-tso. 70 
WU 
- -'a 
EI44:! 
4a 
t4f 42 
'EI45: 
30 
, t4s. 10 '*-Zt44.47 
t4Z. 44 
a 
0 
0 
e 
0 
. P. 
-tM. J4 
-01.25 
.Z 
-toi. 78 
qo. J3 
sqa 
-cZ%" 
60. Le 
---- 
". 7a 
-g: zz Mas 
77.12 
1 
a 
73. a 
73 , ol ? a. 77 
67 It ly: 17 
7,117 6 
07 .M 
Normally 13C NMR spectra are obtained under conditions of complete (broad band) 
proton decoupling and then consist of a set of singlets. In the absence of such 
decoupling these singlets appear as multiplets showing large splittings (IJ) and also 
smaller splittings (2J or 3J) which may not always be resolved. By the use of 
selectivg decoupling at appropriate power levels it is possible to remove the fine 
structure arising from coupling to a chosen proton, only providing that this has a 
sufficient chemical shift difference ftom other protons in the same molecule. Ihis 
technique is of special value for assigning the longer range C-H couplings - 
particularly those of non-protonated carbons. In this manner it is possible to assign 
the remaining carbons. 
The signal furthest downfield (8 167.83) is almost certainly the carbonyl carbon of 
NAD+. This appears as a triplet - or more correctly, a poorly resolved double doublet 
- in the proton-coupled 
13C NMR spectrum. When the proton-coupled 13C NMR 
spectrum is recorded with simultaneous low power irradiation of the N2 proton the 
carbonyl carbon multiplet signal collapses to a doublet. Irradiation at other proton 
frequencies have no effect. Similarly, when this process is repeated with irTadiation 
of the N4 proton, the signal appears as a doublet. In this manner the assignment of 
this signal to the carbonyl carbon was confirmed (see Table 8). 
Irradiation of the A2 proton (8 8.30) causes the doublet centred at 8 152.18 to 
collapse to a singlet. 'Mis signal was assigned to the A6 carbon. Although the A4 
carbon has a 3JC-H coupling to A2 this carbon is discounted since it also has the 
potential to couple to the A8 and A l'proton§ which would lead to a much more 
complicated signal than a doublet. 
The signal at 8 150.18 was assigned to the carbon at A4. In the Proton-coupled 13C 
NMR spectrum this signal appeared as a double double doublet. When the A2 proton 
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was selectively spin decoupled from this signal the largest coupling disappeared to 
leave a double doublet. The mid coupling disappeared when the A8 proton was 
irradiated, while the decoupling of the Al'proton removed the smallest coupling from 
this multiplet. 
The remaining carbons to be assigned are N3 and A5. The N3 carbon (8 136.30) was 
found to have a 3JC-H coupling to the N5 proton wh, ilst the A5 carbon (8 120.62) 
was found to be coupled to the A8 proton. 
A feature of our spectrum, that was not apparent from the earlier workers 
determination, was the presence of doublets due to carbon-phosphorus coupling. A 
value of 9 Hz is seen for the vicinal coupling between each of the C4'-P nuclei; the 
values of the geminal coupling constants are 4.4 Hz for the AY-P nuclei and 4.7 Hz 
for the NY-P nuclei. (A larger vicinal than geminal coupling constant is consistent 
with observations on other nucleotides). 39 
The gerninal. coupling constant is consistent with values obtained for other 
nucleotides and alkyl phosphate esters. 40 The vicinal coupling constant is consistent 
with a trans arrangement within the POC5'C4'parts of the molecule. 41,42,43 
The dihedral angle can be calculated approximately within the POC5'C4' if the 
parameters A, B and C of the Karplus equation (Equation 1), for these elements in 
this type of system, are known. 
J=A. COS20 + B. cosO +c Equation 1 
From studies of the angle POCTC4' in selected cyclic 3', 5'mononucleotides these 
parameters have been determined to be A=6.4, B= -1.3 and C=1.2 and these 
parameters have been used to determine this angle in other similar 3', 5' 
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mononucleotides and 3' --) 5' oligonucleotides. An extension of this approach to the 
angle POC3'C2' required an adjustment of parameter C to zero owing to the 
electronegativity of the base. 44 'Me angle POC5'C4' has apparently not been studied 
in this way but a similar Karplus equation with essentially similar parameters will 
apply. Aplication of this equation to our system yields 0 close to 0', or 180". The 
solution with 0=0 for each dihedral angle is not considered to be a reasonable 
reflection of the conformation of NAD+, since there would be too many steric 
interactions between atoms within the molecule. It is much more plausible to have 0 
= 180' which means that the steric interactions would be minimized, if not totally 
negated. 
This NMR spectroscopic work suggest that in solution NAD+: 
has its bases anti 
has C3'endo sugars 
has a phosphate group fully extended from the 05' atoms 
(iv) exists in a small proportion in a folded conformation 
5c- ppm AssiRnment 1jr-T-1 Alz 3jr_14 /Hz 
167.83 C=O CON2 = CO/N4; 
3.6,3.6 
152.18 A6 A6/A2; 7.6 
15 0.58 A4 A2/A4, A4/A8, 
A4/Al'; 12.8,5.5, 
2.1 
148.49 N4 172 N4/N2 = N41N6; 
5.8 
147.59 A2 215 
145.08 N6 199 multiplet 
144.76 A8 221 A8/Al'; 4.3 
142.41 N2 193 multiplet 
136.30 N3 N3/N5; 7.3 
131.22 N5 178 N4/N6; 3.6 
120.62 AS A5/A8; 11.9 
102.45 Nl' 177 multiplet 
90.44 Al' 168 to 
1 
89.59 N4' 144 If 
86.53 A4' 170 
80.15 NT 152 
77.26 AT 150 
73.24 NT 154.5 
72.70 AT 152 to 
67.76 A5' 146.8,148.3 to 
67.56 NY 152.4,146.6 if 
Table 8 
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3.5 The Assignment of the 500 MHz IH and 125 MHz 13C NMR 
Spectra of NADH 
The complete assignment of the IH and 13C NMR spectra of NAD+ led to the 
expectation that, by using similar techniques, the full assignment of nicotinamide 
adenine dinucleotide hydride (NADH) would be feasible. As well as using the 
techniques that were employed to assign NAD+, an additional NMR experiment was 
I 
used to assign the reduced NADH. This experiment is a two dimensional 
heteronuclear shift correlation (HSC or HETCOR, see earlier) process known as a C- 
IJ/HOHAHA experiment. This is essentially an extension of the normal HETCOR 
experiment in which a given carbon is correlated not only with its directly bound 
proton(s), but also with those protons that are themselves coupled to the directly 
bound one. Thus, if the chemical shift of a proton is known, the chemical shift of the 
carbon it is attached to can be determined from the HETCOR experiment. Using this 
chemical shift it is then possible to determine, from the C-H/HOHAHA spectrum, the 
chemical shift of the proton it is attached to and any chemical shifts of protons 
coupled to the previous proton. This process can be repeated using the new proton 
H2 
NH2 
NH2 N 
N N O-P-O-P-0 Wý Lle-oý 
Uli OH 0 
OH OH 
Yicotinamide Adenine Dinucleotide Hydride (NADH) 
Figure 15a 
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chemical shifts to assign the chemical shifts of the carbons they are attached to and 
hence the chemical shifts of any coupled protons. It effectively provides a means of 
tracing out the carbon skeleton in a sequential manner without recourse to doubly 
labelled species. 
NADH consists of two nucleotides (see Figure 15a) which can be considered as 
individual entities in order to assign the proton spectrum. The assignment began by 
comparing the spectra of similar molecules eg NAD+ (see Spectrum 1), adenosine, N- 
benzyl- 1,4-dihydronicotinamide (63) and N-methyl- 1,4-dihydronicotinamide (64, see 
Spectrum 7). On this basis assignments of A8, A2 and Al'were made (see Table 8a 
for proton chemical shifts) and confirmed by a ROESY spectrum which showed 
correlations of A8 with A 1' and of A8 with resonances in the sugar region (5 4- 5). 
The chen-dcal shift of A2'was obtained from a COSY spectrum of NADH, since it 
was coupled to Al'. The chemical shift of the carbon attached to the proton at AT 
was obtained from the HETCOR spectrum (Spectrum 5b, see Table 8b for carbon-13 
chemical shifts). Using this chemical shift, from the C-H/HOHAHA spectrum 
(Spectrum 5c) the chemical shift of the proton AT was obtained. This process was 
repeated to give the chemical shift of A4' and an indication of where the A5', 5" 
signals were to be found. 
The chemical shifts of the nicotinamide-hydride part of the molecule were also 
initially assigned by comparison with previously assigned spectra (see earlier). Thus, 
N2, Nic4,4", N5 and N6 were assigned (Nic4', 4" represent the two diastereotopic 
protons at N4; N is now referred to as Nic in order to avoid confusion with the sugar 
position N4'). A ROESY spectrum placed Nl'at 8 4.20 but the other protons about 
this part of the molecule were more difficult to assign. It was found that the carbon- 
13 chemical shifts (see Spectrum 5d) of N4', A4'and N5', A5'appeared in similar 
positions (and this was further confirmed by their phosphorus-31 coupling). Since 
the adenosine half of the molecule had been assigned the N4' and N5carbons were 
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assigned by default. Inspection of the HETCOR spectrum gave the chemical shifts of 
the Wand N5', 5" protons which were found to have very similar chemical shifts and 
small coupling constants. 71liese latter factors meant that the asssignment of NY and 
NT by the techniques described earlier was not possible. Thus, of the remaining 
protons it is possible to say in which region they may be found but not to give their 
exact chemical shifts. For example, A5', 5", NYand N2'appear in the region 8 4.10 - 
4.30, with one of these protons appearing at the same position as N5. 
Important features of the 1H NMR spectrum of NADH are the chemical shifts and 
8H Integral Multiplicity Coupling 
Constant 
Assignment 
8.45 1H s A8 
8.19 1H s A2 
6.91 1H S - N2 
6.09 1H d 5.5 Alf 
5.92 1H dd 1.5,8.2 N6 
4.7-4.8 2.511 m N5* 
4.68 1H t 5.2 AT 
4.49 IH t 4.4 AT 
4.45 IH m - A41 
4.12-4.30 4H AS', 5", N3, N2' 
N1 
4.00-4.10 3H m - N4', N5', 5" 
2.75 111 dd 17.8,2.9,2.4 Nic4 
L 
2.65 1H dd 17.8,3.8,1.3 Niq4" 
Table 8a 
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HP 
A B 
The Conf ormations of NADH 
Figure 15b 
coupling constants of the protons Nic4%4". Since NADH is a chiral molecule, Nic4' 
and Nic4" are diastereotopic and hence are expected to have different chemical shifts. 
If the reduced nicotinamide ring is not planar, two boat like conformations are 
possible in which the sp3 carbon N4 can be regarded as being "above" the plane of the 
carbons 2,3,5 and 6 in one form and "below" it in the other (Forms A and B, see 
Figure 15b) with a dynamic equilibrium existing between the two forms. In one 
conformation Nic4' occupies a pseudoaxial position and Nic4" occupies a 
pseudoequatorial position, while in the other conformation the situation is reversed. 
Suppose that when Nic4'occupies a pseudoaxial position (Form A) it has a chemical 
shift Of 5a and when in the pseudoequatorial position (Form B) it has a chemical shift 
Of 8e, and so the chemical shift of Nic4'(5H') is given in equation 2. 
8fl, = 1/2(8a + 8e') equation 2 
8H" ý 1/2(8e + 8a) equation 
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Since the reverse is true for Nic4" its chemical shift (SH,, ) will be given by equation 
3. Ile protons Nic4' and Nic4" are coupled to the proton N5 by a coupling constant 
(3J) whose value will be dependent upon whether the protons (Nic4', 4") were in a 
pseudoaxial (3Jax) or pseudoequatorial (3jeq) Position. 
'Ibus, assuming 
and 
3Jax(A) = 3Jax(B) 
3Jeq(A) = 3Jeq(B) 
For equal populations of the two fonns A and B, equations 4 and 5 would apply. 
3J(H') = 1/2(Jax + Jeq) equation 4 
3J(H") = 1/2(Jax + Jeq) equation 5 
However, in fact 3J(H') # 3J(H") and so it follows that the populations of A and B are 
not equal. The 3J coupling constants of the protons are: 8 2.65,3J = 3.8, and 8 2.75, 
3J = 2.9, Hz (with 4J couplings of 1.3 and 2.4 Hz, respectively). The average of the 
two 3J coupling constants (3.35 Hz) was found to be the same as the 3J coupling 
constant in N-benzyl- 1,4-dihydronicotinamide, while the average of the 4J coupling 
constants is the same as the 4J coupling constant in N-benzyl-1,4- 
dihydronicotinamide. 
HH 00H HI 
-0-p-o-p-0- 
UH UH 
< 
AB 
The Dinucleotide Bridge of NADH 
Figure 15c 
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A consequence of the reduced nicotinamide ring 'flipping' is that this part of the 
molecule becomes chiral. Since the sugar part of the molecule is already chiral the 
boat conformations A and B are diastereoisomers. As diastereoisomers have different 
physical properties from one another, it is expected that one of the diastereoisomers A 
or B is more stable than the other. This phenomenon may explain the difference in 
populations described earlier. Recent studies have described crystal structures of 
simple N-alkyl-1,4-dihydronicotinamides which show that their dihydropyridine rings 
are planar. 45 However, the solution conformation may be different. and in any case a 
planar dihydropyridine ring for NADH would not explain the NMR data. As 
discussed on page 68 a planar dihydropyridine ring would lead to identical 
multiplicities for the two C4 protons hence the NMR data presented gives conclusive 
evidence for the predominance of one diastereotopic conformation of NADH. 
The protons in NADH 'associated' with phosphorus (le the ones close to the 
dinucleotide bridge N4', 5'5" and A4', 5,5", see Figure . 15c) exhibit a special coupling 
phenomenon. For example, for the proton marked'*'in Figure 15c, a doublet would 
naYvely be expected due to the coupling APAH) since presumably APBH) - 0. The 
coupling between the two phosphorus atoms is expected to be approximately 10 Hz 
and their chemical shifts are (fortuitously) equal. Therefore, the system must be 
regarded as AXX' where H=A, PA =X and PB = X- If the chemical shift difference 
between X and X is zero then instead of a doublet, a triplet is seen which has its outer 
lines separated by AHPA) + J(HPB) 1= AHPA) in this case]. This effect is 
sometimes 'called' the virtual coupling46 Of PB to H. 
The 13C NMR spectrum (Spectrum 5d) was partially assigned (see Table 8b) using 
similar techniques to the assignment of NAD+. 
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8(' Multiplicity Assign ent 
174.83 q C=O 
157.53 q 
154.93 d A2 
150.93 q A 
141.80 d A8 
140.67 d N 
126.22 d N6 
120.71 q A 
107.69 d N5 
102.30 q 
97.53 d 
89.58 'd Al' 
85.89 d A4' 
84.64 d N4' 
76.92 d AT 
73.19 d 
72.91 d 
72.58 d AT 
24.28 t N4 
Table 8b 
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Chapter 4 
4.1 Inhibitors at Newcastle 
Below are described two classes of inhibitor: those based upon the cofactor NAD+ 
and those based upon literature inhibitors. 
Inhibitors based upon the cofactor NAD+- 
4.1.1 Adenine Alkyl Benzamides 
These compounds were direct analogues of NAD+. The differences incorporated 
were that benzamide replaced nicotinamide and an alkyl chain (whose length was 
varied) replaced the dinucleotide linkage with adenine. 
These compounds were prepared by converting 3-hydroxy benzamide (29) into 3- 
(bromoalkoxy)benzamides which were further transformed to 3- 
(purinealkoxy)benzamides. From the latter compounds the 3- 
(adeninealkoxy)benzamides were produced (see Scheme 6). 
4.1.2 The Preparation of 3-Hydroxybenzamide (29) 
The title compound was prepared from commercially available 3-hydroxybenzoic 
acid (30). Our strategy was to protect the hydroxyl group and then activate the acid 
part of the molecule toward nucleophilic attack. This was followed by the formation 
of the amide and finally the removal of the protecting group to form the title 
compound. 
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4.1.2.1 The Mixed Anhydride Method47248 
In this preparation 3-hydroxybenzoic acid (30) was treated with ethyl chloroformate 
(31), which serves the dual purpose of protecting (deactivating) the hydroxyl group 
and activating the acidic part of the molecule by forming a mixed acid anhydride 
intermediate (32). This was isolated in 64 % yield. The 1H NMR spectrum of this 
molecule showed oyo ethyl groups of slightly differing chemical shift (200 MHz d6- 
DMS6; 8 1.30 (311, t, CH3), 1.34 (31-1, t, CH3), 4.32 (21-1, q, CH2), 4.39 (211, q, 
CH2)) and the aromatic signals of a meta substituted benzene ring (8 7.50 (11-1, d, H4), 
7.57 (lH, dd, H5), 7.90 (11-1, s, H2), 7.98 (IH, d, H6)). This intermediate (32) was 
treated with liquid ammonia to form the amide and remove the protecting group from 
the hydroxyl part of the molecule (see Scheme 4) 
Unfortunately 3-hydroxybenzamide (29) was isolated in only 5% yield. Another 
problem with this procedure was the formation (and removal) of O-ethyl carbarnate 
(7) a suspected carcinogen. 49,50 
30 0 
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4.1.2.2 The Acetate/Acid Chloride Method5l 
In this technique the hydroxyl of 3-hydroxybenzoic acid (30) was protected 
(deactivated) as its acetate (33) which was formed in 92 % yield (the 1H NMR of this 
compound showed the presence of the acetate signal at 8 2.39). The acid functional 
group was converted into the acid chloride (34) by heating with thionyl chloride 
I under refluxing conditions. 
The arnide was formed by reaction of the isolated acid 
chloride with aqueous ammonia solution, which also removed the acetate protecting 
group. This procedure conveniently produced 3-hydroxybenzamide (29) in ca 70 % 
overall yield (see Scheme 5). 
4.1.3 The Preparation of 3-(Bromoalkyloxy)benzamides 
0 
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ne 3-(bromoalkyloxy)benzamides were prepared by refluxing a dibromo alkane with 
3-hydroxybenzamide (29) in the presence of potassium carbonate. The reactions 
were followed by TLC and work up consisted of evaporation of acetonitrile, flash 
chromatography and recrystallisation. To suppress reaction at both ends of the alkyl 
chain, the dibromoalkane was used in excess (two to one mole ratio). 
The 1H NMR spectra of these compounds corroborated their proposed structures. 
Generally, the spectra had a region that was similar to the spectrum of 3- 
hydroxybenzamide (29), displaying the amide protons and a pattern of signals in the 
aromatic region indicative of a 1,3-disubstituted benzene. The bromoalkyl proton 
signals appeared, as expected, in the upfield region of the spectrum. Common to all 
the spectra were two triplets which were indicative of the methylene signals cc to the 
electronegative substituents oxygen and bromine. The signal furthest downfield 
represented the methylene protons a to the oxygen (5 4.15) whilst the a 
bromomethylene triplet appeared slightly further upfield (8 3.64). The methylene 
protons P to the electronegative substituents were represented by a broad multiplet (8 
1.90 ppm) which was common to all the spectra. The remaining signals in the alkyl 
chain of 3-(5-bromopentyloxy)benzamide (35) appeared as a multiplet (8 1.60) 
which was slightly downfield with respect to the alkyl envelope of the 8-bromo (36) 
and 12-brorno, (37) compounds (8 1.40). 
The 13C NMR spectra become increasingly difficult to assign as the number of 
signals increases in the upfield region. However, they all have the common signals of 
the carbonyl carbon, the aromatic signals and the signals which represent carbons cc to 
the electronegative atoms oxYgen and bromine in the alkyl chain. 
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4.1.3.1 Potency of the 3-(Bromoalkyloxy)benzamides 
Although these compounds were synthesised. with a view to using them to prepare the 
3-(adenine-9-alkyloxy)benzamides and were not expected to show any inhibition 
against PARP, their potency was assessed. A serendipitous result was not expected 
rather, empirical data that could be rationalised was sought. 
Compound No Chain Length 
n 10 RM 
% Inhibition 
30 gM 100 gm 
35 5 ND 57,52 90,72 
36 8 0, ND Insoluble 
37 12 0,0 0,4 Insolub 
Table 9 
3-(5-Bromopentyloxy)benzamide (35) did exhibit some inhibition against PARP, 
whilst the 8-bromo and 12-brorno compounds (36 and 37) were found to be inactive. 
The lack of potency of the latter two compounds was largely due to their aqueous 
insolubility but even at low concentrations there was very little, if any, inhibition 
against PARP. It could be rationalised that the 5-bromo compound (35) behaves in a 
similar manner to inhibitors such as 3-methoxybenzamide (4). In this case the 5- 
bromoalkyl chain is not long enough to interfere any binding sites within the enzyme. 
If this is true, then the 8-bromo and 12-bromo compounds (36 and 37), as well as 
being sparingly soluble, may have their enzyme-substrate binding capacity disrupted 
by their bromoalkyl. substituents. If this rationalisation is correct then attempts to 
increase the water solubility of these compounds, and hence inhibition against PARP, 
would be fruitless. 
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4.1.4 The Preparation of the 3-(Purinealkyloxy)benzamides 
These compounds were prepared from their corresponding 3- 
(bromoalkyloxy)benzamides by stirring them with 6-chloropurine and potassium 
carbonate in DMF. The reactions were followed by TLC and work up consisted of 
removing the solvent under vacuum, followed by flash chromatography to give a 
mixture of the IV7 and N9 isomers of the chloropurine. This mixture was converted to 
the corresponding adenine mixture by reaction with ammonia (high pressure, 50'C, 
overnight). 'Ibis procedure produced a mixture of isomers that was separable by flash 
chromatography. 
(i) 
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The IH NMR spectra of these two classes of compounds were very similar to the 
spectra of the 3-(bromoalkoxy)benzamides (see earlier). The slight differences were 
the presence of the purine signals appearing in the downfield region of the spectra 
(further downfield than the aromatic benzene protons) and a slight downfield shift of 
the two triplets which represent the methylene protons cc to the aromatic oxygen and 
nitrogen atoms at the ends of the alkyl chains. 
4.1.4.1 Potency of the 3-(Purine-9-alkyloxy)benzamides 
Of this class of six compounds, three show some inhibition against PARP: 3-(5-(6- 
chloropurin-9-yl)pentyloxy)benzamide (38), 3-(5-(6-aminopurin-9-yl)pentyloxy) 
Compound No Chain Length 
n 10 4M 
% Inhibition 
30 [tM 100 1.1m 
38 5 16 38,45 68,71,74 
39 8 26,31,32 Insoluble Insoluble 
40 12 2,0 5,20 3 
Table 10 
Compound No Chain Length 
n 10 RM 
% Inhibition 
30 ýffl 100 RM 
41 5 16 38,45 65,69 
42 8 41,29,20 Insoluble 
43 12 14,37 
_52,21,50 
73,75 
Table 11 
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benzamide (41) and 3-(12-(6-aminoPurin-9-yl)dodecyloxy)benzamide (43). The 
potency of the pentyloxy compounds (38 and 41) against PARP can be rationalised in 
the same manner that the potency of 3-(5-bromopentyloxy)benzamide (35) was 
rationalised. That is, they bind to PARP in a similar manner to that in which 
inhibitors such as 3-methoxybenzamide (4) bind to PARP. Since they possess some 
aqueous solubility and their 3-substituent groups are not bulky enough to interfere 
with this binding: they show some inhibition against PARP. 
3-(12-(6-Aminopurin-9-yl)dodecyloxy)benzamide (43) was envisioned and 
synthesised as a direct analogue of NAD+ and as such was expected to show 
inhibition against PARP. ' It is noteworthy that the corresponding 6-chloropurine 
analogue did not show any inhibition, indicating that there may be an adenine 
receptor site within PARP. However, further evidence is required to prove this 
assumption. 
4.1.5 The Preparation of the 3-(Hydroxyalkyloxy)benzamides 
An attempt was made to synthesise these compounds by the preparation of the 
acetates from the bromides and hydrolysing the acetates to the alcohols. 
It was hoped to prepare 3-(8-acetyloctyloxy)benzamide (44) from 3-(8- 
bromooctyloxy)benzamide (36) by heating an ethanolic solution of the latter 
compound under reflux in the presence of sodium acetate. This reaction was 
followed by TLC but no transformation was detected (five hours). The reaction was 
repeated in an aprotic solvent with a different reagent (a consequence of solubility 
problems). Therefore, a solution of 3-(8-b ' rOmooctyloxy)benzamide (36) in 
acetoniaile was heated under reflux in the presence of n-tetrabutylammonium acetate 
and the reaction was followed by TLC. After eight hours the presence of a product, 
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with a similar Rf to the starting material, was observed. Upon work up the reaction 
mixture produced a white solid which, based upon 1H NMR evidence, was thought to 
be a mixture of starting material, reagent and product. The spectrum had signals in 
the downfield region which were in similar positions and had similar splitting patterns 
to those found in the similar region of the spectra of the 3- 
(bromoalkyloxy)benzamides (see Section 4.1.3) which were indicative of a 1,3- 
disubstituted benzene. Two, almost superimposed, triplets appear at 8 4.10 which 
were thought to represent the protons cc to the oxygen atom connected to the aromatic 
ring and the protons cc to the oxygen atom connected to the acetyl group. Another 
triplet (at 5 3.62) had a much smaller integral than the previous signal. This signal 
was assigned to the methylene protons a to the bromine atom of the starting material 
(36) which usually appear at 8 6.64 ppm (see Section 4.1.3). The methylene protons 
(x to the quaternary nitrogen of the reagent (n-tetrabutylammonium acetate) appear as 
a multiplet at 8 3.29. The acetate methyl protons of both the reagent and the product 
appear as a singlet (8 2.10) whilst the remaining methylene protons appear as a series 
of multiplets between 8 2.00 and 8 1.25. Lastly a triplet (at 8 1.11) is seen which 
represents the methyl protons of the reagent. 
AnalYsis of the integrals within this spectrum indicate the ratio of prbduct to the 
starting material is 3 to I and the ratio of the product to the reagent is 2.4 to 1. 
Since the Res of the starting material and the product were so similar the acetate 
within the reaction mixture was hydrolysed to the alcohol, since the alcohol was 
expected to have a lower Rf than the acetate, it was hoped that the alcohol could be 
won from the reaction mixture chromatographically. The transformation was effected 
by stirring the reaction mixture in a methanolic aqueous ammonia solution overnight. 
A TLC of the reaction mixture showed a mixture Of two compounds of widely 
differing Res. These compounds were then separated chromatographically and a 1H 
NMR spectrum obtained of the slower running compound. This spectrum indicated 
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that this fraction contained 3-(8-hydroxyoctyloxy)benzarnide (45) with the salient 
features being two triplets which were thought to the oxygen atom connected to the 
aromatic ring (8 4.49) and the methylene protons oc to the hydroxyl group (8 4.10). 
Unfortunately this spectrum also showed that the reagent was present in this 
chromatographic fraction. In conclusion, it is possible to effect the transformation of 
the bromide to the alcohol via the acetate but the reaction requires further 
optimisation. 
4.2.1 cis/trans-3-Methoxycyclohexanecarboxylic acid (46) 
Inhibitors were designed that were not dependent upon NAD+ as a template but were 
based upon the rationalisation of literature inhibitors. One of these rationalisations 
was that for the molecule to be active some conjugation was necessary within a six 
membered ring that was substituted at the three position and contained an amide 
functionality at the one position. If this hypothesis is correct then the saturated 3- 
methoxycyclohexane carboxamide should not be an inhibitor. This compound was 
synthesised to test this hypothesis. The title compound was obtained commercially 
and consisted of a mixture of four compounds, ie two pairs of enantiomers. The cis- 
pair were the (R, S)- and (SR)-3-methoxycyclohexanecarboxylic acids (46a and 46b); 
whilst the trans-pair consisted of (RR)- and (S, S)-3-methoxycyclohexanecarboxylic 
acids (46c and 46d, see Figure 16). Since the carboxamides produced from these 
compounds were not expected to show any inhibitory properties it was considered 
expedient - since this starting material was readily available - to submit the resultant 
carboxamides in this form for evaluation. 
If this mixture was found to show inhibition of PARP then separation into (firstly) the 
two pairs of enantiorners would be required. Since the pairs of enantiomers were 
diastereomeric toward each other, separation by HPLC was envisaged. The purity of 
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Figure 16 
the two pairs could be checked by 1H NMR spectroscopy. It was for this reason that 
the 1H NMR spectrum of the diastereomeric cisl trans 3- 
methoxycyclohexanecarboxylic acid was determined. 
Determination of the cis to traits ratio of 
3-methoxycyclohexanecarboxylic acid (46) 
by 1H NMR spectroscopy 
A 500 MHz IH NMR spectrum of cisl trans-3-methoxycyclohexanecarboxylic acid 
(46) shows two different NMR signals for (amongst others) the proton at the 3 
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position. These two signals differ both in chemical shift and broadness of signal. It 
was from the broadness of the signal that these two peaks were assigned to their 
constituent molecule. In the cis compound (where 3H is axial) the 3H signal is broad 
due to two axial axial splittings with two equatorial equatorial splittings. The trans 
compound (311 equatorial) has a narrower 3H signal since this proton has no axial 
axial splittings, only axial equatorial and equatorial equatorial splittings (see Figure 
17). The integrals of the two signals showed that the ratio of the cis to trans 
compounds was 1.2 to 1 (see Spectrum 6). 
4.2.2 cisl trans 3-Methoxycyclohexylcarboxamide (47) 
This compound was prepared from 3-methoxycyclohexanecarboxylic (46) acid by 
treatment with thionyl chloride followed by aqueous ammonia. The product was 
recrystallized from ethyl acetate to give cisl trans-3- 
methoxycyclohexanecarboxamide (47). A 100 gM solution of this mixture gave 9, 
15 and 3% inhibition of PARP. 
4.2.3 Attempted Synthesis of 3-Methoxy-1,4-Dihydrobenzamide (48) 
The next class of inhibitors to be assessed was those with partial saturation of the 
aromatic ring. 3-Methoxy-1,4-dihydrobenzamide (48) was expected to be formed 
either by reduction of 3-methoxybenzoic acid (49) and functional group 
transformation of the acid to the arnide, or by reduction of 3-methoxybenzamide (4). 
Upon further reduction a number of tetrahydrobenzamides could be envisioned, This 
latter class of compounds would tell us about the extent of unsaturation necessary for 
inhibition and also where it was most effective. 
4.2.4 The Birch Reduction52 
Birch reductions are carried out in liquid ammonia with a dissolving metal (usually 
sodium) and an alcohol as a proton source. The effect of this reaction is to reduce 
aromatic systems to their dihydro, tetrahydro and fully reduced states. 'Me 
mechanism involves a single electron transfer process. Sodium donates an electron to 
the aromatic system to form a radical anion (50). The radical anion, 50, is then 
protonated to leave a radical (51) which receives another electron from sodium to 
form an anion (52). The anion (52) thus formed is protonated to form the dihydro 
product (53) shown in Scheme 7. 
4.2.4.1 Regioselectivity of the Birch Reduction53 
Regioselectivity - which bonds will be reduced - is seen within the Birch reduction. 
This phenomenon has been explained by molecular orbital theory. Thus, benzene is 
known to form 1,4-cyclohexadiene (53) rather than 1,3-cyclohexadiene (54). 
Molecular orbital treatment of the precursor cyclohexadiene anion shows that there is 
a larger electron density at the 3-position (rather than the equivalent 2- or 4-positions) 
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and hence protonation at this position gives the 1,4-cyclohexadiene product. The 
regioselectivity that is of relevance to the research described in this thesis occurs 
when the aromatic starting materials are substituted. Again molecular orbital theory 
has been used to explain the empirical substitution patterns observed for these 
compounds. 54 A compound with an electron donating group (eg -OMe) will direct 
an incoming electron away from the carbon to which it is attached. A compound with 
an electron withdrawing group will attract an electron toward the carbon to which it is 
attached. 
If 3-methoxybenzoic acid were reduced under Birch conditions then the predicted 
product would be the 1,4-dihydro acid. The electron withdrawing substituent - the 
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carboxylic acid - would attract an incoming electron and stabilise the negative charge 
produced, whilst the electron donating methoxy group would repel any incoming 
electrons: both these effects work in conjunction to give the product. 
4.2.4.2 Synthesis of 3-MethoxY-1,4-dihydrobenzoic acid (55) 
The title compound (55), prepared from 3-methoxybenzoic acid (49) by the Birch 
reduction, was an oil that could not be crystallized and began to decompose upon 
prolonged manipulation. However, a IH NMR spectrum of the compound was 
consistent with the proposed structure and also with the literature. 52 The H1 proton 
of this compound appeared as a broad multiplet (8 3.51) which was coupled to the H2 
doublet (8 4.68). The two vinyl protons H5 and H6 formed a multiplet (8 5.75), as 
did the H4'and H4" protons (8 ). The 13C NMR spectrum of this compound was not 
reported by the earlier workers but our determination was consistent with the 
structure of the acid. Due to the compounds instability no other characterization was 
attempted. 
The dihydro acid (55) was reacted with ethyl chloroformate and liquid ammonia but 
no 3-methoxy-1,4-dihydrobenzamide (48) was isolated. 
4.2.4.3 The Birch Reduction of 3-Methoxybenzamide (4) 
It was supposed that 3-methoxy-1,4-dihydrobenzamide (48) could not be prepared 
from 3-methoxybenzoic acid (49) because the manipulation of the unstable 
intermediate, 3-methoxy- 1,4-dihydrobenzoic acid (55), caused it's decomposition. 
Not only was the reoxidation back to the starting material envisioned but also 
migrations about the ting were possible. 
If 3-methoxybenzamide (4) could be directly converted to 3-methoxy-1,4- 
dihydrobenzamide (48) the manipulation and functional group inter-conversion of an 
unstable intermediate would be avoided. 
3-Methoxybenzamide (4) was prepared by treating 3-methoxybenzoic acid (49) with 
thionyl chloride to give the intermediate acid chloride (56). Quenching this with 
aqueous ammonia gave the desired product (4, see Scheme 8). 
3-Methoxybenzamide (4) was reduced under Birch conditions but did not give 3- 
methoxy-1,4-dihydrobenzamide (48), instead 3-methoxy-1,4,5,6- 
tetrahydrobenzamide (57) was produced. The structure of this compound was 
supported by its 1H NMR spectrum. This contained a multiplet (8 1.7 1) of four 
protons, the 5', 5" and 6', 6" protons. The Hl proton appeared as a broad multiplet (8 
3.01) whilst the methoxy protons gave a narrow singlet (8 3.52). Further, the 
0 0 0 
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vinylic proton appeared as a doublet (8 4.61) in the expected place for an enol ether 
and the amide protons were downfield and separate (8 5.86 and 8 6.01). 
Ibis result can be rationalized by supposing that initially 3-methoxy-1,4- 
dihydrobenzamide (48) was formed but underwent a bond migration. The bond 
migration formed the conjugated 3-methoxy-4,5-dihydrobenzamide (58) which was 
susceptible to further reduction under the reaction conditions. The initial bond 
I 
migration is a consequence of proton extraction at the I position, which in turn, is a 
consequence of the basicity of the alkoxide present. This phenomenon has been 
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studied in the case of 3-methoxybenzoic acid (49). When methanol was used as the 
proton source 3-methoxy- 1,4-dihydrobenzoic acid (55) was formed, but when ethanol 
was used 3-methoxy-1,4,5,6-tetrahydrobenzoic acid (59) was formed. 
55 The 
increased basicity of the ethoxide anion, over the methoxide anion, causes the 
necessary bond migration that allows further reduction of the benzene ring. 
The Birch reduction of 3-methoxybenzamide (4) was carried out with both ethanol 
and methanol as proton sources and for each case the tetrahydro product was 
obtained. The proton at the 1 position was more labile in the dihydro amide (48) than 
the dihydro acid (55). This is because, under the conditions of the reaction, the 
dihydro acid (55) exists as an anion, hence further deprotonation (to form a dianion) 
is difficult. However, the dihydro amide (48) does not exist as an anion and is 
therefore susceptible to deprotonation at the 1 position (and hence bond migration etc, 
see Scheme 9). 
4.3 N-Alkylnicotinamides 
These compounds were simple NAD+ analogues. They were synthesised both to 
determine their inhibitory activity and as precursors to the N-alkyl 
dihydronicotinamides. 
The compounds prepared were the N- methyl (60), ethyl (61) and benzyl (62) 
nicotinamides as their iodides - with the exception of benzyl which was the chloride 
(see Figure 18). '111ey were simply prepared by heating under reflux nicotinamide 
with the alkyl halide in ethanol. All were prepared in good yield and were easily 
purified by recrystallisation. 53,54 
4.3.1 Spectroscopic Properties of N-Alkylnicotinamides 
The IH NMR spectra of this class of compounds can be analysed by considering three 
aspects of the molecules: the alkyl substituent, the amide group and the heterocyclic 
ring system. 
So, considering the alkyl substituent, the protons (x to the positively charged nitrogen 
appear at about 8 5. Thus, the methyl protons of N-methylnicotinamide iodide (60) 
are represented by a singlet at 8 4.5 while the methylene protons of N- 
ethylnicotinamide iodide (61) are represented by a signal at 8 4.8. The protons of the 
methyl part of the latter compound (61) produpe a signal at 8 1.7. 'I'lle spectrum of 
the benzyl compound (62) was obtained by dissolving the compound (62) in D20 
rather than d6-DMSO and so the chemical shifts of the benzyl spectrum can only be 
cautiously compared't6 those of the methyl (60) and ethyl (61) compounds. The 
spectrum of the benzyl compound (62) is further complicated by the presence of an 
HOD peak which integrated for approximately two protons. The spectrum thus has 
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two singlets at 8 4.9 and 8 6.0 (internal standard: sodium salt of 
trimethylsilylpropanesulphonic acid). The heterocyclic signals within the spectrum 
correlate closely with the chemical shifts of the heterocyclic signals of the methyl 
(60) and ethyl (61) compounds and so upon this basis the methylene signal was 
assigned to 8 6.0 and the HOD peak to 8 4.9. The aromatic signals of the benzyl 
group appeared in the usual place (ca 5 7.6) as a narrow multiplet. 
The amide group has two characteristic signals which occur because of the partial 
double bond nature between the carbon and nitrogen atoms. The magnetically 
inequivalent protons appear close to 88 and 8 8.5. These signals are not present 
within the spectrum of the benzyl compound (62) because of proton deuterium 
exchange. 
The heterocyclic ring protons have similar chemical shifts and splitting patterns 
within this series of compounds (60,61 and 62). The signal furthest upfield, a double 
doublet, is the H5 proton (8 8.3 - 8.4). The H5 signal from the benzyl compound (62) 
appears as a triplet rather than a double doublet; this is a consequnece of the solution 
properties of the different solvents. The H4 proton appears as a doublet at 
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approximately the same position within all the spectra (8 9). Next the H6 proton 
appears as a double doublet (ca 8 9.4) and lastly the H2 proton appears as a singlet (8 
9.5). 
4.3.1.1 Potency of the N-AlkyInicotinamides 
. These compounds displayed little 
inhibition against PARP. This was thought to be a 
consequence of of an electron deficient aromatic ring and hence a diminished 
carbonyl electron donor capacity. Although these compounds were similar to NAD+ 
in terms of nicotinamide electronic structure they were dissimilar in that they 
obviously lack the sugars, phosphates and adenine. This result supports the tentative 
rationale used to explain the potency of 3-(12-(6-aminopurin-yl)dodecyoxy) 
benzamide (43, see Section 4.1.4.1). 
Compound No Alkyl Substituent % Inhibition 
(100 ýlm) 
60 Me 0,5 
61 Et 0,10 
62 Bn 0,0 
Table 12 
4.3.2 N-Alkyl-dihydronicotinamides 
These compounds were NADH analogues and were different in two respects from the 
NAD+ analogues: the hýterocyclic ring was not aromatic and the amide oxygen was 
more electron rich. The latter point arises because the nitrogen is no longer positively 
charged and also the nitrogen is conjugated to the oxygen. 
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The compounds in this class were all prepared by the reduction of the corresponding 
N-alkylnicotinamide salts with sodium hydrosulphite (see Scheme 10). 56,57 As 
expected these compounds were -unstable, being susceptible to atmospheric oxidation. 
The benzyl compound (63) was the easiest to prepare and gave a reasonable yield 
upon recrystallisation. The methyl and ethyl compounds (64 and 65) were less stable; 
the methyl compound (64) was prepared as an oil and could not be recrystallised. It 
was, however, pure by TLC -a single blue fluorescent spot - and 
1H NMR 
spectroscopy (see spectrum 7). The ethyl compound (65) was recrystallised with 
difficulty using low temperature (-30"C to O'C) recrystallisation techniques to give 
pure yellow crystals (see experimental for more details). 
The mechanism of this reaction is of interest: it was initially thought to be a single 
electron transfer (SET) process, as depicted in Scheme 11; however, there is literature 
evidence58 suggesting that an intennediate (16, in scheme 12) occurs along the 
reaction coordinate which then breaks down into the products. 
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4.3.3 Spectroscopic Properties of N-Alkyl-1,4-dihydronicotinamides 
The 1H NMR spectra of this class of compounds corroborate their structures and like 
the N-alkylnicotinamide salts (see Section 4.3.1), they can be analysed by considering 
three aspects of their molecular structure: the an-dde functional group, the alkyl 
substituent and the ring system. The simplest member of this class of compounds is 
N-methyl-1,4-dihydronicotinamide (64). Its spectrum will be analysed and 
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comparisons will be drawn between other members of its class and the N- 
alkylnicotinamide salts. 
4.3.1.1 IH NMR Spectrum of N-Methyl-1,4-dihydro 
nicotinamide (64) 
The N-methyl signal, which is (x to the ring nitrogen, appears as a singlet near 63 
rather than 85 as in the case of the N-alkylnicotinamide salts. This is a consequence 
of the lack of positive charge upon the nitrogen. Since the ring has been reduced it 
contains an alkyl methylene group at the four position. The signal for this group 
appears (8 3.06) as a double triplet covering a very narrow range of the spectrum (8 
3.05 to 8 3.07). These protons are coupled to the alkene protons H5 (J = 3), H6 Q= 
1.6) and H2 (J =1.6) forming the multiplet described. The other ring protons appear 
further downfield. The proton H5, appears at 8 4.66 which is further upfield than 
expected for a 1,4-dihydrocyclic ring system (eg the vinylic protons of 5,8-dimethyl- 
1,4-dihydronaphthalene appear at 8 5.78). 51 The H5 proton in this compound is 
pushed upfield by the electron donating capacity of the nitrogen atom in the manner 
0 
c 
0, 
NH2 
CIT) 
NH2 
N+ 
I R 
Electron Density Donation within an 
Y-Alkyl-1.4-dihydronicotinamide Ring 
Figure 19 
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shown (Figure 19). The multiplicity of this signal (1-15) is a double triplet. It is 
coupled to the H6 proton (J = 7.5) and the methylene (H4,4") protons V= 3). The 
coupling to the two methylene protons forms the triplet which is further split by the 
H6 proton. No long range coupling from H2 is seen. The next ring signal downfield 
is produced by the H6 proton which is next to the nitrogen atom. This signal appears 
as a double triple doublet. It is coupled to H5 (J = 8), the ring methylene protons 
(H4', 4"; J= 3) and the H2 proton (J = 1.6). Lastly, the proton between the amide 
function and the nitrogen, H2, appears as a doublet (J = 1.6). This proton is coupled 
to the H6 proton whilst no coupling to the methylene protons (H4', 4") is seen (see 
Spectrum 7). 
The 1H NMR spectrum of N-ethyl- 1,4-dihydronicotinamide (65) is similar to that of 
N-methyl-1,4-dihydronicotinamide (64). The methylene signal of the N-ethyl group 
overlaps with the ring methylene group and complicates the spectrum whilst the 
methyl group appears as a triplet at 8 1.11, the expected position for an alkyl group. 
The IH NMR spectrum of N-benzyl-1,4-dihydronicotinamide (63) is essentially the 
same as the earlier examples. The benzyl methylene protons appear as a singlet (8 
4.25) whilst the phenyl protons appear as a complex multiplet (8 7.28). 
4.3.2 Potency of the N-Alkyl-1,4-diliydronicotinamides 
Only the N-ethyl and N-benzyl compounds (65 and 63) could be prepared pure 
enough to be assayed. The assay found that both of these compounds showed some 
inhibition against PARP which supported the idea that electron carbonyl donor 
capacity was important for inhibition (Table 13). 
Compound No Alkyl 
Substituent 10 RM 
% Inhibtion 
30 gM 100 gm 
65 Et 0 0,48,37 
63 Bn 10 11,30,20 28,54,42 
Table 13 
4.4 Ben zoxazole-4-carboxamides 
It was known from earlier work that a fixed amide orientation and an electron rich 
meta substituent were necessary for inhibition of PARP. 26 The benzoxazole-4- 
carboxamides were synthesized with a view to exploit the entirely new and novel idea 
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Electrophillicity of Benzoxazole-4-carboxan-dde 
Scheme 13 
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of fixing the amide orientation by a'hydrogen bond. That is, the'hydrogen bond' 
between the amide proton and the benzoxazole ring nitrogen. These molecules also 
possess an electron rich meta substituent, the oxygen atom of the benzoxazole 
molecule. 
4.4.1 2-Alkylbenzoxazole-4-carboxamides 
A 2-alkylbenzoxazole-4-carboxamide was chosen for synthesis before the simpler 
homologue, benzoxazole-4-carboxamide (80), because the two position of the latter 
compound has been shown to be electrophilic. 60 Thus, if water behaved as an 
adventitious nucleophile it may attack the benzoxazole at the two position and ring 
open to the formamide (81, see Scheme 13). An alkyl substituent at the two position 
should donate electron density, by hyperconjugation, and thereby decrease the 
electrophilicity of the two position. 
CO2H 
NH2 (1) 
ÖCOH 
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C02Me 
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(i) HCI, MeOH 
82 
(ii) xylene, pyridinium p-toluenesulphonic acid and 
either: acetyl chloride or triethyl orthoformate 
(iii) NH3 fifty degrees fifteen kilobars 
The Preparation of 2-Methylbenzoxazole-4-carboxanýde 
Scheme 14 
4.4.2 2-Methylbenzoxazole-4-carboxamide (82) 
Me 
The title compound was chosen for synthesis since it was the simplest 2- 
alkylbenzoxazole-4-carboxamide and it could be prepared from readily available 
starting materials. It was made from commercially available 3-hydroxyanthranilic 
acid (2-amino-3-hydroxy-benzoic acid, 83) by the cyclisation of the ester, methyl 2- 
amino-3-hydroxybenzoate (84). This ester (84) was prepared by saturating a 
suspension of 83 in dry methanol with dry hydrogen chloride gas and heating this 
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mixture under refluxing conditions. The cyclisation to the benzoxazole was done 
with acetyl chloride which was heated with the ester (84) under refluxing conditions 
in m-xylene. Triethylamine was present to neutralise the hydrogen chloride formed 
and an acid catalyst (pyridinuium p-toluenesulphonic acid) was necessary for the 
reaction to go to completion. The amide (80) was formed by reacting the newly 
formed benzoxazole ester (85) with ammonia under pressure (see Scheme 14). 
The benzoxazole ester (85) was also prepared by the reaction of the methyl 2-amino- 
3-hydroxybenzoate (84) with methylacetimidate by heating a mixture of the two 
compounds in methanol under refluxing conditions. This reaction was found to 
require pyridinium p-toluenesulphonic acid (an acid catalyst) for it to go to 
completion and was not appreciably cleaner than the acetyl chloride reaction. 
4.4.3 1H NMR Spectroscopic Properties of 8 hydroxy-2- 
Methyl-4(31I) -Qu i nazol i none (821) 
Whilst the writing of this thesis was being completed, my successor Louise 
Pemberton59 obtained crystals of compound 82 suitable for X-ray analysis. The 
analysis showed to our surprise that the benzoxazole structure was incorrect. The 
correct structure for 82 is 8-hydroxy-2-methyl-4(3H)-quinazolinone (82'). It is now 
clear that subjecting the ester 85 to liquid ammonia at 50 OC/15 kBar causes some 
kind of molecular rearrangement. One possibility is that 82 is formed, but then 
suffers nucleophilic attack by ammonia at C-2 leading to cleavage of the oxazole and 
eventual formation of a pyrimidine ring: 
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Louise Pemberton has recently prepared the actual benzoxazole 82 (from the 
corresponding carboxylic acid, which was converted into its acid chloride and treated 
with aqueous ammonia at room temperature). She has now prepared a series of 
isomeric benzoxazole and quinazolinone carboxamides. The IH and 13C NMR of 
the benzoxazoles show characteristic differences from those of the quinazolinones. 
By comparing the spectroscopic data for compound 80 with data for authentic 
benzoxazole and quinazolinone carboxamides, it is concluded that 80 is actually 8- 
hydroxy-4(3M-quinazolinone (80'). Experiments are in progress to determine the 
precise mechanism of conversion of 84 into 821. 
A striking feature of the IH NMR spectrum of the title compound is the difference in 
chemical shift of the two acidic protons. One appears as a broad hump at 8 11.75 and 
is thought to be the proton that is at position three, whilst the other proton, the 
phenolic proton, appears as a narrower hump at 8 8.01. The aromatic protons appear 
as, two double-doublets and a triplet. The furthest downfield of these signals is the H5 
double-doublet (6 7.30) which is proximate to the carbonyl carbon. The triplet (8 
6.94) is H6 which lies next to the other double-doublet, H7 (8 6.88). Lastly, the 
86 
NH3 
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methyl appears as a singlet at 8 2.14. 
4.4.4 8-Hydroxy-4(3II)-Quinazoline (801) 
NH3 
IBM 
The title compound was prepared from methyl 2-amino-3-hydroxybenzoate (84) by 
reaction with triethyl orthoformate. The methyl benzoxazole-4-carboxylate (86) was 
transformed into the quinazoline by the reaction with ammonia at high pressure (cf 
Scheme 14 and see above). 
This compound has very similar spectroscopic properties to that of the 2-alkyl 
substituted analogue described earlier. 
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Table 15 Potency of the 2-Alkyl and Non-Substituted 
8-Hydroxy-4(3H)-Quinazolinones 
Compound No 80' 82' 
Substituent H Me 
% Inhibition at: 0.1 RM 17,18 
0.5 gM 18 59 
1.0 RM 36,39 63,68 
2.0 RM 54 
10 gm 78 92 
30 gM 87 92 
100 gm 95 96 
These compounds were the most potent inhibitors against PARP thus far synthesised 
at Newcastle upon Tyne. As such it was considered worthwhile to obtain their IC50's 
(gM) against PARP. The IC50 (gM) of 8-hydroxy-2-methyl-4(3M-quinazoline (82') 
is 0.385 ± 0.039 which compares favourably with the value obtained for the literature 
inhibitor, 3,4-dihydro-5-methoxy-1(2M-isoquinoli none, of 0.40 ± 0.033. 
Chapter 5 
5.1 The Nature of the Amide Functional Group 
It appears that the amide functional group is essential for the inhibitors of PARP to be 
potent. This can be rationalized by supposing that a hydrogen type bond is formed 
within the binding site of the enzyme to the carbonyl oxygen of the amide. A 
consequence of this is that the strength of this bond will depend upon the amount of 
electron density upon the oxygen. A large amount of electron density will give a 
strong bond and hence potency to the inhibitor. Thus, if this supposition is correct, a 
correlation between potency and the extent of electron donor carbonyl ability will be 
observed. Organic chemists often predict qualitatively the extent of carbonyl donor 
ability within molecules, thus an aromatic amide with an electron donating group at 
the para position has a stronger electron donor carbonyl group than the corresponding 
compound that has an electron withdrawing group at the para position. However, in 
order to determine a correlation between the extent of carbonyl donation and 
inhibitory potency, a quantitative measure of carbonyl electron donation capacity is 
required. 
5.1.1 The Determination of Charge Distribution About a Molecule 
A number of physical properties of a molecule depend upon charge distribution about 
that molecule. The measurement of these physical properties can thus give an 
indication of the extent of electron density upon the carbonyl oxygen of an inhibitor 
of PARP. The techniques used to measure some of these physical properties are: 
(i) X-ray Analysis 
(ii) NMR Spectroscopy 
(iii) IR Spectroscopy 
(i) X-ray Analysis 
X-ray analysis is a method that determines the charge distribution or (synonymously) 
electron density about a molecule. Hence, it is possible to use this technique to 
determine the electron density about the carbonyl oxygen of a potential inhibitor of 
PARP. 
(ii) NMR Spectroscopy 
The chemical shift of a nucleus is dependent upon the electron density about that 
nucleus. Thus, the less the electron density about the nucleus, the further downfield 
(the greater ppm) the nucleus' signal will appear within an NMR spectrum. This 
phenomenon can be applied very simply to the amide carbonyl group by measuring 
the chemical shift of this carbonyl carbon in the 
13C NMR spectrum of the molecule. 
Thus, the greater the electron density upon the oxygen, the less there is on the carbon 
and therefore the further downfield the 
13C NMR signal will appear. Thus, in 13C 
NMR spectroscopy there is a quick and convenient method for determining the 
amount of electron density upon the carbonyl carbon atom. Care must be used when 
applying this technique. The chemical shift of a nucleus is related to the electron 
density about that nucleus since an opposing magnetic field is created by the 
movement of these electrons. It is the strength of this magnetic field that is 
responsible for the chemical shift of the nucleus. However, the magnetic field caused 
by the electrons about the measured nucleus is not the only magnetic field within the 
molecule that can affect the measured nucleus. Fields created by electrons about 
bonds and nuclei at relatively large distances from the nucleus under inspection may 
be strong enough to alter the chemical shift of that nucleus. So for this reason, even 
though this technique is valid, it can only be applied with caution. 
(iii) IR Spectroscopy 
This technique probes the vibrational properties of the bonds of a molecule. Briefly, 
a sample is bathed in IR light to produce a spectrum (either by the continuous wave or 
Fourier transform experiment). The spectrum produced consists of a plot of 
absorbance against wavenumber (the reciprocal of wavelength); thus an absorbance is 
seen within the spectrum where the frequency of the IR vibration is equal to the 
vibrational frequency of a chemical bond within the molecule. 
Characteristic vibrational frequencies within IR spectra for the different carbonyl 
functional groups are seen with aldehydes (1740 - 1720 cm-1), ketones (1725 - 1705 
cm-1), carboxylic acids (1725 - 1700 cm-1), esters (1750 - 1735 cm-1) and amides (- 
1650 cm- 1 when primary and in solid state). 61,62 The cause of this difference can be 
ascribed to the proportions of the three forms of the carbonyl group shown in Figure 
21. Further, the proportions of these forms'a%Vand'c', is dependent upon the 
electronegativities of the substituents X and Y. The greater the electronegativities of 
X and Y, the greater the proportion of formW within the system. Similarly, the 
greater the electron donating capacities of X and Y the greater the proportion of form 
V. Also, it can be seen that the greater the amount of form'a', the higher the carbonyl 
stretching frequency (see Table 16). 
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Compound v(C=O)cm-l 
F. CO. F 1928 
F. CO. Cl 1868 
F. CO. H 1834 
cl. co. cl 1827 
H. CO. H 1745 
Table 16 
It follows that the greater the amount of form V, the lower the wavenumber of the 
carbonyl bond. 
In this technique there is an excellent probe for the determination of electron density 
upon the oxygen atom of the carbonyl bond. 
5.1.2 The Cephalosporins and Penicillins 
A similar situation exists in the cephalosporins and penicillins: a labile lactam, 
functional group. The lability of this group and hence drug activity has been 
investigated by researchers using a number of different techniques including IR 
spectroscopy. 63,64,65 It was known from biological work that the penicillins (88) 
and A3 - cephalosporins (89) were active against a number of strains of bacteria 
whilst A2 - cephalosporins (90) were found to be inactive toward the same strains of 
bacteria (see Figure 22 for structures). 
The crystal structures of these classes of compounds show that the lactarn nitrogen in 
RCON s 
C02H 
88 89 90 
Structures of the Cephalosporins and Peniciffins 
FIgure 22 
the biologically active comounds (88 and 89) is pyramidal whilst the similar nitrogen 
in the inactive compounds is planar. The biologically inactive compound was also 
found to have a shorter, carbonyl carbon to nitrogen, bond length. Finally, IR 
correlation studies showed that the biological activity of the compounds increased as 
the carbonyl lactam stretching bond increased. 
Compound V(co)/Cm-l Active 
Penicillins 1780-1770 Yes 
3- cephalosponn 
- 
ý 1776-1764 Yes [fA2 
- cephalospori s 1760-1756 No 
Table 17 
The biological activity of these compounds was also seen to increase with ease of 
basic hydrolysis of the lactarn amide bond. All these results can be rationalized by 
considering the two lactam canonical forms shown in Figure 23. 
In structure, 91a, the nitrogen of the P-lactarn is pyramidal, its carbonyl IR stretch is 
0gN 
91a 91b 
The Canonical Forms of the Beta Lactam Ring 
Rgure 23 
indicative of a short C=O bond and the lactara is susceptible to base hydrolysis. For 
the structure, 91b, to occur the ring must be planar, allowing the nitrogen lone pair to 
overlap with the C=O system. Ile single bond character of the carbonyl group gives 
the compound a shorter IR wavenumber value and further, this structure is not the 
optimum structure for base hydrolysis to occur (since the LUMO of the carbonyl 
carbon is occupied by the nitrogen lone pair electrons). It is structure 91a, that is the 
biologically active form and any compound that has a certain proportion of this 
canonical structure will have a greater biological activity. 
5.1.3 PARP Inhibitors and Activity-Structure Correlations 
By making comparisons with literature work it seems entirely probable that a 
correlation between PARP inhibitory potency and IR carbonyl amide stretch (or 13C 
chemical shift) will be seen. However, there are a number of reasons why a 
correlation may not be seen. 
In the previous activity-structure correlation study there has only been one parameter 
(lactam lability) that has been responsible for the compound's activity. In PARP 
inhibitors the full extent of structural properties other than that of the amide carbonyl 
is not known and in this way the correlation may be obscured. Thus, although the 
amide may have the optimum charge distribution it may have an inappropriate 
ill 
substituent elsewhere within the molecule making the inhibitor inactive. A means of 
avoiding this problem is to place the inhibitors into classes of similar compounds and 
only make comparisons within the same class. However, even when inhibitors belong 
to the same class of compounds correlations between the degree of inhibition of these 
compounds and their spectroscopic properties are difficult to make. Thus, the 3- 
(purine-9-alkyloxy)benzamides, as exemplified in tables 18 and 19 show no 
correlations. For example, 3-(6-chloropurine-5-pentyloxy)benzamide (38) shows 16 
% inhibition of PARP at 10 RM concentration whilst 3-(6-chloropurine-5- 
dodecyloxy)benzamide (40) shows practically no inhibition at the same concentration 
(10 gM). Their spectroscopic properties however have a mean deviation of 0.0105 
ppm between their 13C chemical shifts and a mean deviation of 2 cm- 1 between their 
IRC=o stretching frequencies. 
Table 18 
Compound 
Number 
8C C=O 
PPM 
IR(- 
. =O 
/ 
cm-1 10 gm 
Inhibition 
30 gM 100 LLM 
38 167.925 1680 16 38,45 68,71,4 
39 167.927 1686 26,31,3 Insol Insol 
40 167.946 1684 2,0 5,20 3 
Table 19 
Compound 
Number 
5C C=O 
PPM 
IR(- 
. =O 
cm- 1 10 ýlm 
Inhibition 
30 tiM 100 RM 
41 167.963 1682 16 38,45 65,69 
42 1 167.998 1678 41,29.20 1 NA I Tncr-d I 
1 43 
1 
167.986 1 1679 14,37 
- F52,51,50 - 1 
73, 
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Thus, for the technique of inhibition and spectroscopic property correlation to be 
tenable the compounds in question should show a large degree of inhibition and share 
the same mechanism of inhibition. 
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Chapter 6 
6.1 Vinyl Chloride 
Vinyl chloride (9), the starting material for the industrial synthesis of the plastic 
polyvinyl chloride (PVC), is established as a human carcinogen. Exposure to this 
compound over a period of time can lead to the rare cancer, angiosarcoma of the 
liver 
(so rare, that in 1974 there were only 20 to 25 cases per year of this cancer 
in the 
USA66 and only 3 to 4 cases per year in England and Wales67). Three of the 
reported cases of liver angiosarcoma occurred in workers at an American plant 
manufacturing pVC. 
68 Further investigation of the company personnel led to the 
identification of 2 cases who had died some years previously69 and to the 
identification of 2 additional cases among the current workers. 
70,71 A British study 
of 7000 men who were exposed to vinyl chloride in the manufacture of PVC between 
1940 and 1974, concluded that vinyl chloride could cause liver cancer in a very few 
workers exposed to the chemical. There was no evidence that vinyl chloride causes 
cancers other than those of the liver. 
72 
The ultimate carcinogen of vinyl chloride is produced by metabolic activation in the 
liver. Thus, inhalation of vinyl chloride and liver metabolism lead to the 
characteristic excretion products found in the host's urine (eg S-(2- 
hydroxyethyl)cysteine 92, N-acetyl-S-(2-hydroxyethyl)cysteine 93, S- 
carboxymethylcysteine 94 and thiodiglycolic acid 95). 
73,74,75,76,77 Application of 
the Ames test to vinyl chloride showed a greater mutagenicity when liver microsomes 
were present within the reaction medium. 
78 Furthermore, liver microsomes were 
found to catalyse the covalent attachment of vinyl chloride to macromolecules. 79 
Other studies have demonstrated liver microsomal. uptake of 14C-vinyl chloride and 
its transformation to protein alkylating metabolites in vitro. 80 Lastly, vinyl chloride 
metabolites have been shown to react with RNA both in vitro and in vivo to form 
1, N6-ethenoadenosine (96)81 and 3, N4-ethenocytidine (97). 82 
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The ultimate carcinogen of vinyl chloride is either chlorooxirane (10) or 
chloroacetaldehyde (11). Initially, chlorooxirane (10) is formed in the liver in the 
manner depicted in Scheme 15.74 This compound (10) then rearranges, either 
spontaneously or by acidic catalysis, to chloroacetaldehyde (11). Spontaneous 
rearrangement (nb the half life of chlorooxirane in aqueous solution at physiological 
pH was found to be 1.6 minutes)83 occurs when a carbon oxygen bond of the oxirane 
cleaves to a corresponding zwitterion (98a or 98b), which forms chlordacetaldehyde 
by either a 1,2-hydride (98a) or a 1,2-chloride (98b) shift. Acid catalysed 
rearrangement begins with oxygen protonation, which is followed by carbon oxygen 
bond cleavage to give the cation 99. Deprotonation of 99 forms an enol which 
tautomerises to chloroacetaldehyde (see Scheme 16). 
H+H 
cl 
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Both chlorooxirane (10) and chloroacetaldehyde (11) have been shown to be 
mutagenic, 83 but because chlorooxirane is more reactive than chloroacetaldehyde it 
has been suggested that the former compound is the ultimate carcinogen of vinyl 
chloride. 84,85 Even so, further studies have been undertaken to determine the 
mechanism of the mutagenesis caused by chloroacetaldehyde, 86 since this compound 
is exposed to DNA for a longer time than chlorooxirane. 
6.1.2 The Reaction of Chloroacetaldehyde with Nucleosides 
Chemical carcinogenesis occurs when a chemical interacts with the DNA of a cell. in 
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this process the integrity of the bases of DNA is corrupted and this, if not repaired, 
can lead to cell mutation. This cell mutation may lead to the formation of a cancerous 
cell. Therefore, an understanding of the chemistry between carcinogens and 
nucleosides will lead to a greater understanding of chemical carcinogenesis. 
Chloroacetaldehyde has been used to modify DNA and RNA with a view to 
investigating the structural and functional properties of these molecules. The 
conditions for these reactions were established using N9-methyladenine (100) and 
Nl-methylcytosine (101) as model compounds. 87 It was found that 
chloroacetaldehyde reacted with N9-methyladenine in slightly acidic aqueous solution 
to form N9-methylethenoadenine (102, see Scheme 17). Similarly, the interaction of 
Nl-methylcytosine with chloroacetaldehyde in acidic aqueous solution gave N1- 
methylethenocytosine (103, see Scheme 17). 'Ilie modification of these adenine and 
cytosine species under such mild conditions led to the investigation of the reaction of 
chloroacetaldehyde with the four common nucleosides. 
Aqueous solutions of ribonucleoside (each 0.0 1 M) were incubated with IM 
chloroacetaldehyde (pH. 2.0 - 5.0,50 OC). Adenosine (104) was found to form 
ethenoadenosine (96, optimum pH = 4-5) while cytidine (105) formed ethenocytidine 
(97, optimum pH = 3.5). However, no reaction was observed with uridine (106) or 
guanosine (107). The specificity of chloroacetaldehyde for the adenine and cytidine 
species was further confirmed by a paper chromatographic study. 
The products of the chloroacetaldehyde modification of nucleic acid bases, 1, N6- 
ethenoadenosine (96) and 3, N4-ethenocytidine (97), are fluorescent. 88 The special 
spectroscopic properties of these compounds suggest a number of applications eg the 
extended conjugation of I jV6-ethenoadenosine shifts its absorption spectrum to 
longer wavelengths allowing excitation to occur outside the range of the absorption of 
proteins and nucleic: acids. The fluorescence of 1, N6-ethenoadenosine (, max 415 nm 
in buffered aqueous solution at pH = 7.0) has a Stokes shift of 104.5 W mol-1, which 
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is in a favourable position for detection in the presence of protein fluorescence. The 
quantum yield for this compound was found to be close to 0.6 and it had a fluorescent 
lifetime of 20 nanoseconds, which meant that if it was bound to molecules as large as 
250 kDa, their rotation could still produce appreciable depolarisation of the emitted 
fluorescence. Ile biological activity of some of the adenine coenzymes was 
preserved to a large extent in the corresponding etheno compounds with certain 
enzymes. Both'etheno'ATP and ADP were found to be enzymatically active in tests 
with hexokinase, adenylate kinase, pyruvate kinase, phosphofructokinase, tyrosine- 
activating enzyme and polynucleotide phosphorolyase. 
6.1.3 Reaction Mechanism of Chloroacetaldehyde with either 
Adenosine or Cytidine 
One application of the base modification of nucleic acids by chloroacetaldehyde was 
the examination of the tertiary structures of tRNA's in solution. When a tRNA is 
incubated with a buffered chloroacetaldehyde solution89 any exposed adenine or 
cytosine moieties form etheno derivatives. For example, this technique was used to 
study the conformational changes occurring in yeast tRNAPhe after Y-base 
excision. 90 Before tRNA's were modified with chloroacetaldehyde the reaction at the 
monomer level was re-investigated. 91,92,93 The optimum pH of the reaction 
(adenine at pH = 4.5 and cytosine at pH = 3.5) was confirmed, but at higher pH's 
guanine modification was observed. The specificity of the reaction for adenine and 
cytosine was therefore maintained by keeping the pH in the region 3 to 4. 
Ile reaction mechanism proposed93 consisted of alkylation, cyclisation and 
dehydration. Thus, when the reaction was followed by TLC an intermediate (either 
the alkylation product or the cyclisation product) was observed. Attempts at isolating 
this intermediate (by preparative TLC) gave a compound that was contaminated (- 
5%) by the etheno product. However, analysis of this mixture showed the following: 
119 
no covalently bound chlorine was present within the intermediate; the molecular mass 
was that of the hydrated etheno product; III NMR spectroscopy (of the cytosine 
system) clearly showed the presence of an ABX system. All of these facts led to the 
conclusion that the intermediate is the cyclic compound that occurs before 
dehydration to the etheno product. The reaction mechanism can be described by 
Scheme 18. In the mechanism proposed (Scheme 18), the orientation of attack of 
chloroacetaldehyde is assumed. There is no direct evidence that the exocyclic 
nitrogen of the base reacts with the carbonyl carbon of chloroacetaldehyde, whilst the 
endocyclic nitrogen of the base reacts with the methylene carbon of 
chloroacetaldehyde. If the exocyclic nitrogen of the base reacts with the methylene 
carbon of chloroacetaldehyde and the endocyclic: nitrogen of the base reacts with the 
carbonyl carbon, a reaction sequence can be envisaged (see Scheme 19) that is 
consistent with the data presented above. A hydrated etheno intermediate is formed 
that has no covalently attached chlorine, has the same molecular mass as the hydrated 
etheno compound in Scheme 18 and should have an ABX system in its IH NMR 
spectrum. 
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Nomenclature. The compound ethenoadenosine (96) has the systematic name 3-P-D- 
iibofuranosylimidazo[2,1-i]purine, while ethenocytidine (97) has the systematic name 
5,6-dihydro-5-oxo-6-p-D-ribofuranosylimidazo[1,2-c]pyrimidine. The systematic 
names will be used as a basis for naming any intermediates, while the etheno names 
will be kept for the end products. The systematic numbering is given in Figure 24. 
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The following work investigates the orientation of attack of chloroacetaldehyde 
to nucleic acid bases. 
The literature suggests that the orientation of attack is such that the exocyclic amine 
reacts with the carbonyl carbon. This seems to be the case when 2-bromobutanal 
reacts with adenosine, 
94 because the crystal structure of the product shows that it is 
7-ethyl-3-p-D-ribofuranosylimidazo[2,1-i]purine (108, see Scheme 20). 
However, this result does not prove the orientation of attack of chloroacetaldehyde 
with adenosine. 
6.1.3.1 The Carbinolamine Intermediate 
The orientation of the attack of chloroacetaldehyde to, for example, adenosine, is 
reflected in the structure of the carbinolamine intermediate formed. If the carbonyl 
carbon of chloroacetaldehyde is bonded to the exocyclic nitrogen, ring closure forms 
7,8-dihydro-8-hydroxy-3-5-D-ribofuranosylimidazo[2,1-ilpurine (109), while the 
opposite chloroacetaldehyde orientation forms 7,8-dihydro-7-hydroxy-3-p-D- 
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ribofuranosylimidazo[2,1-i]purine (110, see Figure 25 and Figure 24 for numbering 
system). 
6.1.3.2 Synthesis of N6. (2,2-DimethoxYethyl)adenosine (111) 
In order to investigate the chloroacetaldehyde/adenosine reaction, N6-(2,2- 
dimethoxyethyl)adenosine (111) was prepared. The synthesis of this molecule, in 
terms of the chloroacetaldehyde/adenosine reaction, means that: 
(i) the exocyclic nitrogen (A of adenosine has displaced the chloride anion of 
chloroacetaldehyde (ie the orientation of attack of chloroacetaldehyde to 
adenosine has been unambiguously defined) 
reaction to the cyclic intermediate can be easily effected by mild acid catalysis 
and thus, the cyclisation (and subsequent dehydration) can be monitored. 
The compound (111) was prepared by treating 6-chloropurinriboside (112) with 2,2- 
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dimethoxyethylamine (113, see Scheme 21). The IH NMR spectrum of this 
compound was similar to that of adenosine. 95 The purine signals appeared in similar 
positions (H2,8 8.40 and H8,8 8.25) with the proton attached to the exocyclic 
nitrogen (0) appearing at 8 7.87. The signals for the protons attached to the ribose 
part of the molecule appeared in the same position as the corresponding adenosine 
signals. The ethyl protons were buried within this 'sugar' region. Thus the HT 
multiplet had an integral that was consistent with the presence of an extra proton and 
this signal was assigned to the acetal carbon proton. Similarly, the methylene protons 
(cc to the acetal carbon proton) were found within the H5', 5" multiplet. The methoxy 
protons appeared as a singlet (8 3.30). 
6.1.3.3 The Acid Catalysed Decomposition of N6. (2,2- 
Dimethoxycthyl)adenosine 
A solution of N6-(2,2-dimethoxyethyl)adenosine (111) was dissolved in d4-methanol 
and acidified by the addition of acetyl chloride (1.1 equivalents). By placing this 
124 
mixture into the probe of an NMR spectrometer and heating to 60 "C the acid 
catalysed decomposition of this compound was observed, over a period of 64 hours, 
by IH NMR spectroscopy. The decomposition of this compound was found to follow 
the route depicted in Scheme 22. 
Tle rationale advanced for the acid catalysed decomposition of N6-(2,2- 
dimethoxyethyl)a4enosine, as depicted in Scheme 22, was elucidated by the 
consideration of the IH NMR spectra obtained from the decomposition of this 
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compound. This rationale can be illustrated with five IH NMR spectra taken at time 
zero (or zero plus the time taken to load the NMR spectrometer and determine a 
spectrum), 40 min, 2 h, 8h and 64 h. 
At time zero (spectrum 8) all four compounds depicted in Scheme 22 are present 
within the reaction mixture. The two hemi-acetallaminals (114 and 115) are. 
represented by the protons of the NI-N6 ethyl bridge. Thus, the proton at position 7 
of the two molecules appears as a broad doublet (8 6.5). This signal is assumed to be 
made up of two overlapping double-doublets (cf spectrum 12, after 64 h). The two 
protons at the 8 position of one of the hemi-acetal/aminals begins to appear at 8 4.49 
but does not appear as a double-doublet since the signal is masked by the HY 
nucleoside signal. The two acetals (111 and 116) are represented by their 2-ethyl 
proton which appears as a triplet for each molecule. The depurinated acetal (116) has 
a triplet which appears at 8 4.87 while the analogous proton of the starting material 
(111) lies beneath the nucleoside H2proton's signal. The methylene signals (I-ethyl) 
of either acetal were not distinct within this spectrum. 
Ile second spectrum (spectrum 9,40 min later), shows a relative increase in the 
amount of the hemi-acetal/aminals present, as represented by the signal at 5 6.5. 
Another feature of this signal was that it had slightly resolved itself into a double 
doublet at its apex. This indicated that, of the two hemi-acetal/aminals present, one 
of them was beginning to predominate (the depurinated 7-methoxy-3,7,8- 
trihydroimidazo[2,1-i]purine, 115). Further, the part of the double doublet in view, 
which represents the methylene group at the 8 position of 7-methoxy-3,7,8- 
trihydroimidazo[2,1-i]purine (115), had increased in size. The acetal triplet of the 
starting material (8 4.79) had markedly decreased in size, which was to be expected 
since this signal was affected by both depurination and cyclisation. The acetal triplet 
of the depurinated compound (116,8 4.87) appeared slightly more distinct as the HT 
nucleoside starting material signal decreased in size. 
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Two hours later (spectrum 10) the presence of the hemi-acetal/aminals had increased, 
which was indicated by the presence of the double doublet (S 6.5) representing the 
proton on carbon 7 of these compounds. The signals produced by the two protons on 
carbon 8, two double doublets (8 4.5 and 8 4.3), were increasing in size and clarity. 
The depurinated acetal, represented by the triplet (S 4.87) produced by the proton on 
the acetal carbon, was now very prominent. 
After eight hours (spectrum 11) the reaction was essentially complete. Ile double 
doublet (8 6.5) representing the proton at position 7 of 7-methoxy-3,7,8- 
trihydroimidazo[2,1-i]purine (115) was clearly resolved. The double doublets 
representing the two protons at the 8 position of this compound (115) were clearly 
represented (8 4.5 and 8 4.3), whilst the acetal proton of the depurinated compound 
appeared as a distinct triplet at 8 4.89. Finally, this spectrum indicated that the two 
depurinated compounds were in a proportion of about one to one. 
The last spectrum (number 12, sixty four hours) showed no difference from that taken 
at eight hours. 
6.1.3.4 The Depurination of N6. (2,2-Dii-nethoxYctliyl)adenosine 
Throughout the course of the acid catalysed decomposition of N6-(2,2- 
dimethoxyethyl)adenosine depurination occurs, ie the bond between N9 of the purine 
and Cl'of the sugar is cleaved. This process for adenosine has been shown to be 
unimolecular and acid catalysed (AI), 96 which is what is expected for N6-(2,2- 
dimethoxyethyl)adenosine. Under the conditions of the reaction, upon depurination, 
the sugar initially forms a mixture of a- and P-D-methylribofuranosides (117 and 
118, see Scheme 23). The two furanosides formed are not stable but exist in a 
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dynamic equilibrium with their corresponding pyranosides (cc- and P-D- 
methylribopyranosides 119 and 120, respectively). Protonation of the anomeric 
oxygen of a furanoside and attack by methanol at the anomeric carbon causes the 
molecule to ring open to a dimethyl acetal (121). Ring closure with the 5'-OH group 
rather than the 4'-OH forms the pyranosides. The pyranosides thus formed can revert 
to the furanosides in a similar manner and hence an equilibrium mixture of the four 
molecules is created within the reaction. The (x and D anomers may be formed by two 
routes. The methoxy group of an anomer may be protonated and subsequently depart 
from the molecule to leave a cation (eg 122, Scheme 23). Attack of this cation by 
methanol at either face of the anomeric carbon will form either an cc or D anomer. 
The other route is via the dimethyl acetal which can ring close in the manner 
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120 
described above but with attack at either face of the anomeric carbon. (see Scheme 
24). 
The acid catalysed depurination of N6-(2,2-dimethoxyethyl)adenosine and subsequent 
mutarotation of the released D-methyhiboside is described below and is presented as 
further evidence to corroborate the rationale depicted in Scheme 22. 
At zero time (spectrum 8) the anomeric proton of the starting nucleoside is 
predominant and appears as a doublet at 8 6.18. The hemi-acetal/aminal (114) 
anomeric proton appears next to the starting material signal (8 6.19) as a very small 
doublet. Further downfield in this spectrum it is possible to see that depurination has 
begun by the presence of the two furanosides. These two sugars are represented by 
their anomeric protons: a doublet at 8 5.05 (a-D-methylribofuranoside 117) and a 
singlet at 8 4.92 (0-D-methylribofuranoside 118). 
In spectrum 9 (determined forty minutes later) the two anomeric doublets of the 
nucleosides, Ill and 114, (5 6.19 and 8 6.18, respectively) are in equal proportion 
but have decreased in size. Meanwhile the proportions of the two (X- and D-D- 
methylribofuranosides have increased but it is not possible to determine whether or 
not any pyranosides are present within the system. This is because a signal from 
0 
OH 
OMe 
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1134 
another part of the molecule occupies the region where these signals are expected to 
occur (see below). 
Two hours later (spectrum 10), the two nucleosides have almost completely 
disappeared whilst the two furanosides are clearly present with P-D-methylfuranoside 
(118) in predominance. A trace amount of a-D-methylribopyranoside (119) is seen at 
5 4.65, but as yet it is not possible to say whether or not there is any P-D- 
methylribopyranoside (120) present. 
Spectrum II (eight hours later) clearly shows the presence of the four mutarotated 
molecules of D-methylriboside, with the D-D-methylribopyranoside (120) present in a 
slightly larger amount than the corresponding P-D-methylribofumnoside (118). 
Sixty four hours later (spectrum 12) the four sugar molecules appear to be in the same 
proportion as they were after eight hours. Unfortunately cc-D-methylribofuranoside 
(117) is indicated in this spectrum only by the presence of a shoulder on the methanol 
OH peak. 
In order to corroborate the rationale depicted in Scheme 22, the following compounds 
were synthesised: 
(i) N6-(2,2-dimethoxyethyl)adenine (116) 
(ii) 7-methoxy-3,7,8-trihydroimidazo[2,1-ilpurine (115) 
(iii) P-D-Methylribofuranoside (118) 
and their IH NMR spectroscopic properties determined. Further, the 1H NMR 
spectroscopic properties of P-D-methylribofuranoside were determined after standing 
in acidified d4-methanol overnight and an attempt was made to synthesise 7,8- 
dihydro-7-methoxy-3-p-D-ribofuranosylimidazo[2,1-ilpurine (114). 
6.1.3.4 (i) The Synthesis of N6-(2,2-Dimethoxyethyl)adenine (116) 
The synthesis of the title compound was attempted by employing the same reaction 
conditions which were used in the synthesis of N6-(2,2-dimethoxyethyl)adenosine. A 
mixture of 6-chloropurine, 2,2-dimethoxyethylamine and triethylamine was stirred 
together in DNIF, but no reaction was observed by TLC. This was thought to be 
because triethylamine extracted the N9 proton from 6-chloropurine to form a 
negatively charged species which repelled any nucleophiles that were present in the 
system. An attempt was made to overcome this problem by synthesising the 
protected purine: 6-chloro-N9-dimethylsilylthexylpurine. However this reaction 
proved difficult to follow and the silylated purine was never isolated. 
A search of the literature was then made in an attempt to find a model compound, ie a 
compound that was prepared from 6-chloropurine (124) and a nitrogen nucleophile. 
'Me model compound found was N6-benzyladenine (123) which was prepared by 
heating a mixture of 6-chloropurine and benzylamine (2.1 equivalents) in 2- 
methoxyethanol under refluxing conditions. This method was adapted to the 
preparation of the title compound by replacing benzylamine with 2,2- 
dimethoxyethylamine. Upon work up of the reaction mixture the title compound was 
obtained in good yield (see Scheme 25). 
The IH NMR Spectrum of N6. (2,2-DimethoxyethyI)adenine (116) 
The N9 proton of the title compound appeared furthest downf ield (8 13.04) as a broad 
singlet. The two purine peaks, H2 (8 8.03) and H8 (8 8.21), appeared next to the N6 
proton's signal (a broad singlet at 8 7.65). The ethyl protons were poorly resolved 
cl 
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with the 2-ethyl proton appearing as a broad singlet (8 4.74) while the I-ethyl protons 
appeared as a broad singlet (8 3.69). Lastly, the methoxy protons appeared as a 
singlet at 5 3.38. 
6.1.3.4 (ii) The Synthesis of 7-Methoxy-3,7,8-trihydroimidazo 
[2,141purine (115) 
The title compound was prepared by heating a mixture of N6-(2,2- 
dimethoxyethyl)adenine (116) and D-camphorsulphonic acid (1.1 equivalents) in 
acetonitrile under refluxing conditions. The apparatus was fitted with a Dean-Stark 
trap which had its solvent dead volume replaced with fresh solvent on an hourly basis. 
The reaction was thought to be a reversible reaction. By replacing the solvent, the 
concentration of the methanol in the system, which is liberated upon cyclisation, was 
decreased to zero. In this way the reaction was taken to completion (see Scheme 26). 
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The 1H NMR Spectrum of 7-Methoxy-3,7,8-trihydroimidazo[2,1-i]purine (115) 
The N3 proton of the title compound appeared at 8 13.09. The purine protons, (H5 
and H2) appeared at 8 8.75 and H8 8 8.35 (respectively). The proton on carbon seven 
appeared as a double doublet (8 6.25) coupled to two other double doublets (S 4.18 
and 8 3.98) which are the protons on carbon eight. Lastly, the methoxy protons 
appear as a singlet at 8 3.50. 
6.1.3.4 (iii) The Synthesis of P-D-Methylribofu ran ose (118) 
To a methanolic solution of D-ribose was added a catalytic amount of acetyl chloride; 
this mixture was then stirred and the reaction followed by TLC. After fifty minutes 
the starting material had disappeared and the reaction was quenched with sodium 
carbonate. In this manner the kinetic product P-D-methylribofumnose (118) was 
obtained after work up and purification. (It was thought that the (x anomer (117) was 
also formed but this did not crystallise out in the work up procedure). 
The 1H NMR spectrum of the title compound has a distinctive singlet peak at 8 4.92 
which represents the anomeric proton Hl'. The remaining protons are represented by 
multiplets appearing between 8 4.40 and 8 3.60, with the methoxy protons appearing 
as a singlet (8 3.52). 
A solution of P-D-methylriboside was prepared in d4-methanol and acidified by a 
catalytic amount of acetyl chloride. This mixture was left to stand overnight and a 
1H NMR spectrum of the solution was obtained. This showed four anomeric protons 
indicating the presence all of the four forms of D-methylriboside. The anomeric 
protons of the four compounds appeared as follows (ref): 
a-D-methylribofuranoside (117) 
P-D-methylribofuranoside (118) 
P-D-methylribopyranoside (120) 
a-D-methylribopyranoside (119) 
8 5.09 doublet 
8 4.92 singlet 
8 4.81 doublet 
8 4.71 doublet 
Tberefore, the 1H NMR evidence presented above supports the rationale of the acid 
catalysed decomposition of N6-(2,2-dimethoxyethyl)adensosine depicted in Scheme 
22. 
6.1.3.5 The Attempted Synthesis of 7,8-diliydro-7-metlioxy-3-p- 
D-ribofuranosylimidazo[2,1-i]purine (114) 
In order to substantiate further the rationale of the acid catalysed decomposition of 
N6-(2,2-dimethoxyethyl)adenosine (111), it was considered necessary to synthesize 
7,8-dihydro-7-methoxy-3-0-D-ribofuranosylimidazo[2,1-ilpurine (114). In principle, 
1 
_, IQ 
this could be done by attaching a suitably modified ribose, to 7-methoxy-3,7,8- 
trihydroimidazo[2,1-ilpurine (115), a process known as nucleoside synthesis. Two 
requisites are necessary to achieve this process: the bond formed must be 0 and the 
sugar must react as a furanoside. Both of these requirements are usually satisfied by 
initial sugar modification. For example, 2-deoxyadenosine97 (125) was formed when 
6-chloropurine (124) and 1-chloro-2-deoxy-3,5-di-0-p-toluyl-ec-D- 
erythropentofuranose (126) were reacted together and the product modified by 
methanolic ammonia. In this case the sugar was locked into its furan form by the 
initial formation of 2-deoxy-methylribofuranoside (127). This compound was then 
converted to the protected chloride (126) in the manner shown in Scheme 27.98 
Before adapting this literature procedure to the synthesis of 7,8-dihydro-7-methoxy-3- 
P-D-ribofuranosylimidazo[2,1-ilpurine (114) a novel preparation of 2- 
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deoxynucleosides was explored. This consisted of the reaction of a base with 1,3-(5- 
(2,2'-dimethoxytrityl))-2-deoxyribofuranose carbonate (128) which was prepared by 
treating 2-deoxy-D-ribose (129) with 2,2-dimethoxytriyltetrafluoroborate to give 5- 
(2,2'-dimethoxytrityl)-2-deoxyribofuranose99,100 (130). This reaction locked 2- 
deoxy-D-ribose into its furanose form which was about to be activated by forming the 
carbonate (128, see Scheme 28). 
The suitability of triphosgene (which was thought to be safer than phosgene) was 
tested by reacting it with 1,2-diphenylethanediol (131). The reaction yielded the 
carbonate cis-4,5-diphenyl[1,3]dioxalan-2-one (132) but unfortunately the reaction 
conditions were not applied to 5'-(2,2'-dimethoxytrityl)-2'-deoxyribofumnose (128). 
6.1.3.6 The Dehydration of the Carbinolamine Intermediate 
When chloroacetaldehyde reacts with adenosine, ethenoadenosine is formed by 
dehydration of a carbinolamine intermediate (either 109 or 110, Figure 25). This 
dehydration goes via one of two carbocations, the nature of which is dependent upon 
the precursor carbinolamine. Thus, the proposed 7,8-dihyro-8-hydroxy-3-0-D- 
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ribofuranosylimidazo[2,1-i]purine intermediate (109) dehydrates via the styreneoidal 
carbocation 133, while the proposed 7,8-dihyro-7-hydroxy-3-p-D- 
ribofuranosylimidazo[2,1-i]purine intermediate (110) dehydrates via the 
orthoquinoidal carbocation 110, as depicted in Scheme 29. 
Applying this rationale to the acid catalysed decomposition of N6-(2,2- 
dimethoxyethyl)adenosine, loss of methanol can only occur via the orthoquinoidal 
carbocation. No ethenoadenosine was formed under the conditions of the 
decomposition (1.1 equivalents of acid, 60 T, 64 hrs) therefore, it appears that 
(irrespective of the differing leaving group abilities of methanol and water) the 
orthoquinoidal cation presents a significant energy barrier towards ethenoadenosine. 
142 
6.1.3.7 The Deuteriation of Ethenoadenine (133) 
Two mechanistic pathways have been described for the conversion of adenosine, by 
chloroacetaldehyde, to ethenoadenosine. These two postulated pathways are 
dependent upon the orientation of attack of chloroacetaldehyde to adenosine, with 
each proposed route forming its particular carbinolamine (Figure 25,109 or 110), 
which dehyrates via its particular carbocation (either 134 or 135, Scheme 29) to 
ethenoadenosine. If one of the two proposed carbocations presents a lower energy 
pathway to ethenoadenosine, then the carbinolamine and hence 
chloroacetaldehyde/adenosine orientation that creates this particular carbocation is the 
one that occurs. A method of determining which of the two carbocations is the most 
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The Deuteriation of Ethenoadenine 
Scheme 30 
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accessible is provided by the deuteriation of ethenoadenine. (Ethenoadenine rather 
than ethenoadenosine was chosen for simplicity). By heating ethenoadenine in 
acidified d4-methanol a proton may be exchanged for a deuterium via one of the two 
carbocations shown in Scheme 30. Further, which particular proton is exchanged 
(HIO or HI 1: nb if ethenoadenine is named 3-hydro-imidazo[2,1-i]purine position 10 
becomes position 8 and position II becomes 7) will depend upon which mechanistic 
pathway is followed. Exchange of HIO occurs via an orthoquinoidal carbocation I 
(136) while HI I exchange occurs via a styreneoidal. carbocation (137, see Scheme 
30). Therefore, IH NMR spectroscopy can determine which proton has been 
exchanged. 
6.1.3.7.1 The 1H NMR Spectrum of Ethenoadenine (133) 
The IH NMR spectrum of the title compound contained four signals which were 
assigned as follows: 
Ethenoadenine 3-Hydro-imidazo[2,1-il 
purine 
Chemical Shift 
H2 H5 89.32 
H8 H2 88.43 
H10 H8 88.21 
1111 H7 87.76 
Table 18 
The following work is described using the etheno numbering system. A NOESY 
spectrum of this compound showed that a strong correlation existed between 1110 and 
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H1 1 and a weak correlation was observed between HI I and H2. No other 
correlations were observed. 
The solution was then acidified (1.1 equivalents of acetyl chloride) causing the 
ethenoadenine to precipitate. This was redissolved by heating and a IH NMR 
spectrum taken at 60 'C. When the spectrum was observed there were three peaks at: 
8 8.90,8 8.27 and 8 7.88. It was not possible, using this evidence, to say which 
proton had been exchanged. 
The reaction mixture was neutralised by passing it through an ion exchange column, 
the solvent removed and the compound dried under high vacuum. The mixture was 
then redissolved in d4-methanol and gave a IH NMR spectrum which showed the 
presence of five peaks. These peaks were all broad singlets, the first appearing at 8 
9.38 was assigned to 1-12; the next peak, which had a smaller integral, was assigned to 
118 (S 8.48); a slightly smaller peak appeared next at 8 8.28 which was thought to be 
H10. A small peak, that did not integrate, appeared at 5 7.81 which was thought to be 
the remains of the exchangeable H1 I signal. (A relatively large peak was observed at 
8 7.55 - thought to be an unknown decomposition product of the reaction). 
6.1.3.8 Conclusion 
The reaction mechanism of the formation of ethenoadenosine from 
chloroacetaldehyde and adenosine can be inferred from our experimental results. The 
acid catalysed decomposition of N6-(2,2-dimethoxyethyl)adenosine studied by III 
NMR suggests that the orthoquinoidal pathway is a hindrance, in which case the 
accessible intermediate is the styrencoidal carbocation (134). This carbocation is 
derived from 7,8-dihydro-8-hydroxy-3-p-D-ribofuranos'ylimidazo[2, I-i]purine (109) 
formed when the carbonyl carbon of chloroacetaldehyde reacts with the exocyclic 
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(N6) nitrogen of adenosine and the NI nitrogen reacts with the methylene carbon of 
chloroacetaldehyde. 
The results of the ethenoadenine deuterium exchange reaction also indicate that the 
mechanistic pathway is via the styrenoidal cation. 
In conclusion, our results support the initial assumption of the Polish research 
workers. The reaction intermediate observed during the formation of 
ethenoadenosine from adenosine by chloroacetaldehyde is 7,8-dihydro-8-hydroxy-3-0 
-D-ribofuranosylimidazo[2,1-i]purine (109). 
Future Work 
Direct evidence of the mechanism of the reaction of chloroacetaldehyde could be 
obtained by isotopic labelling studies. 
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Chapter 7 
7.1 Materials and Methods 
1.1 Chemicals 
The major sources of chemicals were the Aldrich Chemical Company, BDH Limited, 
Janssen Chemicals and the Sigma Chemical Company. 
Unless other wise stated, the chemicals were used as supplied without further 
purification. 
7.1.2 Solvents 
The solvents used were either Analar grade, which were used directly, or standard 
laboratory grade purified using the methods outlined in the Newcastle University 
Department of Chemistry research guide or in Perrin and Armarego. 101 
7.1.3 Methods 
Nitrogen was obtained from a standard BOC industrial cylinder. Thin layer 
chromatography (TLC) was done on aluminium backed Kieselgel 60 F254 plates 
(Merck catalogue number 5554), 0.2 mm thickness. Flash chromatographyl02 was 
done with C60-H (40 - 60 gm) silica gel from Rhone - Poulenc. Thin layer 
chromatograms were taken in the usual way except when an acid chloride was being 
detected. In this instance a small amount of the reaction mixture was added to 
methanol (which contained a catalytic amount of triethylamine). A thin layer 
chromatogram was determined from this mixture: the amount of ester observed was 
thought to represent the amount of acid chloride present in the reaction mixture. 
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7.1.4 Instrumentation 
Elemental Analysis Combustion analyses were performed using a Carlo Erba 
1106 CHN analyser. 
Infra - Red Spectrometry 
Infra-red spectra were recorded on a Nicolet 20-PC 
Fourier Transform IR spectrophotometer. 
Mass Spectroscopy Mass spectra were recorded on a Kratos 
MS80 RF spectrophotometer. 
Melting Points Melting points were determined using a Kofler Block Hot 
Stage apparatus and are uncorrected. 
Nuclear Magnetic Resonance Spectroscopy 
IH, 13C and 31P NMR spectra were recorded on either a 
Hitachi Perkin Elmer R24B (60 MHz), a Bruker WP-200 (200 MHz), 
or a Bruker WM-30OWB (300 MHz) NMR spectrometer. 
Ultra violet Spectroscopy 
UV spectra were recorded on a Kontron 
UVIKON-810 spectrophotometer. 
7.1.4 PARP Assay 
This assay was carried out by Dr B Durkacz at: 
The North of England Cancer Research Unit, The Royal Victoria Infinnary, 
Victoria Road, Newcastle upon Tyne. 
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NMR Parameters for NAD+/NADII Determination 
Proton and 13C NMR spectra were recorded on a Bruker AMX500 spectrometer at 
measuring frequencies of 500.13 and 125.76 MHz respectively using samples 
dissolved in D20 in 5mm od soda glass tubes. For the proton spectra the residual 
HOD resonance was suppressed by pre-saturation and typically 64 transients were 
acquired into 32768 data points. A sine-bell weighting function was applied to the 
FID which was then zero filled prior to Fourier transforination into 65536 data points 
over a spectral width of 16 ppm. Proton chemical shifts were determined relative to 
internal dioxane at 5 3.74 ppm. For the 13C spectra 2048 transients were acquired 
under proton decoupling by the waltz- 16 sequence into 65536 data points and 
transformed after application of a 0.5 Hz exponential weighting function into 65536 
data points over a spectral range of 160 ppm. 13C chemical shifts are relative to 
TMS at 80 ppm. 
Two dimensional proton double quantum filtered COSY spectra were obtained using 
a 900-tl-9011 900 - acquire pulse sequence with appropnate phase cycling. The HOD 
resonance was suppressed by pre-saturation and typically 8 transients were acquired 
for each value of tj to yield a 512 x512 data matrix which was subject to a sine-bell 
multiplication and zero-filling in each dimension prior to Fourier transformation into 
a 1024 x 1024 data matrix. Base-line smoothing routines were used in each 
dimension, and some artifacts were removed by symmetrization. Two dimensional 
rotating frame nuclear Overhauser effect (ROESY) spectra were obtained similarly 
using a 90'x-tl-(spin-lock)y - acquire pulse sequence with a typical spin-lock time of' 
350 ms and spin-field of ca 12000 HZ- 
Two dimensional 1301H correlatiorý spectra were acquired by 13C observation using 
sequences due to Bax103,104 which for one-bond correlations included a binary 
rotation pulse to remove homonuclear coupling in the proton (t I) dimension and with 
4 
proton decoupling during acquisition. Normally ca 96 transients were acquired into 
2048 data points for each 512 values of tj and the resulting data matrix was 
transformed into 2048 x 1024 data points after zero-filling in the tj dimension and 
multiplication by sine-bell weighting functions in each dimension. Inverse 1ii/13C 
correlation spectra with broadband (GARP) 
13C decoupling were acquired into a 512 
x 1024 data matrix with 16 transients for each of the 1024 values of 
J again using a 
sequence due to Bax. 105 
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Experimental 
3-Methoxybenzamide (4) 
0 
"'ýNH2 
ome 
4 
3-Methoxybenzoic acid (2.0 g, 13.2 mmol) and thionyl chloride (16.3 g, 137.1 mmol) 
were heated together under refluxing conditions (I hr), afterwhich the thionyl 
chloride was distilled away under reduced pressure (12 mmHg) to leave a brown 
liquid. This liquid was dissolved in THF (5 n-fl) to form a pale brown solution which 
was slowly added to a 35 % aqueous ammonia solution (15 ml). Upon cooling 
(ice/water bath) a white/yellow solid was formed which was collected by filtration. 
71be solid was recrystallised from ethyl acetate (charcoalation) to give white crystals 
(1.3 g, 8.6 mmol, 65.2 % yield). mp 124 - 125 *C (literature106 134 'Q, (Found: C, 
63.16; H, 5.89; N, 9.13. C8H9NO2 requires C, 63.58; H, 5.96; N, 9.27 ft 5H (200 
MHz, CDC13) 3.47(lH, 's, H2), 3.90 (3H, s, OMe), 7.18 (1H, m, H6), 7.4 - 7.5 QH, 
in, H4,5, NH), 8.09 (1H, s, NH). 
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3-Hydroxybenzamide (29) 
0 
3-Acetoxybenzoic: acid (29,1 g, 5.56 mmol) was heated under refluxing conditions 
(2.5 h) in thionyl. chloride (3 ml, 4.89 g, 41.1 mmol) or until the reaction was 
complete by TLC, afterwhich the excess thionyl chloride was distilled away under 
reduced pressure (12 mmHg) to leave a yellow tinged oil (ca 0.5 ml). The oil was 
carefully pipetted. into a cooled (ice) 35 % aqueous ammonia solution and left to stir 
(ca 0.25 h). 'Ibis mixture was boiled to reduce its volume (ca 10 ml) and left to cool, 
crystals formed which were recrystallised. from water to give white crystals (0.5 g, 65 
% yield) mp 136 - 137 IC (literaturel07 169 'C)(Found: C, 61.5; H, 5.1; N, 10.4. 
C7H7NO2 requires C, 61.3; H, 5.1; N, 10.2 %); vmax(KBr)/cm- 13403 (Phenol OH), 
3245 (NH2), 1653 and 1615 (Amides I and 11), 1451 (benzene), 1258 (OH); 8H(200 
MHz, d6-DMSO) 9.8 (IH, s, OH), '8.0 (IR, s, NH), 7.6 - 7.2 (4H, m, NR, U2,5,6), 
7.1 (1H, m, H4); 8C(50.28 MHz, d6-DMSO) 168 (CO), 157 (CI), 136 (C3), 129 
(C2), 118 (C6), 118 (C4), 114 (C5); nx/z 137 (M+), 121 (M+ - 0), 93 (M+ - 
CONH2)- 
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3-Acetoxybenzoic acid (33)49 
0 
33 
Acetic anhydride (0.8 g, 8 mmol) was added to a cooled (ice) aqueous solution (2 ml) 
of sodium hydroxide (0.6 g, 15 mmol) and 3-hydroxybenzoic acid (I g, 7.3 mmol) 
along with some pieces of ice (ca 2 g). After stirring (I h), the mixture was acidified 
with 6M hydrochloric acid Q ml, 18 mmols) whereupon a milky white precipitate 
was formed. The mixture was extracted with dichloromethane (3 x 30 ml), the 
resulting solution was dried (magnesium sulphate) and the solvent was removed by 
rotary evaporation to give a white solid (1.21 g, 92 % yield). Recrystallisation gave 
white crystals (115 mg, 88 % yield) mp 129 - 131 'C (from water, literaturelO8 133 
C from water) (Found: C, 59.7; H, 4.3. CqH804 requires C, 60.0; *H, 4.5 %); v 
max(KBr)/cm-1 3087 and 3021 (OH), 1761 (OAc), 1678(C02H), 1586 and 1455 
(benzene CH), 1204 (CO stretch); 8H(200 MHz, CDC13) 7.92 (IH, dt, J 7.8,1.3, 
H6), 7.7 (1H, t, J 1.3, H2), 7.4 (1H, t, J 7.. 
_8, 
'H5),, 7.3 (IH, dt, J 7.8,1.3, H4), 2.23 
(3H, s, OCOCH3); BC (50.28 MHz, CDC13) 171 (COA, 169 (0-COCH3), 150 (CI), 
131 (C3), 129 (C2), '127 (C6), 127 (C4)1', 123 (C5)s'21 (OCO-CH3); nl/z 180 (M+)v 
163 (M+ - OH), 121 (M+ - OH - ketene). 
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3-(BromoalkylOxy)benzamides 
General Procedure A 
A solution of 3-hydroxybenzamide, potassium carbonate and a dibromoalkane in 
acetonitrile was heated under refluxing conditions until the reaction was complete by 
TLC (ca 2h). The solvent was removed by rotary evaporation to give a white sticky 
solid which was purified by flash chromatography and recrystallisation. 
3. (5-Bromopentyloxy)benzamide (35) 
NH2 
0.. 
Br M5 
35 
The title compound was p1repar ed from a solution of 3-hydroxybenzamide (0.50 g, 
3.65 mmols), potassium carbonate (0.50 g, 3.65 mmol) and 1,5-dibromopentane (1.8 
g, 7.30 mmol) in acetonitrile (18 ml) by the general procedure A. Recrystallisation 
gave 35 as white flaky, crystals (0.74 g, 70 % yield) mp 98 - 99 "C (from petrollethyl 
acetate), (Found: C, 50.7, H, 5.4_, N, 4.95. C15H22NO213r requires C, 50.4, H, 5.6, 
N, 4.9 ft vmax(KBr)/cm-1 3345 and 3160 (NH), 2932 (CH2), 1665 and 1632 
(Amides I and 11), 1601 and 1586 (benzene CH), 1451 (CH2), 1252 (CO stretch); 8 
H(200 MHz, d6-DMSO) 8.09 (IH, s, NH), 7.49 (4H, m, 112,5,6 and Nm, 7.1 (IH, d, 
J 7.99, H4), 4.11 (2H, t, J 6.2, CH20), 3.67 (2H, t, J 6.6, CHDr), 1.90 (4H, m, 
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CH2CH2CH2), 1.62 (2H, in, CH2CH2CH2), ÖC(50.28 MHz, d6-DMSO) 168 (CO), 
158.85 (C3), 129.63 (C2), 120 (C4), 117.79 (C6), 113.53 (C5), 67.73 (OCH2), 35.36 
(CH2Br), 32.30 (-CH2CH20), 28.12 QCH2CH2Br), 24.63 *(OCH2CH2_CH2); MM 
285/287 (M+). 
3-(8-Bromooctyloxy)benzamide (36) 
NH2 
0. 
" .. 
Br 
m8 
36 
The title compound was prepared from a solution of 3-hydroxybenzamide (0.50 g, 
3.65 mmol), potassium carbonate (0.50 g, 3.65 mmol) and 1,8-dibromooctane (2.0 g, 
7.3 rnmol) in acetonitrile (18 ml) by the general procedure A. Recrystallisation gave 
36 as white crystals (0.78 g, 65 % yield) mp 111 - 112 'C (from ethyl acetate), 
(Found: C, 54.9; H, 6.7; N, 4.3. C15H22NO2Br requires C, 54.9; H, 6.8; N, 4.3 ft 
vmax(KBr)/cm-1 3366 and 3173 (amide NH, stretch), 2938 and 2923 (aliphatic CH 
stretch), 2857 (ether CH stretch), 1659 (amide I CO stretch), 1626 (amide Il - NH 
bending), 1603 and 1584 (benzene ring); 8H(200 MHz, d6-DMSO) 8.07 (IH, s, NH), 
7.52 (4H, m, NH and aromatic H2,5,6), 7.18 (1 H, m, H4), 4.09 (2H, t, J 8, OCI12)f 
3.62 (2H, t, J 8, BrCH2), 1.87 (4H, m), 1.44 (8H, s, alkyl envelope); 5C (50.28 MHz, 
d6-DMSO) 167.96 (CO), 158.89 (C3), 135.99 (Cl), 129.59 (C5), 119.93 (U), 
117.79 (C4), 113.49 (C2), 67.86 (OCH2), 35.44 (-CH2CH2Br), 32-57 (CH2-QH2Br), 
28.96 (OCH2jCH2CH2_QH2), 28.42 (QH2CH2CH2CH2Br), 27.82 (-CH2CH2CH2Br), 
25.764 (OCH2CH2-CH2); m/z 327/329 (M+). 
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3-(12-Bromododecyloxy)benzamide (37) 
0 
P'0`0ý NH2 
0 Br 
Nýý12' 
37 
The title compound was prepared from a solution of 3-hydroxybenzamide (0.50 g, 
3.65 mmol), potassium carbonate (0-50 g, 3.65 mmol) and 1912-dibromododecane 
(2.48 g, 7.5 6 mmol) in acetonitrile (18 ml) by the general procedure A. 
Recrystallisation gave 37 as white flaky crystals (0.94 g, 68 % yield) mp 117 - 11811C 
(from petrol/ethyl acetate), (Found:, C, 59.4; H, 7.9; N, 3.5. Cl9H3ONO2Br requires 
C, 59.4; H, 7.9; N, 3.6 %); vmax(KBr)/cm -13370 and 3175 (NH), 2938 and 2921 
(CH2), 2853 (OCH2), 1659 and 1626 (Amides I and 11), 1603 and 1584 (benzene 
CH), 1449 (CH2), 1252 (CO stretch); 8H(200 MHz, d6-DMSO) 8.08 (IH, s, NM. 
7.46 (4H, m, NH and aromatic H2,5,6), 7.15 (1 H, d, -J 8, H4), 4.09 (2H, t, J 61 
OCH2), 3.61 (2H, t, J 6, CH2Br), 1.85 (4H, m), 1.36 (16H, m ); 8C(50.28 MHz, d6- 
DMSO) 167.93 (CO), 158.89 (C3), 135.99 (CýI), 129.56 (C5), 119.93 (C6), 117.76 
(C4), 113.49 (C2), 67.87 (OCH2), 35.43 - 25.87 (alkyl chain); m/z 383/385 (M+). 
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3-(5. (6-Chloropurin-9-yl)pentYloxy)ben7, amide (38) 
oool rN 
,,, . /N ý M5 
38 
A solution of 3-(5-bromopentyloxy)benzamide (500 mg, 1.7 mmol), 6-chloropurine 
(270 mg, 1.7 mmol) and potassium carbonate (240 mg, 1.7 mmol) in DMF (7.5 ml) 
was stirred for two days (n). The solvent was then removed under vacuum (0.001 
mmHg) and the remaining white solid (of IV7 and N9 isomers) was chromatographed 
(silica, 10 % MeOH/ CH2C'2) to give a single product (N9 isomer) as a glass. This 
was triturated with ether (- 5 ml) to give a white solid which was recrystallised to 
give the product (38,120.3 mg, , 20 % yield) mp 132 - 133*C (from ethyl acetate), 
(Found: C, 56.7, H, 4.3, N, 19.4. Cl7Hl8N502CI requires C, 56.57, H, 5.0, N, 19.5 
ft vmax (KBr)/cm- 13376 and 3173 (amide NH2), 2951,2928 and 2851 (CH2), 
1680 and 1624 (amide I and 11), 1593 and 1584 (benzene ring); 8H(200 MHz, d6- 
DMSO) 8.88 (IH, s, purine H8), 8.85 (IH, s, purine H2) 8.05 (IH, s, CONH). 7.56 
(4H, m, NH and aromatic H2,5,6), 7.15 - 7.10 (IH, m, H4), 4.44 (2H, t, J 7,0012), 
4.08 (2H, t, J 6.3, CHA, 2.12 - 1.98, (2H, m, OCH2CH2), 1.94 - 1.80 (2H, rn, 
NCH2CH2), 1.59 - 1.43 (2H, m, CH2CH2CH2); BC(50.28 MHz, d6-DMSO) 167.93 
(CO), 158.77 (0), 152.31 (pC4), 151.76 (pC8), 149.29 (pC5), 147.86 (pC2), 136.02 
(C 1),, 131.18 (pC6), 129.60 (C5), 119.96 (C6), ý 17.80 (C4), 113.46 (C2), 67.59 
(OCH2), 44.03 (NCH2), 29.07 (OCH2-CH2), 28.337 (-QH2CH2N). 22.890 
(CH2-CH2CH2), m/z 359/361 (W). (nb p= purine) 
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3-(8-(6-Chloropurin-g. yl)octyloxy)benzamide (39) 
0 
r cl 
y8 
39 
A solution of 3-(8-bromooctyloxy)benzamide (500 mg, 1.5 mmol), 6-chloropurine 
(236 mg, 1.5 mmol) and potassium carbonate (210 mg, 1.5 mmol) in DMF (7.5 ml) 
was stirred for two days (rt). The solvent was removed under vacuum (0.001 mnfflg) 
and the white solid (of IV7 and N9 isomers) was chromatographed (silica gel, 5% 
petrol/THF) to give a single product (N9 isomer) a white solid (74 mg) which was 
recrystallised (2x) to give (39,58.7 mg, 10 % yield) mp 116 - 117*C (ethanol) 
(Found: C, 59.2, H, 6.1, N, 16.9. C20H24N502Cl requires C, 59.8, H, 6.0, N, 17.4 
vmax(KBr)/cm-1 3382 and 3189 (amide NH2), 2938 and 2857 (CH2), 1686 and 
1611 (amides I and 11), 1597 and 1586 (benzene ring); 511(200 MHz, d6-DMSO) 8.87 
(1H, s, purine H8), 8.83 (IH, s, purine H2), 8.05 (IH, s, CONII). 7.54 - 7.38 (411, m, 
CONH and aromatic H2,5,6), 7.16 - 7.12 (IH, m, H4), 4.38 (2H, t, J 7, OC112), 4.06 
(2H, t, J 6.3, CH2N), 1.99 - 1.74 (4H, m, OCH2CH2 and CH2CH2N), 1.39 (8H, m, 
alkyl env); SC(50.28 MHz, d6-DMSO) 167.93 (CO), 158.85 (C3), 151.74 (PC8) 
151.66 (pC2), 135.199 (Cl), 1297-60 (C5 119.90 (U), 117.79 (C4), 113.46 (C2)t 
67.82 (OCH2), 44.11 (NCH2), 29.29 (OCH2-CH2), 28.87 (OCH2CH2, CH2 and 
NCH2-CH2), 25.69 (NCH2CH2CH2-CH2); m/z 401/403 (M+). 
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3-(8-(6-Chloropurin-9-yl)dodecyloxy)benzamide (40) 
I 
40 
A mixture of 3-(12-bromododecyloxy)benzamide (500 mg, 1.3 mmol), 6- 
chloropurine (201.3 mg, 1.3 mmol) and potassium carbonate (180.0 mg, 1.3 mmol) in 
DMF (6.5 ml) was stirred for three days (rt). The solvent was removed under 
vacuum (0.001 mmHg) and the white solid (of Y7 and N9 isomers) was 
chromatographed (silica gel, 5% petrolfrHF) to give a single product (N9 isomer) a 
white solid (204 mg) which was recrystallised to give ( 204.1 mg, 34.3 % yield) mp 
135 - 1370C (DMSO and water) (Found: C, 63.0, H, 6.9, N, 15.4. C20H24N502CI 
requires C, 62.95, H, 7.0, N, 15.3 %); V'max(KBr)/cm-1 3306 and 3205 (amide N112), 
2906 and 2845 (CH2), 1690 and 1622 (amides I and 11), 1586 (benzene ring); 8H(200 
MHz, d6-DMSO) 8.84 (IH, s, purine H8), 8.81 (IH, s, purine H2), 8.10 (IH, s, 
CONH). 7.5 - 7.4 (411, m, CONH and aromatic U2,5,6), 7.2 - 7.15 (111, rn, 114), 
4.34 (2H, t, J 7, OCH2), 4.10 (2H, t, J 6.3, CH2N), 1.91 - 1.72 (411, m, OCI 12CH2 
and CH2CH2N), 1.37 (16H, m, alkyl env); 
ýCý50.28 MHz, d6-DMSO) 169.33 (CO), 
159.13 (0), 151.83 (pC8) 151.77 (pC2), 134.31 (C 1), 127.66 (C5), 120.11 (C6), 
117.05 (C4), 115.34 (C2), -7 i. 25 (OCH2), 44.1 19 (NCH2, ), 29.89 (OCH20207.62 
(OCH2CH2-CH2 and NCH2-CH2), 24.11 (NCH2CH2CH2-CH2); nVz 457/459 (M+). 
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3-(5-(6-Aminopurin-9-yl)penyloxy)benzamide (41) 
r=N NH2 
N 
N "XN 
41 
A bomb was charged with a mixture (392 mg, 1.1 mmol) of 3-(6-chloro-7-(5- 
pentyloxy)purine)benzamide, 3-(6-chloro-9-(5-pentyloxy)purine)benzamide and 
liquid ammonia (60 ml) and heated under pressure (66 "C, 30 bar, 16 h). The 
ammonia was evaporated away to leave a yellow solid which was chromatographed 
(silica gel, 10 % methanol/dichloromethane) to give a pale yellow solid which was 
recrystallised to give the title compound (204 mg, 54 % yield) mp 148 - 149 *C 
(from water), (Found: C, 60.4; H, 6.0; N, 25.0. Cl7H2ON602 requires C, 60.0; H, 
5.9; N, 24.7 ft 8H(200 MHz, d6-DMSO) 8.25 (2H, m, purine H8,2), 8.06 (1 H, s, 
CONH). 7.61 - 7.3 8 (4H, m, CONH and aromatic U2,5,6), 7.31 (2H, s, NH2) 7.15 - 
7.11 (IH, m, H4), 4.27 (2H, t, J 7, OCH2), 4.07 (2H, t, 16.3, CHA, 2.05 - 1.78 
(4H, m, OCH2CH2CH2CH2CH2N), 1.56 - 1.41 (2H, m, NCH2C-112), 1.59 - 1.43 
(2H, m, CH2CH2CH2); 8C(50.28 MHz, d6-DMSO) 167.96 (CO), 158.81 (0), 
156.28 (pC2), 152.70 (pC8), 149.11 (pC5), 141.18 (pC4), 135.99 (C 1), 129.60 (0), 
119.97 (U), 119.09 (C4), 117.80 (C2), 87.68 (CH20), 50.43 (CHA, 29.45 
(CH2CH20), 28.41 (-CH2CHA, 22.95 (CH2-CH2CH2); nVz 340 (M+). 
16P 
3-(8. (6-Aminopurin-9-yl)octyloxy)benzamide (42) 
0 
rN 
N 
NH2 
N 
42 
A bomb was charged with a mixture (110 mg, 0.27 mmol) of 3-(8-IV7-(6- 
chloropurine)octyloxy)benzamide, 3-(8-N9-(6-chloropurine)octyloxy) benzamide and 
liquid ammonia (60 ml) and heated under pressure (64 *C, 30 bar, 16 H). The 
ammonia was evaporated away to leave a yellow solid which was chromatographed 
(silica gel, 15 % methanol/dichloromethane) to give a pale yellow solid which was 
recrystallised to give the title compound (56 mg, 62 % yield) mp 199 - 19951C (from 
methanol) (Found: C, 62.4, H, 6.5, N, 21.9 C20H26N602 requires C, 62.8, H, 6.9, 
N, 22.0 %); vmax(KBr)/cm-1 3445 (NH2), 3297 and 3108 (amide NH2), 2936 and 
2921 (CH2), 1678 and 1601 (amides I and 11), 1512 (benzene); BH(200 MHz, d6- 
DMSO) 8.24 (IH, s, purine H8), 8.23 (IH, s, purine H2), 8.06 (IH, S, CONJI). 7.55 - 
7.39 (4H, m, CONH and aromatic H2,5,6), 7.30 (2H, s, N1120.17 - 7.13 (1 H, rn, 
aromatic H4), 4.23 (2H, t, J7, OCH2), 4.07 (2H, t, J 6.3, CHA, 1.94 - 1.76 (411, m, 
OCH2CH2 and CH2CH2N), 1.40 (8H, m, alkyl env); SC(50.28 MHz, d6-DMSO) 
167.998 (CO), 158.85 (C3), 152.71 (pC8), 141.21 (pC2), 136.05 (Cl), 129.67 (C5), 
119.97 (C6), 117.87 (C4), 113.59 (C2), 67.90 (OCH2), 43.22 (NCH2), 29.698 
(OCH2-CH2), 28.96 (OCH2CH2-CH2 and NCH2_CH2), 26.31 (OCH2CH2CH2012), 
25.76 (NCH2CH2CH2-CH2); m/z 338 (M+ - CON112)- 
161 
3-(8-(6-Aminopurin-9-yl)dodecyloxy)benzamide (43) 
0 
NH2 
1: ý: ýN 
N NH2 "K12 
NN 
43 
A bomb was charged with a mixture (436.3 mg, 0.954 mmol) of 3-(8-Ar7-(6- 
chloropurine)dodecyloxy)benzamide, 3-(8-N9-(6-chloropurine)dodecyloxy) 
benzamide and liquid ammonia (60 ml) and heated under pressure (64 *C, 30 bar, 16 
H). The ammonia was evaporated away to leave a yellow solid (359.6 mg) which 
was chromatographed (silica gel, 15 % methanol/dichloromethane) to give a pale 
yellow solid which was recrystallised to give the title compound (32 mg, 7.7 % yield) 
mp 205 - 206"C (decomposition, from methanol) (Found: C, 65.8, H, 7.65, N, 19.21 
C24H34N602 requires C, 65.75, H, 7.76, N, 19.18 ft vmax(KBr)/cm- 13455 
(NH2), 3293 and 3100 (amide NH2), 2941 a' nd 2928 (CH2), 1676 and 1601 (amides I 
and 1 1), 1515 (benzene); 8H(200 MHz, d6-DMSO) 8.23 (1H, S, purine 118), 8.21 (111, 
s, purine H2), 8.10 (IH, s, CONH). 7.6 - 7.4 (4H, m, CONH and aromatic 112,5,6), 
7.28 (2H, s, NH2), 7.19 (1 H, m aromatic H4), 4.25 (2H, t, J 7, OC112), 4.11 (211, t, J 
6.3, CHA, 2.04 - 1.75 (4H, m, OCH2CH2_and CH2CH2N), 1.40 (1611, m, alkyl 
env); 5C(50.28 MHz, d6-DMSO) 168.017 (CO), 159.58 (C3)9 152.01 (pC8), 141.81 
(pC2), 136.53 (Cl), 129.36 (C5), 119.89 (C6), 118.84 (C4), 112.09 (C2), 69.94 
(OCH2), 42.32 (NCH2), 31.23 (OCH2-CH2), 30.06 (OCH2CH2, CH2 and NC112012), 
25.81 (OCH2CH2CH2-QH2), 25.64 (NCH2CH2CH2-QI12); m/z 438 (M+ - CON112). 
16ý 
cis/trans-3-Methoxycyclohexanecarboxamide (47) 
0 
47 
To a solution of cis/trans-3-methoxycyclohexanecarboxylic acid (0.5 g, 3.1 mmol) in 
THF (3 ml) was added thionyl chloride (0.41 g, 3.5 mmol) dropwise over 5 minutes 
with stirring. The resulting solution was stirred at 22 *C (24 h) until the reaction 
was complete as indicated by TLC. 'Me reaction mixture was then carefully pipetted 
into 35% aqueous ammonia (10 ml), afterwhich excess ammonia and THF were 
removed at the water pump. The resulting solution was extracted with 
dichloromethane (5 x 10 ml), then dried WgS04) and the solvent removed by rotary 
evaporation to leave an off white solid. The crude product was recrystallisation from 
ethyl acetate to give shinywhite crystals (0.41 g, 84 % yield), mp 117 - 118 *C (from 
ethyl acetate), (Found C, 61.4; H, 9.7; N, 8.9. C8HI5NO2 requires C, 61.1; H, 9.6; 
N, 8.9 %); vmax(KBr)/cm-1 3349 and 3173 (NH), 2936 (CI12), 2859 and 2820 
(OCH3), 1663 and 1632 (Amides. 1 and 11), 1429 (CH3), 1100 and 1088 (CO); 8 
H(500 MHz, CDC13) 10.81 (4H, brs, NH2 cis + trans), 3.49 (1 H, tt, J 2.8,4.8, 
H3trans), 3.32 (3H, s, OCH3cis), 3.28 QH, S, OCH3trans), 3.13 (111, tt, J 4.0,10.8, 
H3cis), 2.67 (1 H, tt, J 3.8,10.2, HI trans), 2.28 (1 H, tt, J 3.7,12.0,111 cis), 2.26 - 1.0 
(16H, m, (H2', 2", 4,4", 5', 5", 6', 6")Cis + trans); m/z 157 (M+), 142 (M+ - C113), 125 
(M+ - CH30H), 113 (M+ - CONH2)- 
163 
3-Methoxy-1,4-dihydrobenzoic Acid (55) 
55 
Ammonia (110 ml) was condensed into a stirred solution of 3-methoxybenzoic acid 
(5.0 g, 33 mmol) in dry methanol (45 ml). Sodium (3.6 g, 327 mmol) was added to 
this mixture which was left to stir until the blue colour dissipated. The reaction was 
then quenched with excess ammonium chloride (20.0 g, 374 mmol) and the ammonia 
allowed to evaporate from the mixture (0.5 h). The residual ammonia was then 
removed under vacuum (12 mmHg) keeping the reaction flask below 0 OC. 
Hydrochloric acid was then carefully added to the mixture until the pH = 4.5 all the 
time the flask temperature was kept below 0 "C. The reaction mixture was then 
extracted with dichloromethane (5X 100 ml), dried (MgS04) and the solvent 
removed by rotary evaporation to give a pale yellow'oil (3.73 g, 74 % yield), SH(200 
MHz, CDC13) 2.65 (2H, m, 114%4"), 3.51 (3H, s, OCH3), 3.84 (IH, m, Ill), 4.68 (111, 
d, J 4,112), 5.75 (2H, m, H5,6), 10.59 (IH, brs, C02M; BC(50.28 MHz, CDC13) 
28.41 (C4), 42.98 (OMe), 53.96 (Cl), 89.20 (C2), 121.78 (0), 125.63 (U), 154.70 
(C5), 179.48 (CO); m/z 154 (M+). 
164 
3-Methoxy-1,4,5,6-tetrahydrobenzamide (57) 
57 
Ammonia (20 ml) was condensed into a stirred solution of 3-methoxybenzamide (1.0 
g, 6.6 mmol) in dry methanol (9 ml). Sodium (0.84 g, 76.4 mmol) was added to the 
reaction mixture, after the blue colour dissipated (5 mins) the reaction was quenched 
with ammonium chloride (8.0 g, 149.5 mmol). The liquid ammonia was left to 
evaporate under a stream of nitrogen gas (2.5 h), afterwhich water (30 ml) was added 
forming a white milky precipitate which was filtered off. The filtrate was extracted 
with dichloromethane (5 x 50 ml), dried (MgSO4) and the solvent removed by rotary 
evaporation to leave an oil. This was triturated with ether to give a solid which gave 
the title compound upon recrystallisation (25.0 mg, 2.4 % yield) mp 122 - 123 *C 
(from petrol/ethyl acetate), (Found: C, 62.1; H, 8.5; N, 9.2. C8Hl3NO2 requires C, 
61.9; H, 8.4; N, 9.0 %); vmax(KBr)/cm-1,3350 and 3169 (NII), 1658 and 1634 
(amides I and 11); 5H(500 MHz, CDC13) 1.71 (4H, m, H5', 5", 6', 6"), 2.06 (2H, m, 
H4', 4"), 3.01 (IH, m, HI), 3.52 QH, S, OCH3), 4.61 (IH, 0, J 2.1, H2), 5.86 (111, brs, 
NH), 6.01 (IH, brs, NH); m/z 155 (M+), III (M+ - CONH2)- 
165- 
N-Alkylnicotinamide Salts 
General Procedure B 
A stirred solution of nicotinamide, and alkylhalide in ethanol was heated under 
refluxing conditions overpight. The solvent and excess alkylhalide were carefully 
removed by distillation to leave a solid which was purified by recrystallisation. 
N-Methylnicotinamide Iodide (60) 
60 
The title compound was prepared from a solution of nicotinamide (5.00 g, 41 mmol) 
and methyl iodide (6-84 g, 48 mmol) in ethanol (50 mi) using the general procedure 
B. Recrystallisation gave 60 as yellow crystals (9.5 g, 88 % yield) mp 203-2040C 
(from water), (Found: C, 31.9; H, 3.3; N, 10.5. C7H9N20l requires C, 31.8; H, 3.4; 
N, 10.6 %); vmax(KBr)/cm- 13326 and 3156 (NH), 2955 (CH3), 1686 and 1642 
(Amides I and 11), 1584 and 1507 (Pyridine), 1462 (CH3), 1393 (CH3), * 811(20() 
MHz, d6-DMSO) 4.51 (31-1, s, CI-13), 8.19 (IH, s, NH), 8.35 (Ili, dd, J 8,6,115), 8.55 
(111, s, NH), 8.98 (IH, d, J 8, H4), 9.23 (Ili, d, J 6, HO, 9.56 (111, s, 112); 8C(50.28 
MHz, d6-DMSO) 48.93 (CH3), 127.83 (C5), 133.34 (C4), 143.34 (C6), 145.83 (C2), 
147.46 (CO, 163.22 (CO); m/z 137 (M+), 93 (M+ - CONH2)- 
166- 
N-Ethylnicotinamide Iodide (61) 
0 
61 
The title compound was prepared from a solution of nicotinamide. (5.00 g' 41 mmols) 
and ethyl iodide (8.70 g, 56 rnmol) in ethanol (50 ml) using the general procedure B. 
Recrystallisation gave 61 as yellow crystals (8.7 g, 76 % yield) mp = 196 - 1980C 
(from water methanol and ether literature 54 198 OC) (Found: C, 34.5; H, 4.0; N, 10.0. 
C8HI IN201 requires C, 34.55; H, 4.0; N, 10.1 %); vmax(KBr)/cm- 13337 and 3168 
(NH), 2942 (CH2CH3), 1676 and 1634 (amides I and 11), 1609 and 1504 (pyridine), 
1385 (CH3); 5H(200 MHz, d6-DMSO) 1.64 QH, t, J 7.3, CH3), 4.82 (211, q, J 7.3. 
CH2), 8.20 (1 H, s, NH), 8.37 (1 H, dd, J 8,6, H5), 8.57 (1 H, s, NII), 8.99 (111, d, J 8, 
H4), 9.38 (IH, d, J 6, H6), 9.63 (1H, s, H2); 8C(50.28 MHz, d6-DMSO) 16.57 
(CH3), 57.22 (CH2), 128.30 (C5), 133.90 (C4), 143.74 (C6), 144-70 (C2), 146.50 
(C3), 163.22 (CO); m/z 151 W, 100 %), 136 (M+ - NH2), 123 (M+ - Et), 108 (M+ 
- CONH2)- 
1§7 
N-Benzylnicotinamide Chloride (62) 
62 
The title compound was prepared from a solution of nicotinamide (5.0 g, 41 mmol) 
and benzy1chloride (7.8 g, 62 mmol) in ethanol (41 ml) using general procedure B. 
Recrystallisation gave 62 as white crystals (8.6 g, 84 % yield) mp 221-2220C (from 
methanol, literature 54 236 OC with decomposition) (Found: C, 62.5; H, 5.5; N, 11.5. 
C13H13N20CI requires C, 62.8; H, 5.3; N, 11.3 %); 'Omax (KBr)/cm-1 3382 and 
3130 (NH), 2940 (CH2), 1701 and 1651 (amides I and 11), 1588 and 1512 (pyridine), 
1439 (CH2); 5H(200 MHz, D20 internal standard sodium 3- 
trimethylsilylpropanesulphonoate) 6.0 (2H, S, C112Ph), 7.53 - 7.61 (511. rn, Ph), 8.30 
(I H, t, J 6, H5), 8.99 (1 H, d, J 8, H4), 9.21 (1 H, d, J 6,116), 9.49 (1 H, s, 112); 8 
C(50.28 MHz, D20 internal standard sodium 3-trimethylsilylpropanesuiplionoate) 
169 (CO), 147.98 (0), 145.76 (0), 135.43 (C6), 133.74 (C4), 133.62 (C5), 131.62 
(iBn), 131.14 (mBn), 130.73 (oBn), 130.12 (pBn), 66.59 (CH2PI); m/z 213 (M+), 
170 (M+ - CONH2), 122 (M+ -B n), 91 (B n). 
168 
N-Benzyl-1,4-dihydronicotinamide (63) 
0 
63 
into an aqueous solution of N-benzylnicotinamide chloride (1.0 g, 4.0 mmol) and 
sodium carbonate (1.5 g, 14 mmol) at 60 *C was added sodium dithionite (2.8 g, 16.1 
mmol). This solution was left to stir (45 mins) as a pale yellow precipitate was 
formed which was filtered off and recrystallised. to give pale yellow crystals (0.52 g, 
61 % yield) mp 121 - 122 *C (from ethyl acetate, literature54 123 'Q (Found: C, 
72.7; H, 6.4; N, 13.4. C13Hl4N20 requires C, 72.9; H, 6.6; N, 13.7 v 
max(KBr)/cm-1 3357 and 3171, (NH), 2818 (CH2), 1684 and 1645 (amides I and 11), 
1563 (C-`Q; BH(200 MHz, CDC13) 3.13 (2H, dd, J 3,1.6, H4', 4"), 4.25 (2H. s, 
CH2Ph), 4.71 (IH, ddd, J 8,3,1.6, H5), 
_ 
5.51 (2H, 
' 
brs, NH2), 5.70 (111, m, H6), 7.11 
(IH, d, J=1.6 H2); 5C(50.28 MHz, CDC13) 22.93 OCH2N), 57.50 (C4), 98.09 (C3)t 
103.31 (C5), 127.28 (pPh), lý27.90 (oPh), 128.93 (C6 and mPh), 129.10 (iPh), 140.04 
(C2), 171.23 (CO); m/z 214 (M+), 123 (M+ -B n), 91 (Bn). 
19. 
N-Methyl-1,4. dihydronicotinamide (64) 
0 
64 
Into a stirred aqueous solution (10 ml) of N-methylnicotinamide iodide (1.0 g, 3.8 
mmol) and sodium carbonate (3.0 g, 28.3 mmol), purged with nitrogen, was added 
sodium hydrosulphite (2.8 g, 16.1 mmol) and the solution left to stir (2h). The 
yellow solution was extracted with peroxide free ether (10 x 20 ml) dried (MgS04) 
and left to stand in the refrigerator (-25"C, 16h). The mother liquor was decanted 
from the small crystals that were formed whilst the remaining ether was blown off by 
nitrogen (all these operations were done at -20 *Q. The crystals were then put under 
high vacuum and allowed to warm to room temperature, whereupon they formed a 
yellow oil (0.27 g, 52 % yield); 5H(200 MHz, CDC13) 2.87 (3H, S, C113), 3.05 (211, 
dt, J 3,1.6,1.6, H4', 4"), 4.66 (lH, dt, J 8,3,3, H5), 5.53 (2H, brs, N112), 5.61 (111, 
ddd, J 8,3,1.6, H6), 6.92 (11-1, d, 1 1.6, H2); 'BC(50.28 MHz, CDC13) 22.53 (CH3)9 
40.70 (C4), 98.02 (C3), 102.84 (C5), 129.85 (C6), 140.44 (C2), 170.64 (CO); m/z 
138 (M+), 123 (M+ - CI-13), 94 (M+ -'CONH2)- 
170 
N-Ethyl-1,4. dihydronicotinamide (65) 
0 
65 
An aqueous solution (20 ml) of sodium carbonate (3.6 g, 34 mmol) and N- 
ethylnicotinamide iodide (1.0 g, 3.6 mmol) was purged with nitrogen (0.5 H). 
Sodium disulphite Q g, 17.2 mmol) was added and the solution was left to stir (40 
mins). Upon addition of the disulphite the solution changed colour from orange and 
formed a yellow precipitate, the solution was extracted with ether (10 x 10 ml), the 
ether extracts were then dried (sodium sulphate) and the ether removed under vacuum 
to give a yellow transparent oil (0.47 g, 85 % yield). (TLC 10 % MeOH in CH202 
Rf = 0.35, blue fluorescent spot). 
The oil was partially dissolved in ethyl acetate to give a yellow supernatant liquid 
over a thin yellow tar. The solution was transferred to another round bottomed flask 
and cooled (0 "Q. Petrol was added dropwise to the solution until the cloud point 
was almost reached. The flask was stoppered and placed in the freezer (-25 IQ 
overnight. Bright yellow crystals formed. The temperature of the flask was kept 
between minus thirty and minus forty degrees whilst the mother liquor was pipetted 
away and the crystals washed with cold petrol. The petrol was then pipetted away to 
leave yellow crystals which were dried under high vacuum (0.05 mmlig, n, dark). 
(First crop 104 mg, 19 % yield, second crop 66 mg, 12 % yield) mp 88 - 89 OC (from 
petrol/ethyl acetate) (Found. C, 63.3; H, 7.9; N, 18.3. C8H 12N20 requires C, 63.1; 
H, 7.95; N, 18.4 %); vmax(KBr)/cm-1 3382 and 3206 (NE), 2978 (CH3), 2807 
171 
(CH2N), 1684 and 1645 (amides I and 11), 1563 (C=C); BH(200 MHz CDC13) 1-09 
(3H, t, J 7.2, CH3), 3.10 (4H, q, J 7.2, CH3CH2. m, CH2), 4.69 (IH, dt, J 3.5,8.0, 
CH=CHN ), 5.43 (2H, brs, NH2), 5.68 (IH, ddd, J 1.62,3.33,8, CH=CHN), 7.01 
(IH, d, J 1.61, NCH=C); BC(50.28 MHz, CDC13) 15.18(CH3), 22.93(CH2), 48.59 
(NCH2), 98.12 (C=-CCO), 102.92 (C=. CCH2), 128.64 (-C=CCH2), 139.41 (-C=CCO), 
170 (C=O); rn/z 152 (M+), 151 (M+ - H), 136 (M+ - NH2), 123 (M+ - Et), 106 (M+ - 
CONH2). 
8-Hydroxy-4(3H)-Quinazolinone (80') 
0 
801 
A mixture of methyl 4-benzoxazolecarboxylate (275 mg, 1.56 mmol) and liquid 
ammonia (60 ml) was placed into an autoclave and heated (55 OC, 15 KBar) until the 
reaction was complete (18 H). The ammonia was evaporated from the product to 
leave a brown solid which was purified by sublimation (140 *C, 0.00 1 mmHg) to give 
a pale yellow solid (13 mg, 5% yield) mp 233 - 234 *C (Found: C, 59.9; 11,3.9; N, 
17.6. C8H6N202 requires C, 59.6; H, 3.7; N, 17.3 %); vmax(KBr)/cm-1 3319 (NII), 
1695 and 1674 (amides I and 11); 5H(200 MHz; d6-DMSO); 8.13 (111, s, 112), 7.62 
(IH, d, J 8, H5), 7.41 (11-1, t, J 8, U6), 7.28 (IH, d, J 8, in), 5.83 (411, brs, NII + 011 
+ HOD); m/z 162 (M+ 61 
172 
8-Hyd roxy-2-Methyl-4- (3H)-Qui nazol i none (821) 
0 
NH 
OH 
82' 
A mixture of methyl 2-methyl-4-benzoxazolecarboxylate (218 mg, 1.1 mmol) and 
liquid ammonia (60 ml) were placed into an autoclave and heated (55 OC, 15 KBar) 
until the reaction was complete (16 h). The ammonia was evaporated from the 
product to leave an orange solid which was sublimed (160 *C, 0.001 mmHg) to give 
2-methyl-4-benzoxazolecarboxamide as a yellow solid (58 mg, 30 % yield) mp 249 
250 'C, (Found: C, 61.4; H, 4.4; N, 15.9. CgH8N202 requires C, 61.4; H, 4.6; N, 
15.9 %); vmax(KBr)/cm-1 1672 (amide 1), 1627 (amide II); 5H(200 MHz; CDC13 
and d6-DMSO) 2.14 QH, s, CH3), 6.87 (IH, dd, J 7.5,2, R7), 6.94 (IH, t, J 8,116), 
7.29 (IH, dd, J 7.5,2, H5); SC(50.28 MHz; CDC13) 162.05 (CO), 152.86 (C8), 
152.60 (C9), 132.27 (C2), 126.54 (C5), 121.76 (0), 118.45 (C6), 115.77 (C4), 21.72 
(CH3); nVz 176 (M+ 100 %), 107 (M+ - 69). 
Methyl 2-Amino-3-Ilydroxybenzoate (84) 
0 
., 
', T NH2 OH 
84'ý 
173 
To a suspension of 2-amino-3-hydroxybenzoic acid (1.0 g, 6.54 mmol) in dry 
methanol (30 ml) was added dry hydrogen chloride until saturation. The reaction 
mixture was heated under refluxing conditions (17 h) and the solvent removed by 
rotary evaporation to leave a brown solid. The solid was dissolved in water (20 rni) 
and neutralised with sodium bicarbonate until effervescence stopped. Sodium 
chloride (ca 3 g) was added to the aqueous solution and the product was extracted 
with ethyl acetate (5 x 20 ml). The pooled aliquots were dried (magnesium sulphate) 
and the solvent removed by rotary evaporation to give a malty brown solid which was 
recrystallised to give the title compound (815 mg, 75 % yield) mp 95 - 96 IIC (1009 
97 - 98 *Q, (Found: C, 57.8; H, 5.8; N, 8.6. C8H9NO3 requires C, 57.5; H, 5.4; N, 
8.4 ft Vmax (KBr)/cm-1 3410 (OH), 3327 (NH), 3024 (ArH), 1705 (CO); 811(200 
MHz; CDC13) 3.86 (3H, s, Me), 5.74 QH, br s, OH and NH2), 6.48 (1 H, t, J 7, H5), 
6.80 (IH, d, J 7, H4), 7.45 (1H, d, J 7, H6); 8C(50.28 MHz; CDC13) 51 (Me), III 
(Cl), 115 (C5), 118 (C4), 123 (C6), 140 (C2), 143 (0), 169 (CO); m/z 167 (M+, 88 
135 (M+ - 32), 107 (M+ - 60). 
Methyl 2-Methyl-4-Benzoxazolecarboxylate (85) 
85 
To a solution of methyl 2-amino-3-hydroxybenzoate (0.50g, - 3 mmol) in m-xylene 
(50 ml) were placed: acetyl chloride (0.28 g, 3.6 mmol), triethylarnine (0.36 g, 3.6 
mmol) and pyridinium p-toluenesulphonate (0.20 9,0.80 Mmol). This mixture was 
refluxed (18 h), then the solvent was removed by rotary evaporation to give a brown 
174, 
oil, which was column chromatographed (10% MeOH in CH2Cl2 on silica) to give a 
yellow solid which was recrystallised to give the title compound (504 mg, 88 % 
yield) mp = 74 - 75 'C (petrol); (lit57 77 - 79 *Q; (Found: C, 63.1; H, 4.5; N. 2.4. 
C10119NO3 requires C, 62.8; H, 4.75; N, 2.1 ft vmax(KBr)/cm-1 3088 (aromatic 
H), 1724 (CO), 1607 (C=C), 1566 (C=C), 1487 P--Q; 5H(200 MHz; CDC13) 2.69 
(3H, s, CCH30.99 QH, s, OCH30.33 (111, t, J 8, H6), 7.63 (IH, dd, J 8,1, H7), 
7.94 (1 H, dd, J 8,1, H5); 8C(50.28 MHz; CDC13) 165.93 (CO), 151.64 (U), 141.06 
(C9), 126.65 (C5), 123.93 (0), 121.66 (C4), 114.60 (C6), 52.52 (OCH3), 14.81 
(CH3); m/z 191 (M+ 38 %), 160 (M+ - OCH3), 133 (M+ - C02CH3) 
Methyl 4-Benzoxazolecarboxylate (86) 
86 
A mixture of methyl 2-amino-3-hydroxybenzoate (0.50 g, 3 mmol) and 
triethylorthoformate (1.46 g, 9.8 mm0l) wasý refluxed, (16 h) in m-xylene (100 mi). 
The solvent was then removed to give a brown oil which was column 
chromatographed (1% to 5% MeOH in CH2CI2 on silica) to give the product as a 
sticky brown solid which was recrystallised (ethyl acetate) to give the title compound 
(273 mg, 51 % yield) mp (Found: C, 60.8; H, 3.9, 'N, 8.3. C9H7NO3 requires C, 
61.0; H, 4.0; N, 7.9 %); vmax(KBr)/cm-1; SH(200 MHz; I CDC13) 4.08 (311, s, 
OCH3), 7.50(IH, t, 'J8, H6), 7.82(IH, d, J8, h"7), 8.10(IH, d, J7.5,115), 8.28(IH, 
s, H2); m/z 177 (M+ 65 %), '146 (M+ - OMe), 118 (M+ - C02Me). 
175 
N6-(2,2-Dimethoxyethyl)adenosine (111) 
MeO YýýNH 
Me 0k 
Ill 
A solution in DMF (10 ml) of 6-chloropurine riboside (I g, 3.48 mmol), 2,2- 
dimethoxyethanamine (0.73 g, 7 mmol), and triethylamine (1.05 g, 10.4 mmol) was 
left to stir (64 h, RT) until the reaction was complete (by TLC). The precipitate 
formed (triethylammonium chloride) was filtered off (aided by DW) and the solvent 
was removed under vacuum (0.01 mmHg) to leave a viscous oil, which was 
recrystallised (methanol) to give white shiny crystals (1.063 g, 86% yield). 
mp 177 - 178 *C (methanol), (Found: C, 47.3, H, 5.9, N, 19.7. C14112 I N506 
requires C, 46.7, H, 5.9, N, 19.5, %); vmax(KBr)/cm-1 3400 (OH), 1620 (C=N- 
conjugated, cyclic), 1100 (C-0); 5H(200 Mliz; d6-DMSO) 8.38 (IH, s, 112), 8.23 
(111, s, H8), 7.82 (111, brs, NM, 5.89 (111, d, J 6.16, Hl'), 5.45 (211, m, OH-5', 011- 
1 
315.36 (1 H, d, J 4.60, OH-2'), 4.60 (2H,, m; HT, (CH30)2CII), 4.14 (Ili, m, 113'), 
3.96 (IH, m, H4'), 3.60 (4H, br m, H5', 5", CH2NH2), 3.28 (611, s, (CI130)2); BC 
(50.28 MHz; d6-DMSO) 154.86 (C6), 152.62 (C2), 149 (C4), 140.26 (C8), 120 (C5), 
101.77 ((CH30)2-0,88.21 (Cl'), 86.15 (C4'), 73.70 (C2'), 70.85 (CY), 61.68 (U), 
53.25 (_CH2NH2)- m/z 356 (M+), 324 (M+ CH30H), 224 (depurination), 192, 
(depurination and loss of methanol). 
ý176 
7-Methoxy-3,7,8-trihydroimidazo[2,1-ilpurine (115) 
115 
A flask was charged with N6-(2,2-dimethoxyethyl)adenine (100 mg, 0.45 mmol), 
D-(-)-camphor sulphonic acid (115 mg, 0.5 mmol), and acetonitrile (25 ml). This 
was fitted with a Dean-Stark trap (dead volume of 14.5 ml) and set to reflux, with the 
trap being drained and replenished every hour for eight hours. The solvent was then 
removed by rotary evaporation to leave a pinkly tinged glass. An aqueous solution of 
this glass was then passed through an ion exchange column (Amberlite IRA-67 free 
base, I g). The aqueous solution of the free base was then freeze dried to leave a pale 
yellow fluffy solid (101 mg) which was recrystallised to give a white solid (76 mg, 88 
% yield). mp 188 'C (dec) (methanol) 8H(200 MHz; d6-DMSO) 8.31 (111, s, 118), 
7.95 (IH, s, H2), 5.88 (IH, dd, J 2.0,6.7, HI 1), 3.93 OH, dd, J 6.7,14.9, HIO'), 
3.75 (IH, dd, J 2.0,14.9, HIO"); 8C(50.28 MHz, d6-DMSO) 164 (C4), 160.76 (C6)9 
157.33 (C5), 149 (C2), 148 (C8), 97.96 (Cl 1), 62.16 (CIO), 61.21 (CH30); m/z 191 
(M). 
177 
N6-(2,2-Dimethoxyethan)adenine (116) 
MeO"", ýNll 
MeO 
N 
N 
116 
A 2-methoxyethanol (I ml) solution of 6-chloropurine (200 mg, 1.3 rnmol) and 2,2- 
dimethoxyethanamine (287 mg, 2.73 mmol) was heated under reflux (125 *C, 1.5 H) 
until the reaction was complete (by TLQ- The solvent was removed under vacuum 
(0.001 mniHg), to leave a mixture of white and brown solids which were triturated 
with water to give a pink solid within a brown solution. The solid was collected by 
filtration and washed with water. The pink solid was then decolourised with charcoal 
and recrystallised to give white flaky crystals (198 mg, 68% yield). mp 228 -229 "C 
(ethanol), (Found C, 48.3, H, 5.8, N, 31.2. C9Hl3N5 02 requires C, 48.4, H, 5.8, N, 
31.4); vmax(KBr)/cm-1 2834 (OMe, C-H stretch); 1626 (purine ring), 1597 (purine 
ring), 1539 (NH); 8H(200 MHz; d6-DMSO) 12.96 (IH, brs, 119), 8.21 (IH, s, 118), 
8.13 (IH, s, H2), 7.53 (IH, brs, N6M, 4.65 (1H, t, J 5.4, (CH30)2CjI), 3.64 (211, 
brs, CH2NH), 3.29 (6H, s, (CH30)2); 5C(50.28 MHz; d6-DMSO) 154.48 (C6), 
152.60 (C2), 139.31 (C8), 102.04 (-C(OCH3)2), 53.31 (. QH2NIi)- rnh 224 (M+), 192 
(M+ - CH30H). 
178 
a, P-Methylribofuranosides (117,118)110 
Ho-ý 
me 
HO OH 
117 and 118 
To a methanol solution of D-ribose (0.25 M, 5.2 ml) was added two drops of acetyl 
chloride from a Pasteur pipette. This mixture was stirred until it was non-reducing 
(Fehlings solution) and the starting material could not be detected by TLC (50 min, 
RT). Potassium carbonate was then added to the reaction mixture, the mcthanolic 
solution was then decanted from the excess potassium carbonate . Dichloromethane 
(5 ml) was used to wash the reaction flask, the washings were combined with the 
methanolic solution and both solvents were removed by rotary evaporation to leave a 
white oil. This oil was then Kugelrohr distilled (200 OC, 0.01 mmHg) to give a 
colourless oil (189.6 mg, 89% Yield). (Found C, 43.8; H, 7.4. C6111205 requires C, 
43.9, H, 7.3 %); vmax(KBr)/cm-1 3377.79 (OH), 2839.58 (OMe); 811(200 MHz; 
D20) 4.94 (IH, s, HI), 3.92 (111, dd, J 3.31,11.78, H5'), 3.71 (Ili, dd, J 6.28,11.76, 
HY); 5C(50.28 MHz, D20) 110.15,104-93 (PaCl), 86.77,85.16 (ocDC2), 76.48, 
73.45 (apO), 72.99,71.63 (DaC4'), 65.31,63.60 (PaC5), 55.70,55.71 (cEOOMe); 
m/z 164.089. 
179 
N6-Benzyladeninc (123)1" 
NH 
N 
(f 
CýT 
N 
'ýý--N 
x H 
123 
A 2-methoxyethanol (I ml) solution of 6-chloropurine (200 mg, 1.3 mmol) and 
benzylamine (293 mg, 2.73 mmol) was refluxed (0.5 H) until the reaction was 
complete (by TLC). The excess benzylamine and the solvent were then removed 
under vacuum (0.05 mmHg) to leave a yellow solid. This solid was triturated with 
water to form an off-white solid wWch was recrystallised from a 1: 1 mixture of ethanol 
and water to give 
beige rod shaped crystals (182 mg, 62% yield) mp 226 - 228 'C (ethanol and water 
(1: 1)), (Found: C, 64.2; H, 5.1; N, 3 1.1. C12H1 1N5 requires C, 64.0, H, 4.9, N, 3 1.1 
'70), 5H(200 MHz; d6-DMSO) 8.32 (IH, s, H8), 8.26 (IH, s, H2), 7.30 (5H, m, Ph), 
4.82 (2H, s, PhCH2). 8C(50.28 MHz; d6-DMSO) 152.70 (C2), 140.54 (C8), 139.48 
(Ph, C 1), 128.49 (oPh), 127.53 (mPh), 126.91 (pPh), 43.31 (-CH2Ph); nVz 225 (M+), 
148 (M+ - Ph), 135 (adenine), 120 (protonated purine), 106 (BnNH). 
cis-4,5-Diphenyl[1,3]dioxalan-2-one (132)102 
132 
To a dry (under nitrogen), cooled (ice/salt) dichloromethane (4 ml) solution of 
hydroxybenzoin (1.07g, 5 mmol) and triethylamine (I ml) was added triphosgene (49 
mg, 17 mmol). The temperature of this mixture was slowly allowed to rise (RT) until 
the reaction was complete (0.5 H, by TLC). Water (10 ml) was then added to the 
reaction mixture and the product extracted with dichloromethane Qx 20 mi), the 
extracts were pooled, dried (MgS04) and the solvent removed by rotary evaporation 
to leave a white solid (93 mg) which was recrystallised from aqueous ethanol to give 
white needles (59.4 mg, 61% yield) mp 127 'C (Found C, 74.8; H, 5.12; CHO 
requires C, 75.0; H, 5.0 %); vmax(KBr)/cm-1 1788.24 (CO), 1653.21 (Ph), 1452.58 
(Ph); 8H(200 MHz, CDC13) 7.2 - 6.8 (10H, m, 2x Ph), 5.91 (2H s, CH); 8C(50.28 
MHz, CDC13) 82.19 ( PhQ, 126.19 ( C2), 128.31 (C4), 128.87 (0), 132.91 (CI), 
155.00 (C=O); m/z 241 (M+), 197 (M+ - C02), 179 (PhCHPhC). 
181 
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